UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE FISCAL YEAR ENDED DECEMBER 31, 20212023

 

Commission File Number: 000-17284

 

 

AIXIN LIFE INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

AIXIN LIFE INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)

 

Colorado 84-1085935
(State or Other Jurisdiction IRS Employer
of Incorporation) Identification Number

 

Hongxing International Business Building 2, 14th FL, No. 69 Qingyun South Ave., Jinjiang District

Chengdu City, Sichuan Province, China

(Address of principal executive offices)

 

86-313-6732526

(Registrant’s telephone number, including area code)

 

Securities Registered Pursuantregistered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of Thethe Act:

Common Stock, $0.00001 par value

(Title of class)

Title of Each ClassTrading Symbol(s)

Name of each Exchange on Which Registered

Common Stock, $0.001 Par ValueAIXNOTCQX

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. (Check one):

 

Large accelerated filer ☐ Accelerated filer ☐
   
Non-accelerated filer ☐ (Do not check if a smaller reporting company)Smaller reporting company
   
  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No No

 

As of June 30, 2021,2023, the aggregate market value of our common stock held by non-affiliates was $116,701,29425,656,989, based on 17,161,9558,580,933 shares of outstanding common stock held by non-affiliates, and a price of $6.80$2.99 per share, which was the last reported sale price of our common stock on OTC MarketOTCQB on that date.

 

As of March 31, 2022,29, 2024, we had outstanding 49,999,89124,999,945 shares of common stock.

 

DOCUMENTS INCORPORATED BY REFERENCE: None

 

 

 

 

 

AIXIN LIFE INTERNATIONAL, INC.

 

  Page No.
PART I  
   
Item 1Business4
Item 1ARisk Factors9
Item 1BUnresolved Staff Comments2831
Item 1CCybersecurity Policy31
Item 2Properties2832
Item 3Legal Proceedings3228
Item 4Mine Safety Disclosures2833
   
Part II  
   
Item 5Market For Registrant’s Common Equity, Related Stockholder Matters And Issuer Purchases Of Equity Securities2833
Item 6[Reserved]29
Item 7Management’s Discussion And Analysis Of Financial Condition And Results Of Operations3530
Item 7AQuantitative And Qualitative Disclosures About Market Risk3741
Item 8Financial Statements And Supplementary Data3741
Item 9Changes In And Disagreements With Accountants On Accounting And Financial Disclosure3741
Item 9AControls And Procedures3741
Item 9BOther Information42
Item 9CDisclosure Regarding Foreign Jurisdictions That Prevent Inspections3842
   
Part III  
   
Item 10Directors And Executive Officers And Corporate Governance3942
Item 11Executive Compensation4246
Item 12Security Ownership Of Certain Beneficial Owners And Management And Related Stockholder Matters4347
Item 13Certain Relationships And Related Transactions, And Director Independence4347
Item 14Principal Accountant Fees And Services4449
   
Part IV  
   
Item 15Exhibits And Financial Statement Schedules4550
 
Consolidated Financial Statements4550

 

2

 

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

 

This Annual Report on Form 10-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on forward-looking statements. Forward-looking statements include, among other things, statements relating to:

 

 our goals and strategies;
   
 our future business development, financial condition and results of operations;
   
 our expectations regarding demand for, and market acceptance of, our products;
   
 our expectations regarding keeping and strengthening our relationships with merchants, manufacturers and end-users; and
   
 general economic and business conditions in the regions where we provide our services.

 

Also, forward-looking statements represent our estimates and assumptions only as of the date of this report. You should read this report and the documents that we reference and filed as exhibits to the report completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, even if new information becomes available in the future.

 

REVERSE STOCK SPLIT

 

WeOn February 17, 2023, we effected a 1 for 41-for-2 reverse split of our shares of common stock October 27, 2020. As a result of the reverse split and the elimination of fractional shares,reducing the number of shares of our outstanding common stock outstanding was reduced from 200,000,00049,999,891 to 49,999891. Unless explicitly stated29,999,842. Except as otherwise indicated, all share and per share numbers contained herein including those set forth in this Reportthe financial statements beginning on page F-1, have been adjusted to give effect to the 1-for-2 reverse stock split.

 

3

 

PART I

 

Item 1Business.

 

Overview

As used in this report, unless the context requires otherwise, all references to “AiXin Colorado” refer to AiXin Life International, Inc., a Colorado holding company, and references to “Aixin Life,” we,” “us,” “our,” the “Registrant,” the “Company” or “our Company” are to AiXin Colorado and its subsidiaries. 

 

We are a Colorado holding company and conduct substantially all of our operations through our operating companies established in the People’s Republic of China, or the PRC.* Our focus is on providing health and wellness products to the growing middle class in China. We currently develop, manufacture, market and sell premium-quality healthcare, nutritional consumer products in China. Originally, we offeredand wellness supplements, including herbs and greens, traditional Chinese remedies, functional products, such as weight management products, probiotics, foods and drinks. We also provide advertising and marketing services to clients which engage us to market and distribute their products. We offer our products and those of third partiesclients for which engaged us to marketwe provide marketing services, through a diversified, omni-channel business model which generates revenues through retail and sell their products directly to consumers at ourwholesale product sales, offices, through person—to-personcompany-owned pharmacies, direct marketing and at events we organize and sponsor, at which, on occasion, representatives of the manufacturers promote their products. In mid-2021 we acquired a chain of pharmacies which we will use to supplement our marketing efforts while maintaining their traditional retail businesses. As part of our direct marketing efforts, we rely on a portion of our clients who market and sell products to others. We offer discounts to distributors who purchase a sufficient quantity of products for the purpose of incentivizing them to distribute products to their friends, family members and others. We also offer clients who purchase significant quantities of products paid vacations, travel and other benefits. Products we sell can now be purchased at our pharmacies, online direct from our representatives, including at any of the sales offices we maintain in Chengdu and at marketing events held by us.activities.

 

Before promotingThrough our subsidiary, AixinZhonghong, we offer nutritional products through a product,direct marketing team, at large scale entertainment style events which we research itorganize for the benefit of our clients and its manufacturermore recently, through online activities. AixinZhonghong also provides marketing and distribution services to determine the manufacturer’s reputationother manufacturers and suppliers of healthcare products. We have a proactive approach to marketing, reaching out to customers to provide information as to whether it delivers unadulterated products, and whether there ishow to live a basis for claiming the product can deliver the benefits claimed. As part of this effort, a group of our employees use the products and provide feedback based upon their personal experiences. We base our evaluation of products on the assessments received from our employees. We also review and to the extent feasible confirm information and reports received from the manufacturer and distributor. We do not rely upon any other third-parties to independently test products to determine their efficacy.

Once we determine to offer a product we seek to purchase large quantities, enabling us to acquire products at prices we believe are below those available to the many smaller distributors that operate in Chengdu.

We offer our clients personalized services, including educating them through seminars on the benefits of the products we distribute, maintaining sales offices at which our clients can engage in recreational and social activities where the products we offer are prominently displayed and can be picked up, conducting promotions with representatives of the manufacturers of the products, and encouraging customer loyalty with incentives such as rewards and discounts based upon the quantities of products purchased for individual use or sold to others.healthy lifestyle. We believe ourthis approach is ideally suited to marketing strategy which emphasizeshealth and wellness products as sales of these products are strengthened by ongoing personal contact and support, coaching and educating oureducation of clients, as to the benefits of a healthy and active lifestyle.

In September 2021 we completed the productsacquisition of nine pharmacies located in Chengdu. Since that time we have added additional pharmacies and currently operate 25 pharmacies. We utilize these pharmacies to distribute is ideally suited for selling nutritionalour health and wellness products and builds confidence in us and customer loyalty to us and the products we sell. We believe this is particularly the case in China where the middle class is growing in size yet, due to lax enforcement and limited laws and regulations, many manufacturers and distributors, particularly those of new and innovative products, are not trusted by consumers. Thus, although our focus isserve as learning centers for our clients along with their traditional business. We intend to seek to continue to expand our chain of pharmacies and to use these outlets as part of our overall marketing strategy. As part of our marketing efforts, we will educate the manufacturers weemployees at our pharmacies as to the benefits of our health and wellness products so they can closely work with getour clients.

In September 2022, we acquired Yunnan Runcangsheng which engages in the benefitresearch, development, manufacture and wholesale distribution of health and wellness products. Yunnan Runcangsheng operates a 13,000 square meter production facility, including, R&D centers, extraction facilities, preparation workshops and a warehouse. Yunnan Runcangsheng has more than 30 brand names under which it distributes products and maintains and operates planting facilities where it grows some of the trust our clients have placedkey ingredients used in us. Consequently, although certainits products. Many of the products it has developed are specifically targeted to alleviate ailments associated with the increasingly competitive and pressured lifestyle of Chinese people, such as hypertension and obesity, which result from a more pressured yet sedentary lifestyle, symptoms associated with changing eating habits and the presence of environmental toxins that are becoming more widespread through the use of western style pesticides and fertilizers. When we entered into the agreement to acquire Yunnan Runcangsheng we began to distribute are produced by a variety of manufacturers, we require the manufacturer or distributor from which we purchase a productits products through our distribution channels and continue to provide us with exclusive distribution rights for an agreed upon time period within a prescribed territory or package the product so that while we are offering a product, it is distinct from products sold to our competitors.do so.

4

 

In addition to distributingour acquisitions in the health and nutritional products,sector, in July 2021, we also operate acquired Chengdu AiXin Shangyan Hotel Management Co., Ltd (“AiXin Shangyan Hotel”). Until the end of March 2024, AiXin Shangyan Hotel operatedthe Shangyan Hotel located in the Jinniu District, Chengdu City. TheWe terminated the lease for the Shangyan Hotel effective March 31, 2024, and entered into a 30-year lease for a hotel covers more than 8,000 square metersin the Xindu District of Chengdu. While we will continue the hotel’s pre-acquisition business, we intend to use the hotel to host events at which we educate our team members and hascustomers as to the benefits of a large restaurant that can accommodate 600 people, 6 luxury dining rooms, a 200 square meter music tea house, 13 private tea rooms, 108 guest roomshealthy lifestyle, introduce new products and other supporting facilities. The hotel is equipped with all modern facilities, including central air conditioning. To accommodate businesses, the banquet hall is equipped with advanced audio-visual equipment and dedicated high-speed wireless Internet to facilitate large group presentations. The staff includes a professional banquet team to ensure the success of any private function or business gathering. A full range of catering services, including Chinese-style boutique Sichuan cuisine are provided in a stylish environment.offer our complete product line for sale.

 

In additionWe intend to our ongoing operations,look for additional opportunities to profit from the growing healthcare market in China. Though currently we are seekingnot party to acquire interestsany agreements, we will explore, among other opportunities, expanding our product line through internal research and acquiring complementary products from third parties, acquiring additional pharmacies and other retail outlets and operating nursing homes and possibly clinics which provide medical care to clients.

* Our “Chinese Operating Companies” are Chengdu AiXinZhonghong Biological Technology Co., Ltd, (“AiXinZhonghong”), AiXin Shangyan Hotel Management Co. Ltd. (“AiXin Hotel”), Chengdu Aixintang Haichuan Pharmacy (which together with certain affiliated entities is referred to as “Chengdu Aixintang Pharmacies”), and Yunnan Runcangsheng Technology Co., Ltd. (“Runcangsheng).” The Chinese Operating Companies are wholly owned through an intermediary company established in additional businesses through opportunities locatedHong Kong named HK AiXin International Group Co., Limited (“AiXin HK” and collectively with our Chinese Operating Companies our “PRC Subsidiaries”), which is owned by our management or presented by persons or firms which desire to take advantage ofan intermediary company (AiXin (BVI) International Group, Ltd., “AiXin BVI”) established in the perceived advantages of an Exchange Act registered corporation.British Virgin Islands. We are not restrictinga Chinese operating company. We are a holding company and do not directly own any substantive business operations in China. Therefore, you will not directly hold any equity interests in our search to any specific business, industry,Chinese Operating Companies, AiXin BVI or geographical location and may participate in a business venture of virtually any kind or nature.AiXin HK.

4

Business Objectives

 

ItKey elements of our strategy are detailed below:

Leading brand of nutritional supplements. Our primary goal is to develop recognized brand names with a reputation as a provider of quality health and wellness products which deliver demonstrable benefits to our customers. Our objective is to provide members of the growing Chinese middle class with the information necessary to maintain a healthy lifestyle and to offer them a broad and deep mix of products whether the customer is looking to treat a specific health-related issue, maintain their overall wellness or improve their performance. Our premium, value-added offerings will include both proprietary branded products and other branded products provided by third parties to meet needs not met by our in-house products.

We believe that by offering a variety of branded exclusive products and a wide range of merchandise, and close customer support and services, we will be able to differentiate our Company from competitors and effectively compete against other food, drug and mass channel players, specialty stores, independent vitamin, supplement and natural food shops and online retailers. We further believe that if we succeed in developing and maintaining a positive reputation, we will be able to offer additional products and services to our clients.

Product development and innovation. With the acquisition of Yunnan Runcangsheng we have the facilities and, more importantly, knowledgeable, experienced personnel, to develop high-quality, innovative health foods and nutritional supplements that will be offered by our direct marketing team and available through our company-owned pharmacies, our website and, as demand grows other, select marketplaces and wholesale partners. To the extent desirable we will grow some of the key ingredients in our products. When we choose to use ingredients of third parties, they will be rigorously tested before they are added to our products, undergoing multiple quality checks to ensure that they meet our high standards for purity, composition and absence of contaminants.

We believe our capability to innovate and respond to customer needs by designing new products gives us a significant competitive advantage. At Yunnan Runcangsheng we directly employ scientists, nutritionists, formulators, and quality control experts who work at our research and manufacturing facilities.

A differentiated customer experience. One of the key differentiators to our marketing strategy is the goalcontinued development of well-trained team members that work closely with customers. We will provide our team members with training and education focused on the benefits of a healthy lifestyle, the advantages of our management,products and solution-based selling. We will also maintain and make available to our team members data bases of our customers purchasing patterns. With their knowledge of the available products our team members can engage customers in particular,conversation, access the customer’s purchasing history through our Chairman, Quanzhong Lin,data base, share product information and testimonials and recommend solutions and help customers add complimentary products and build wellness regimens. We operate in a highly personalized, aspirational sector and believe that health food and nutritional supplement consumer often desires and seeks out product expertise and knowledgeable customer service.

We have developed loyalty programs to reward customers and incentivize them to introduce our products to their friends. A number of our customers in fact act as independent marketers, buying products from us and distributing them to others at a profit. We intend to continue to use loyalty programs to develop and maintain a large and loyal customer base, provide targeted offers and information, and connect with our customers on a regular basis. We will harness data generated by these programs to better understand customers’ buying behaviors and needs, so we can deliver a more rewarding experience, encourage our customers to introduce our products to their friends and make well-informed decisions about the direction of our business.

As we grow and develop our businesscustomer base, we can use our hotel as a site for educational seminars, conferences and marketing events featuring well known experts in the wellness sector. These events can be used to increase customer loyalty and to modify its capital structureeducate our team members as to the benefits of a healthy life style and our products so they can better serve our customers by guiding them to products that meet their needs.

Omni-channel development. We believe our diversified, omni-channel model, which includes company-owned offices open to clients, pharmacies, direct marketing by our team members, individually and at large scale company sponsored marketing events, wholesale locations and online activities, can differentiate us from many of our competitors, particularly those that rely exclusively on online marketing efforts. Our strategy is to give consumers a seamless, integrated experience across digital, mobile and in-store channels and in orderevery interaction with us and our products.

5

Through our website and in conversations with our well-trained team members, customers can research our products and purchase them online or at one of our local pharmacies or sales offices. We believe our physical store base provides a competitive advantage, allowing customers to qualify for a listing on NASDAQ or the NYSE-American exchange. As part of this effort, we will continue to seek to acquire more businessesexperience our products and to modifyget expert advice from our capital structure as necessary to meet the requirements of the exchange to which we apply for a listing.team members.

 

Our executive officesomni-channel model can enhance the customer experience and increase the value of a customer to us and we will implement strategies to blend our digital, online and in-store platforms, always stressing the availability and benefits of a conversation with one of our team members. These initiatives will include increased cross-channel marketing, online and in-store subscription services, giving customers the option of picking up online purchases at our stores, delivering products purchased via e-commerce directly from stores, and providing educational content, information and advice online, at our pharmacies or through a personal visit by one of our team members.

Vertical Integration. We believe that our multi-channel distribution model, combined with our research, development and manufacturing capabilities offers us a unique advantage over our competitors. The daily feedback received from interactions between our team members and customers will be monitored to recognize what our customers want and rapidly develop products to meet their desires. Instead of simply responding to trends in the market, we will seek to bring new topical products to the market before they are at Hongxing International Business Building 2, 14th FL, No. 69 Qingyun South Ave., Jinjiang District, Chengdu City, Sichuan Province, China, and our telephone number is +86-28-8669-1072.generally available.

 

Products

Our pharmacies offer a wide variety of personal healthcare products and traditional Chinese remedies in addition to our health and wellness products. They began to carry the products developed by Yunnan Runcanscheng prior to completion of that acquisition. The primary products currently distributed by us, including those of Yunnan Runcangsheng, include rhino king, colostrum powder derived from goat’s milk, tong li ke, gammaoling granules, amoxicillin capsules, loratadine tablets, and fuyang granules.

Marketing

Our target customer is the growing population of middle- and upper-class Chinese who are willing to devote increasing amounts to healthcare products as their incomes grow. We Offerbelieve that as this group grows, becomes more affluent and adopts a more western sedentary life-style and diet, it will experience obesity, hypertension, heart disease, back pain and some of the negative symptoms common in developed countries. Our marketing efforts include proactively approaching these customers through person-to-person marketing and by hosting educational and informative events, which we believe is ideally suited to marketing our products and those of our clients for which we perform advertising services because sales of health and wellness products and supplements are strengthened by ongoing personal contact and support, coaching and education towards how to achieve a healthy and active lifestyle.

 

We offer a variety of nutritional products and supplements on behalf of our Company and our marketing clients, which change over time in response to the consumer market. We source and purchase all ofcurrently market our products through third party distributorsour pharmacies, at large scale marketing events which feature popular local entertainers, at our offices which customers are encouraged to use for social gatherings, at wholesale and manufacturers which we carefully research before determining to distribute a product.

Marketing and Sales Strategy

We market and sell the products we offer directlyonline. Key to our clients on-line and off-line through our direct marketing efforts through our chain of retail pharmacies and through thoseare the members of our clientsmarketing team who act as resellers. Wemake themselves available to individual customers and work with such customers to develop a healthy well balanced dietary regimen. As part of our educational efforts, we distribute informational videos to our clients on lineon-line and make multiple posts on social media daily. Off-line, in addition to distributing products through our pharmacies, we utilize person-to-person marketing to promote and sell products. These personal marketing efforts include hosting educational events and allowing customers to utilize our facilities for social gatherings. We believe our marketing strategy is effective because:

we educate consumers about products face-to-face, which we believe is more effective for differentiating our products than using traditional mass-media advertising, particularly when introducing a new product to an older unsophisticated group of consumers in an environment where it is difficult to obtain accurate, reliable product information;
it provides for actual product demonstrations and use by potential consumers;
it allows us to provide personal testimonials of product efficacy; and
as compared to other marketing methods, we have the opportunity to provide consumers higher levels of service and encourage repeat purchases.

5

 

In addition to the retailour marketing efforts, through our loyalty program we encourage our customers who frequent our pharmacies, we market the products we offer to clients who buy our products directly from us for personal or family consumption and clients who buy, use and distribute our products to others.

We offer our clients high-quality, innovative products that provide demonstrable benefits. We attempt to obtain detailed personal information about each of our clients so that we can direct each of them to products that best suit their needs and distribute new products that will appeal to our existing clients. We track the purchases made by every individual who purchases products directly from us. Based upon their purchasing history, we believe a significant majority of our clients purchase the products we sell primarily for personal or family consumption and are not actively pursuing the opportunity we offer to generate income by marketing and reselling products.

Our strategyprogram for increasing the number of clients interested in reselling the products we offer and for developing new clients who demonstrate the ability to sell our products to others, is to provide them with compensation, in the form of quantity purchase discounts and other incentives, such as free meals, travel or vacations. We track the amount of products purchased and frequency of purchases by those clients who sell our products to others and reward them when we think it is appropriate

 

We offer our clients a customer satisfaction guarantee. Our sales policy allows for the return of unopened products for cash after deducting certain service and transaction fees. As an alternative to returning a product, customers can exchange a product for another of the same value.

 

6

Because of restrictions on direct selling and multi-level market in Mainland China, we structured our business model to avoid being placed in either category based on the guidance we received from government officials, our interpretation of applicable regulations, our understanding

Manufacturing

As a result of the practicesacquisition of international direct selling companies operatingYunnan Runcangsheng, we now have a 13,000 square meter manufacturing center inclusive of office space, R&D centers, extraction workshops, preparation workshops, traditional Chinese medicine decoction pieces workshops and storage areas. The activities include research and development, extraction and intensive processing of traditional Chinese medicines and processing to incorporate active ingredients into tablets, capsules, granules and pills according to market demand and product attributes. The facility was designed and constructed and is operated in Mainland China,compliance with applicable national health food and pharmaceutical standards (GMP), and has achieved ISO quality system certification and HACCP food safety system certification.

Raw Materials

The raw materials used in products we manufacture are generally readily available, subject to fluctuations in price due to supply and demand issues. We do not look to enter into long term contracts with any of our understandingsuppliers as the materials we need shifts as demand for our products changes.

Intellectual Property

We believe that we need to how regulatorsdevelop well recognized brand names and, when possible, obtain patents covering products we develop, their formulae or the processes by which they are interpretingmanufactured. Runcangsheng has received patents on certain manufacturing processes and enforcinghas used multiple brand names for its products. Given the regulations.early stage of Runcangsheng’s development and the limited historical operations of AiXinZhonghong, our products and brand names have yet to achieve the widespread recognition we envision. See, “Item 1A. Risk Factors – Risks Associated with Our Company -, Our ability to adequately protect our trade names, trademarks and patents could have an impact on our brand images and ability to penetrate new markets.

 

Competition

Products

 

The category of nutritional products is very competitive and there are various channels through which such products are marketed to consumers, including direct selling, through the internet, through specialty retailers, pharmacies and discount channels of food, drug and mass merchandisers. We seek to differentiate ourselves by being familiar with our clients and providing a personalized sales experience and focusing on after-sale services where sales employees focus on the consultative sales process through product education and the frequent contact and support that many sales employees have with the clients. From a competitive standpoint, there are many providers and sales outlets of nutritional products in China. We believe that none have effectively combined the product, personal coaching, education and the product access provided by our sales employees and, further, that these efforts are compounded by the peer pressure our clients generate through our organized group sales presentations.

 

Our Competitive Advantages / StrengthsEmployees

 

Client Base

We have clients who primarily join for a discount on products they consume and introductions to new products they might desire, along with clients who also choose to profit by reselling our products. We currently have around 100,000 clients nation-wide in China. The majority purchase products for personal and family use, while others purchase products for their own use and for distribution to others.

When customers purchaseAs of April 1, 2024, we had approximately 207 employees allocated amongst the products we offer, information such as the customer’s name and the products purchased, is entered into our computer system, enabling us to develop a profile of more active customers. We do not initially identify a new customer as a preferred client or client distributor but monitor each member’s purchase patterns over time in order to match products to their desires and, eventually, categorize them as a preferred customer or distributor.

6

We do not pay salaries or commissions to client distributors. It is our practice to offer client distributors discounts on quantity purchases and to reward them through incentives, such as free meals, travel or vacations.,

People become our clients for a number of reasons. Many first start out as consumers looking to improve their health through better nutrition and join simply to receive a better price on products they and their families consume and enjoy, while others join so they can resell our products and generate income.

Competitive Advantagesfunctions set forth below.

 

FunctionWe study the attributesNumber of new products which become available and after researching the benefits which they claim to offer we organize a group of professionals to experience and evaluate the products. Only after we determine that a product is safe, manufactured in conformance with appropriate standards, and has a basis for the claims made, do we recommend a product to our clients. This process ensures our clients get safe, quality products that suit their personal needs and upon which they can rely.
employees
Administration30
FinanceOur clients vary greatly in age, background, health and physical condition. We organize activities and events so that we might learn each client’s family background, physical condition and personal health needs, and categorize them into different groups for different products. For example: “cardiovascular and cerebrovascular group”, “bones and joints”, and “heart health.”27
Manufacturing11
Marketing (sales)We also focus on after-sale services. Due to the large number of clients that are in the middle-to-older aged groups, we have the ability to have products delivered to our clients’ homes by sales personal who can explain the product and demonstrate its use. Our sales personnel are available on a 24-hour basis for questions from clients. Once a client purchases a product, our in-house health advisors will contact him or her to give appropriate professional advice and consultation both over the phone, of face-to-face if needed.118
R&D6
Procurement15

 

Our Strategies

On-site Publicity. We have rooms available at our sales offices throughout Chengdu at which our clients can gather to play cards, enjoy afternoon teas, and engage in other social activities. The products we distribute are displayed at each of our facilities along with appropriate literature and can be purchased by clients and visitors.
Marketing Events. We periodically host small and large-scale marketing events for up to approximately 1000 participants. These events are held at our premises or at restaurants and during travel. At each event products are demonstrated and our personnel explain the benefits of the products and, if available, representatives of the manufacturer or distributor are on hand to respond to questions or make a presentation. We use holidays, such as “National Day,” “New Year Day,” and “Mid-Autumn Day” as opportunities to host large-scale themed activities or events appropriate for the season.
One-on-one marketing. Salespeople will explain and market products to clients one-on-one at our facilities, during marketing events or at a client’s home or office, which gives a personal touch and more detailed explanation of products.
Convenience of Local Pharmacies.  Clients who live or work near the pharmacies we have acquired to date and any we might acquire in the future will be able to more conveniently purchase any of our products they may have originally purchased through our direct marketing programs.  

Seasonality

In general, there is no seasonality in the sale of nutritional products.We believe that we maintain a good working relationship with our employees, and to date we have not experienced any significant labor disputes.

 

7

 

RegulationGovernment Regulations

 

General

TheWe are subject to numerous regulations applicable to businesses generally, including regulations relating to working conditions, employee compensation and the maintenance of welfare plans, environmental regulation and truth in advertising. In addition, the manufacture and distribution of nutritional products is subject to many laws, governmental regulations, administrative determinations and guidance. Such laws, regulations and other constraints exist at the national, provincial and local levels, including regulations pertaining to: (1) the formulation, manufacturing, packaging, labeling, distribution, importation, sale and storage of products; (2) product claims and advertising, including direct claims and advertising by us, as well as claims and advertising by manufacturers and distributors of the products we offer, for which we may be held responsible; and (3) taxes. As a distributor, we are subject to only a portion of these laws and regulations. We believe that we are fully compliant with those applicable to our activities.

 

Products

Prior to commencing manufacture or distribution of a product, the manufacturer or distributor may be required to obtain an approval, license or certification from the national, provincial or local government in China. Although we attempt to determine whether all regulatory requirements have been met, we cannot monitor the manufacture of products we acquire for distribution from third parties and cannot be certain that all applicable regulations are satisfied. Moreover, even if we were to determine that a manufacturer or distributor had the requisite license or certification at the beginning of a relationship, we might not become aware if it were to forfeit any regulatory approvals or fail to adhere to applicable requirements.

 

Regulation of Nutritional Products.

Dietary supplements are subject to regulation by the China Food and Drug Administration. Mainland China has highly restrictive nutritional supplement product regulations. Products marketed as “health foods” are subject to extensive laboratory and clinical analysis by government authorities, and the product registration process in Mainland China generally takes one to two years, but may be substantially longer. We market both “health foods” and “general foods” in Mainland China. As a secondary distributor,foods.” For products we distribute on behalf of or acquired from others, we are not in a position to obtain any required license, though we may be held liable if we were to distribute a product which had not been properly tested and registered with the authorities. There is some risk associated with the common practice in Mainland China of marketing a product as a “general food” while seeking “health food” classification. If government officials feel the categorization of a product distributed by us is inconsistent with product claims, ingredients or function, this could end or limit our ability to market such products.

 

As the middle class has grown, the number of manufacturers and distributors of nutritional supplements in China has dramatically increased. Many of these enterprises have often ignored applicable laws and distributed adulterated or inferior products. We believe this has created a marketing opportunity which we have tried to exploit as a trusted source of products on which our clients can rely. To the extent our reputation results from reviewing and testing products prior to distributing them, and then distributing only products determined to be safe, it is incumbent upon us to ensure that the manufacturers and distributors upon which we rely are trustworthy. A failure by any of these third parties could cause substantial damage to our reputation, business and financial results.

Direct Selling and Multi-Level Marketing Regulations

 

Direct selling and multi-level marketing are two forms of marketing regulated by various national, provincial and local government agencies in China. These laws and regulations are generally intended to prevent fraudulent or deceptive schemes, including “pyramid” schemes, which compensate participants primarily for recruiting additional participants without significant emphasis on product sales to consumers.

 

Under PRC regulations, “direct selling” refers to a type of business mode in which a company recruits door-to-door salesmen to sell products directly to ultimate consumers outside the companies’ fixed places of business. Businesses engaged in “direct selling” are required to obtain a license from the PRC government. A direct selling company is required to provide vocational training for, and conduct an examination of, any sales promoter it recruits, and obtain a certificate for each sales promoter after the sales promoter has passed the examination. A direct selling company is also required, when commencing operations, to deposit RMB 20RMB20 million ($2.9 million) in a special account with a designated bank, which deposit is adjusted on a monthly basis to equal 15% of the operator’s sales from direct selling products up to RMB 0.1RMB0.1 billion ($14.5 million).

8

 

We do not engage in direct selling activities subject to regulations prevalent in China since we do not employeeemploy sales personnel engaged in door-to-door sales outside our place of business.

 

Under PRC regulations, “multi-level marketing” refers to marketing, promotional and sales activities whereby organizers or operators take in new members and compensate each member based upon the number of new members introduced by such member, directly or indirectly, or based upon the level of sales generated by the members introduced by such member. The regulations also prohibit an organizer from requiring new members to deposit a sum of money as a condition to membership or requiring that members recruit additional members to establish a multi-level relationship. PRC regulations distinguish direct selling from multi-level marketing in that all direct sellers are normally trained by the direct selling company and any direct seller is not allowed to develop new followers or form multiple levels.

 

We are not in the direct selling category or multi-level marketing category since (i) we do not pay salaries or commissions to our member distributors, who decide as a matter of personal preference whether to introduce our products to relatives or friends based on their own personal experience of usage and/or trust of our company’s products; (ii) we do not require individuals to deposit a sum of money to become a member; and (iii) we do not pay members to recruit individuals to join in or to form a multi-level relationship.

 

Nevertheless, the laws and regulations governing direct selling and multi-level marketing may be modified or reinterpreted from time to time, which may cause us to change our business model. Regulations are subject to discretionary interpretation by regulators and governmental authorities. There is often ambiguity and uncertainty with respect to the implication of direct selling and anti-pyramiding laws and regulations.

 

Employees

8

 

As of March 15, 2022, we had approximately 217 full-time employees, of which approximately 18 were in management and administration, 62 were sales and service personnel, 53 were in public relations and sales support, 40 were in retail at the pharmacies and 44 were in management and staffing at the Shangyan Hotel.

Corporate History

We were incorporated under the laws of the State of Colorado on December 30, 1987.

In February 2017, Mr. Quanzhong Lin, our President, purchased approximately 65% of our then outstanding shares of common stock. In December 2017, we issued additional shares of our common stock to Mr. Lin, the sole stockholder of AiXin BVI, for all of the outstanding shares of AiXin BVI, pursuant to a share exchange agreement. Mr. Lin then owned approximately 80.8% of our outstanding shares.

Effective February 1, 2018, we changed our name to AiXin Life International., Inc. (“AiXin”).

Item 1A.Risk Factors

 

An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below, together with all of the other information included in this report, before making an investment decision. If any of the following risks actually occurs, our business, financial condition or results of operations could suffer. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.

 

9

Risks Related toAssociated with Our BusinessCompany

 

Covid – 19 Pandemic

In March 2020, the World Health Organization announced that infections caused by the coronavirus disease of 2019 (“COVID-19”) had become pandemic. Economies throughout the world, including that of China, have been severely disrupted by the effects of the pandemic and the quarantines, stay at home orders, business closures and the reluctance of individuals to leave their homes resulting from the outbreak of the Covid-19 Pandemic. China adopted and continues to rely uponWe operate in a “zero-tolerance” policy pursuant to which it has declared a number of total and partial lockdowns in cities throughout China, including Chengdu. These lockdowns and any accompanying travel restrictions have adversely impacted many industries in China. As a company which does business exclusively in Chengdu, a city in Western China, our business has been adversely impacted by the outbreak of Covid-19, travel restrictions and lockdowns in Chengdu. These impacts included difficulty in obtaining adequate quantities from our suppliers, lower occupancy rates at our hotel and decreased sales of certain products. We cannot forecast with any certainty whether the disruptions caused by the COVID-19 pandemic will increase, or the extent to which our business may be negatively impacted by an increase in cases as a result of the spread of a new variant and restrictions imposed by the Chinese governments in response to any such increase. Any such disruption may materially impact our businesshighly competitive industry and our consolidated financial position, results of operations,failure to compete effectively could adversely affect our market share, revenues and cash flows.

The Russian invasion of Ukraine and the retaliatory measures imposed by the United States, United Kingdom, European Union and other countries and the responses of Russia to such measures have caused significant disruptions to domestic and foreign economies.growth prospects.

 

The invasionmarket for health and wellness products is large, highly fragmented and intensely competitive. Current and prospective participants include specialty retailers, supermarkets, drugstores, mass merchants, multi-level marketing organizations, online merchants, mail-order companies and a variety of Ukraineother smaller participants. The market is also highly sensitive to the introduction of new products, which may rapidly gain consumer acceptance. We compete for sales with heavily advertised brands manufactured by the Russian Federation had an immediate impact on the global economy resulting in higher prices for oillarge pharmaceutical and food companies, as well as other brands, some of which have greater market presence, name recognition and financial, marketing and other commodities.resources, including some competitors that may spend more aggressively on advertising and promotional activities than we do. Further, the ability of consumers to compare prices on a real-time basis through the use of smartphones and digital technology puts additional pressure on us to maintain competitive pricing. We compete in multiple product categories and sales channels, including pharmaceutical stores, wholesale to specialty store formats, direct marketing and increasingly internet-based and direct-sell retailers and vendors. Many factors affect the extent to which competition could affect our results, including as it relates to pricing, quality, assortment, marketing, promotions and advertising, service, locations, capital expenditures, category share and reputation, any of which could have a material effect on our results of operations. If we fail to compete effectively, we may lose business to other retailers.

We have a limited operating history on which to judge our performance and assess our prospects for future success.

We first entered the health and wellness business in December 2017 when we acquired AiXin BVI, which at that time owned all of the equity of AiXin Zhonghong, then engaged in the distribution of health and wellness foods. Consequently, we have a limited operating history on which to evaluate our prospects in the health and wellness industry. We may fail to continue our growth. You should not consider our historical growth and expansion of our business through acquisitions as indicative of our ability to grow in the future.

Our acquisition of Yunnan Runcangsheng is subject to uncertainties and risks.

There is no assurance that we will realize the benefits anticipated from our acquisition of Yunnan Runcangsheng. The United States, United Kingdom, European Unionprocess of combining the operations of Yunnan Runcangsheng with our existing operations could have a material adverse effect on us and our financial condition.

9

Our future expansion plans are subject to uncertainties and risks.

We intend to seek to expand our operations through acquisitions. The implementation of such plan requires us to integrate any newly acquired business and its management teams. If we fail to effectively and efficiently implement our plan for acquisitions, we may not be successful in achieving profitable results. Even if we effectively and efficiently implement our future plans, there may be other countries respondedunexpected events or factors that prevent us from achieving success. Our management has limited experience in effecting a rapid expansion and in managing larger operations. Our business, financial condition, results of operations and growth prospects may be materially and adversely affected if our future expansion plans fail to Russia’s invasion of Ukraine by imposing various economic sanctionsachieve positive results.

Failure to effectively anticipate consumer preferences could negatively impact the demand for our products and bans. Russia has responded with its own retaliatory measures. These measures have impactedour ability to generate revenues and the availability andmarket price of certain raw materials. The invasionour common stock.

Our success depends on our ability to anticipate and retaliatory measures also disrupted economic markets. The global impact of these measures is continually evolvingrespond in a timely manner to changing consumer demand, consumer preferences, and shopping patterns regarding health and wellness products. Consumer preferences cannot be predicted with certainty and there is no assurance that Russia’s invasionare subject to continual change and evolution. Additionally, our customers may have expectations about how they shop in stores or through online activities or more generally engage with businesses across different channels or media (through online and other digital or mobile channels or particular forms of Ukraine and responses thereto will not further disrupt the global economy and supply chain. Further, there is no assurance that even when the invasion of Ukraine ceases, that nations will not continuesocial media), which may change over time which may make it more difficult for us to impose sanctions and bans on other nations.adapt to rapid changes in consumer preferences.

 

While these eventsOur sales may decline significantly if we misjudge the market for our new products, which may result in significant inventory markdowns and lower margins, missed opportunities for other products, or inventory write-downs, and could have not interrupteda negative impact on our operations or materially impacted our ability to obtain raw materials, these or future developments resulting from the invasion of Ukraine could make it difficult for or increase the cost of certain raw materials, or make it difficult to access debtreputation and equity capital on attractive terms, if at all, and impact our ability to fund business activities and repay debt on a timely basis.

In reading the remaining risk factors set forth below, in each case, consider the additional uncertainties caused by Global events such as COVID-19 and the war in Ukraine.profitability.

 

We require significant investmentResources devoted to expand or maintain the current level of our business.product innovation may not yield new products that achieve commercial success.

 

We will require significant expenditures in the future to fund future growth. We intend to fund our growth out of internal sources of liquidity or through additional financing from external sources, including our principal stockholder. Given our recent results of operations, we cannot rely upon internally generated cash to significantly expand our current level of operations. Our ability to obtain external financing in the future at a reasonable cost is subjectdevelop new and innovative products or identify and acquire new and innovative products from third-party vendors, depends on, among other factors, our ability to a variety of uncertainties, including:

our future financial condition, results of operations and cash flows;
the condition of the global and domestic financial markets; and
changes in the monetary policy of the PRC government with respect to bank interest rates and lending practices.

understand evolving market trends and translate our insights into identifying, and then designing and manufacturing or otherwise obtaining, commercially successful new products. If we require additional fundsare unable to do so, our customer relationships and cannot obtain them on acceptable terms when requiredproduct sales could be harmed significantly. The health and wellness industry is characterized by rapid and frequent changes in demand for products. Our failure to accurately predict these trends could harm our customer relationships and cause us to fail to grow our revenues. The development of new and innovative products requires significant investment in research and development and testing of new ingredients, formulas and possibly new production processes. The research and development process entails considerable uncertainty. Products may appear promising in development but fail to reach market within the expected time frame, or at all, weall. Further, products also may fail to achieve commercial success. There is no guarantee that our development teams will be unableable to fulfill our working capital needs, upgrade our existing facilities or expand our business, and may havesuccessfully respond to reduce the levelcompetitive products that could render some of our operations. These factors may also prevent us from entering into transactions that would otherwise benefit our business or implementing our future strategies. Any of these factors may have a material adverse effect on our business, financial condition and results of operations.offerings obsolete.

 

10

 

We face intense competition, and ifIf we do not compete successfully against existingdevelop and new competitors, we may lose market share and suffer losses.

We face intense competition. We believemaintain a robust omni-channel experience for our ability to compete depends upon many factors both within and beyond our control. Some of our current and potential competitors may have greater financial, marketing, user traffic and other resources than we have. Certain of our competitors may be able to devote greater resources to marketing and promotional campaigns and devote substantially more resources to website and system development than us. Increased competition may reduce our market share and require us to increase our marketing and promotional efforts, which could negatively affect our operating margins or force us to incur losses. There can be no assurance that we will be able to compete successfully against current and future competitors, and competitive pressures may have a material adverse effect oncustomers, our business prospects, financial condition and results of operations.

We may have difficulty in managing our future growth and any associated increased scale of our operations.

We expect to expand through both organic growth and acquisitions. Our future expansion may place a significant strain on our managerial, operational, technical and financial resources. In order to better allocate our resources to manage our growth, we must hire, recruit and manage our workforce effectively and implement adequate internal controls in a timely manner. If we are unable to effectively manage our growth and the associated increased scale of our operations, our business, financial condition and results of operations could be materially and adversely affected.

Omni-channel retailing where customers are accessed through various coordinated channels, is rapidly evolving, and we must keep pace with changing customer expectations and new developments by our competitors. The growing middle class in China is increasingly seeking relevant information regarding healthy lifestyles and products that promote a healthy life. In addition, customers are increasingly shopping for products online instead of in traditional brick-and-mortar shopping centers and retail locations. As part of our omni-channel strategy, we anticipate the need to continue making investments in technology and to provide ready means for our customers to access the information and products they want in a comfortable environment. If we are unable to make, improve, or develop relevant channels to interact with customers in a timely manner, our ability to compete and our business and results of operations could be materially and adversely affected. In addition, if our online activities or our other customer-facing technology systems do not function as designed or we are unable to effectively blend our digital, online and in-store platforms, we may experience a loss of customer confidence, lost sales, or data security breaches, any of which could materially and adversely affect our business and results of operations.

 

The operation of our hotel is subject to the business, financial and operating risks inherent to the hospitality industry, any of which could reduce the revenues derived at our hotel.

The operation of a hotel is subject to a number of business, financial and operating risks inherent to the hospitality industry. These include significant competition from multiple hospitality providers in which compete for the business of our guests; the financial condition of the owner of the property on which our hotel is situated; decreases in business and leisure travel; changes in operating costs, including employee compensation and benefits, energy, insurance, food and beverage and other supplies; increases in costs due to inflation or other factors that may not be fully offset by increases in revenues in our business, as well as increases in overall prices and the prices of our offerings due to inflation, which could weaken consumer demand for travel and the products and services we offer and adversely affect our revenues; changes in taxes and governmental regulations that influence or increase our operating costs; the costs and administrative burdens associated with complying with applicable laws and regulations; significant increases in cost for health care coverage for employees and potential government regulation with respect to health care coverage; shortages of labor or labor disruptions; changes in the desirability of the region in which our hotel is located; changes in the supply and demand for hotel services, including rooms, food and beverage and other products and services; and the costs required for climate change initiatives, including those resulting from regulatory changes or stakeholder or customer expectations.

Any damageof these factors could increase our costs or limit or reduce the prices we are able to charge hotel customers for hospitality products and services, or otherwise affect our reputation orability to maintain our hotel. As a result, any of these factors can reduce our revenues and limit opportunities for growth.

Our efforts to utilize our hotel in Chengdu City to conduct marketing events for customers and training sessions for our employees may not anticipated benefits.

We envision using the hotel we acquired in Chengdu City to conduct marketing events for our customers and training sessions for our personnel. These efforts may not result in increased sales and may not improve our ability to train our personnel.

The failure to enhancemaintain permits and licenses could adversely impact our recognitionoperations.

The manufacture and distribution of food products, and the sale of food and beverages at our hotel, as well as other aspects of our business, require that we maintain various permits and licenses and conduct our operations in accordance with applicable safety requirements and other regulations. Should we be unable to renew any of our licenses and permits, it could have a material adverse effect on our results of operations and the profitability of our business, even if the disruption is for only a limited period of time.

11

We may incur material product liability claims, or experience product recalls, which could increase our costs and adversely affect our sales and margin, reputation, revenues and operating income.

As a retailer, distributor and manufacturer of products for human consumption, we are subject to product liability claims if the use of our products is alleged to result in injury. The products that we sell consist of minerals, herbs, supplements and other ingredients that are classified as foods or dietary supplements. The products that we sell could contain contaminated substances, and some of the products we sell contain ingredients that do not have long histories of human consumption. Previously unknown adverse reactions resulting from human consumption of these ingredients could occur.

In addition, third-party manufacturers produce many of the products we sell. We rely on these manufacturers to ensure the integrity of their ingredients and formulations. As a distributor of quality nutritional products manufactured by third parties, we may also be liable for various product liability claims for products we do not manufacture. Our ultimate liability for these products that are manufactured by third parties depends on a number of factors, including our contractual relationship with the vendor, the creditworthiness of the vendor and any insurance that we have. Therefore, we may be unable to adequately protect ourselves against claims with respect to products manufactured by a third-party.

We may be subject to product liability claims, including, among others, that our products include inadequate instructions for use or inadequate warnings concerning possible side effects and interactions with other substances. Product liability claims could significantly damage our reputation and consumer confidence in our products, regardless of the merits or outcomes of such claims. Our litigation expenses could increase as well, which also could have a material adverse effect on our results of operations even if a product liability claim is unsuccessful or is not fully pursued.

We may be subject to product recalls, withdrawals or seizures if any of the products we manufacture or sell are believed to be adulterated, cause injury or illness or if we are alleged to have violated governmental regulations in the manufacturing, labeling, promotion, sale or distribution of such products. A significant recall, withdrawal or seizure of any of the products may require significant management attention, would likely result in substantial and unexpected costs and may materially and adversely affect our business, financial condition andor results of operations. Furthermore, a recall, withdrawal or seizure of any of the products that we sell may adversely affect consumer confidence in our brands and thus decrease consumer demand for such products.

If we fail to develop and protect our brand names and reputation, we may not attract and retain new customers, which could adversely affect our revenues and financial performance.

We will invest significant resources to promote our brand names to obtain favorable public recognition for us and our products. If we do not achieve the reputation we envision, we may not be able to attract and retain a significant customer base, which could in turn adversely affect our revenues, profitability and the market price of our common stock.

Our ability to adequately protect our trade names and trademarks could have an impact on our brand images and ability to penetrate new markets.

 

We believe that trade names and trademarks will be an important aspect of our business and an essential element of our strategy. We have applied for the registration of many of our trade names, trademarks and patents in China. Some of these applications have been granted and some of these registrations are currently pending approval from the corresponding departments. There can be no assurance that we will obtain such registrations or that the registrations we obtain will prevent the imitation of our products or infringement of our intellectual property rights by others. In particular, the laws of the PRC may not protect proprietary rights to the same extent as the laws of the U.S. Claims that others are infringing our intellectual property would be costly and would divert the attention of management and key personnel. Our failure to successfully protect our trademarks could diminish the value and effectiveness of our past and future marketing efforts and could cause customer confusion. This could in turn adversely affect our revenues, profitability and the market recognition and reputation we achieved have significantly contributed to the successprice of our business. Maintaining and enhancing our reputation is critical to our success and ability to compete. Many factors, some of which are beyond our control, may negatively impact our reputation, such as:common stock.

 

any failure to maintain a pleasant and reliable experience for clients;
any adverse reaction of one or more of our clients to any product we distribute, including reactions caused by the delivery of inferior or adulterated products by one of our suppliers; and
any negative publicity about us, including any actual or perceived product quality problems.12

If we are unable to maintain a good reputation, further enhance our recognition as a distributor of quality nutritional products, continue to develop our user loyalty and increase positive awareness of the products we offer, our results of operations may be materially and adversely affected.

 

Changes in economic conditions andUnfavorable publicity about us or consumer confidence in China may influenceperception of our products, , including the market for nutritional products, consumer preferences and spending patterns.

Our business and revenue growth primarily depend on the size of the market for nutritional products in China. As a result, our revenue and profitability may be negatively affected by changes in national, regional or local economic conditions and consumer confidence in China. In particular, as we focus on our expansion in metropolitan markets, where living standards and consumer purchasing power are relatively high, we are especially susceptible to changes in economic conditions, consumer confidence and customer preferences of the urban Chinese population. External factors beyond our control that affect consumer confidence include unemployment rates, levels of personal disposable income, national, regional or local economic conditions, and acts of war or terrorism. Changes in economic conditions and consumer confidence could adversely affect consumer preferences, purchasing power and spending patterns. A decrease in overall consumer spending as a result of changes in economic conditions could adversely affect our sales of nutritional supplements we distribute, the ingredients they contain and negatively impactany similar products distributed by other companies could cause fluctuations in our profitability. In addition, acts of war or terrorism may cause damage to our facilities, disrupt the supply of the products we marketoperating results and sell or adversely impact consumer demand. Any of these factors could have a material adverse effect on our business, financial conditionreputation, the demand for our products and resultsour ability to generate revenues and the market price of operations.

11

We may not be able to timely identify or otherwise effectively respond to changing customer preferences, and we may fail to optimize our product offering and inventory position.common stock.

 

The market for nutritional products in China is rapidly evolvingWe are highly dependent upon consumer perception of the safety and is subject to rapidly changing customer preferences that are difficult to predict. Our success depends on our ability to anticipate and identify customer preferences and adapt our product selection to meet these preferences. In particular, we must optimize our product selection and inventory positions based on sales trends. We cannot provide assurance that our product selection will accurately reflect customer preferences at any given time. If we fail to accurately anticipate either the market forquality of our products, including our nutritional supplements, and the ingredients they contain, as well as that of similar products distributed by other companies. Consumer perception of products and the ingredients they contain can be significantly influenced by scientific research, national media attention and other publicity, including that generated via social media. A research report or customers’ purchasing habits or fail to respond to customers’ changing preferences promptly and effectively, we may not be able to adapt our product selection to customer preferences or make appropriate adjustmentspublicity related to our inventory positions, whichproducts and the ingredients they contain that is perceived by our consumers as less favorable or that questions earlier favorable research or publicity could significantly reduce our revenue and have a material adverse effect on our business, financial conditionability to generate revenues. . Adverse publicity, in the form of published scientific research or otherwise, whether or not accurate, that associates consumption of our products or the ingredients they contain or similar products distributed by other companies with illness or other adverse effects, that questions the benefits of our or similar products, or that claims that such products are ineffective could have a material adverse effect on our reputation, the demand for our products, our ability to generate revenues and the market price of our common stock.

We may be subject to health or advertising claims related to our customers.

Our products do are not medical treatments and we do not provide or medical advice, and we do not engage physicians or nurses to monitor the progress of our customers. A customer who uses our products and experiences health problems could allege or bring a lawsuit against us on the basis that those problems were caused or worsened by using our products. Further, customers who allege that they were deceived by any statements that we made in advertising or labeling could bring a lawsuit against us under consumer protection laws. We may ultimately be unsuccessful in defending ourselves against such claims. Also, defending ourselves against such claims, regardless of their merit and ultimate outcome, may be lengthy and costly, and could adversely affect our brand image, customer loyalty and results of operations.

 

We market a relatively fewrely on third parties to provide us with nutritional products from a limited numbersupplements, fulfillment, customer service and Internet and networking services, the loss of manufacturers.any of which could cause our revenue, earnings or reputation to suffer.

 

In addition to the nutritional supplements we manufacture, we rely on third-parties to supply us with additional manufacturer the nutritional supplements we sell. We currently mainly offerdo not know if our vendors vendor directly sells the same product under a limited numberdifferent brand or provides their supplements to other parties under private label brands. In each of nutritionalthese instances, sales of the same product under different brands could cause us to lose revenues and health productsadversely impact our abilities to market our products. While we believe we could locate replacement suppliers for all supplements we acquire from third parties, it would likely take time to engage replacement suppliers which could adversely impact our revenues during such transition period and there are no assurances our costs would not increase to a limited numberlevel which makes the product unattractive to our customers.

We depend on the services of manufacturers. Unless we are able to significantly increase the number of nutritionalkey executives and other products we market and sell and the number of manufacturers who distribute their products through our distribution channel, we will be unable to increase our revenues.

Our business depends substantially on the continuing efforts of our executive officers and key employees,skilled professionals and our ability to attract, train and retain highly qualified associates. Any failure to attract or retain such individuals could affect our business may be severely disrupted if we lose their services.strategy and adversely impact our performance and results of operations.

 

We currently depend onOur senior executives are instrumental in setting our strategic direction, operating our business, identifying, recruiting and training personnel, identifying opportunities, designing new products and arranging necessary financing. In addition, other key employees below the continued services and performance of the key membersexecutive level, with deep knowledge of our management team, in particular Mr. Quanzhong Lin, our Presidentbusiness, are critical to the execution and Chief Executive Officer (“CEO”). Mr. Lin is our founder and his leadership has played an integral role in our growth. Our future success depends substantially on the continued efforts of our executive officersstrategy. We must attract, train and key employees. If one or moreretain a growing number of qualified individuals.

13

Losing the services of any of these groups of individuals could adversely affect our executive officers or key employees werebusiness and we may be unable or unwilling to continue their service, we might not be able to replace them easily,identify candidates of sufficient experience and capabilities in a timely manner,fashion or at all, andwhich could negatively impact our business may be severely disrupted,and operations. Further, our financial conditionsability to control labor and results of operations may be materiallybenefit costs is subject to numerous external factors, including regulatory changes, prevailing wage rates, and adversely affectedhealthcare and we may incur additional expenses to recruit, trainother insurance costs. We compete with other retail and retain personnel.

Our current management may have no experiencenon-retail businesses for these store and field associates and invest significant resources in operating businesses we may acquire.

If we acquire a new business, it may be in an industry in which our management has no experience. In such event, we may need to engage new management personnel to manage such business.training and motivating them. There is no assurance that we will be able to retain the services of qualified individuals or that they will be able to integrate with our current management and successfully operate our new business and that our current management will not be distracted from operating our current businesses. Any failure to attract new or retain key these individualsqualified store and field associates in the future, which could have a material adverse effect on our business, financial condition and results of operations.

 

There are risks associatedCompliance with offering new products.and existing laws and governmental regulations could increase our costs significantly and adversely affect our results of operations.

 

The processing, formulation, safety, manufacturing, packaging, labeling, advertising and distribution of our products are subject to numerous Chinese laws and regulations as well as laws and regulations imposed by provincial and local governments and agencies. Government regulations may prevent or delay the introduction, or require the reformulation, of newour products, typically carries risks associated with determining whether there will be consumer acceptancewhich could result in lost revenues and increased costs to us. Manufacturers and distributors of health and wellness products and dietary supplements and dietary ingredients are prohibited from marketing products that are adulterated or misbranded, and the appropriate pricing strategygoverning agencies may take enforcement action against any adulterated or misbranded health and wellness product or dietary supplement on the establishmentmarket. If we violate applicable regulatory requirements, we may be subject to enforcement actions against us, which could have a material adverse effect on our business, prospects, financial condition, and results of reliable sourcesoperations. The government may not accept the evidence of supply. In addition,safety for any new product or ingredient we may wish to market, may determine that a particular product or ingredient presents an unacceptable health risk based on reported serious adverse events or other information, and may determine that a particular claim or statement of efficacy or nutritional value that we use to support the marketing of a product is not substantiated, or is an unauthorized version of a “health claim.” Any of these actions could prevent us from marketing particular products or making certain claims or statements with respect to those products. We could also be required to remove a particular product from the market. Any future recall or removal would result in costs to us, including lost revenues from any products that we are required to remove from the market, any of which could be material. Any product recalls or removals could also lead to an increased risk of litigation and liability, substantial costs, and reduced growth prospects.

Additional or more stringent laws and regulations of health and wellness products have been considered from time to time. These developments could require reformulation of some products to meet new standards, recalls or discontinuance of some products not able to be reformulated, additional record-keeping requirements, increased documentation of the properties of some products, additional or different labeling, additional scientific substantiation, or other new requirements. Any of these developments could increase our costs significantly. In addition, regulators’ evolving interpretation of existing laws could have similar effects.

We depend upon a limited number of suppliers for certain raw materials and any disruption to our timely receipt of raw materials and inventory could adversely impact sales and operations or increase our transportation costs, which would decrease our profits.

We depend upon a limited number of suppliers for the raw materials necessary to produce certain of our products. Unexpected delays in the deliveries of raw materials from our vendors or inventories or increases in transportation costs (including through increased fuel costs) could significantly decrease our ability to make sales and earn profits. We must maintain sufficient levels of raw materials and inventories to operate our business successfully. However, we also must guard against accumulating excess inventory. If we fail to gain acceptance after significant expenditures are made. Ifanticipate accurately either the market for the merchandise we are unsuccessful in identifying new products that appealoffer or our customers’ purchasing habits, we may be forced to our clients, thenrely on markdowns or promotional sales to dispose of excess or slow moving inventory, which could have a material adverse effect on our business, financial condition, and results of operations.

In addition, sales of adulterated products received from third parties could result in a product liability judgment or a widespread product recall that may negatively impact our sales and profitability for a period of time depending on product availability, competition reaction and consumer attitudes. Even if the product liability claim is unsuccessful or is not fully pursued, the negative publicity surrounding any assertions could adversely impact our reputation with existing and potential customers and our brand image.

Natural disasters (whether or not caused by climate change), unusually adverse weather conditions, pandemic outbreaks and terrorist acts in China and the response of the Chinese governments to such occurrences, could impair our ability to purchase, receive or replenish inventory or raw materials or cause customer traffic to decline, all of which could result in lost sales and otherwise adversely affect our financial performance.

The occurrence of one or more natural disasters, such as hurricanes, fires, floods and earthquakes (whether or not caused by climate change), unusually adverse weather conditions, pandemic outbreaks (including the outbreak of the coronavirus, or COVID-19) or terrorist acts in China and the response of the Chinese government to such occurrences, could adversely affect our operations and financial performance. To the extent these events result in the closure of one or more of our pharmacies, manufacturing facility or our corporate headquarters, or impact one or more of our key suppliers, our operations and financial performance could be materially adversely affected through lost sales. Such events could also cause a disruption in travel making it difficult for consumers to order our products, such as has happened as a result of recent lock-downs in Chengdu. In addition, these events could result in increases in fuel (or other energy) prices or a fuel shortage, the temporary lack of an adequate work force in a market, the temporary or long-term disruption in the supply of products from some suppliers, the temporary disruption in the transport of goods, the temporary reduction in the availability of products in our stores, expiration of inventory and disruption to our information systems.

14

We rely on third parties for the vast majority of our computing, storage, and other services related to our business. Any disruption of or interference with our use of the services of these third parties would negatively affect our operations and could seriously harm our business.

We rely upon third parties, including cloud based platforms and services, to process and store information and for online interactions with our customers. Any transition of the cloud services currently provided by the parties we rely upon to other platforms or to another cloud provider could be difficult to implement and would cause us to incur significant time and expense. Given this, any significant disruption of or interference with the cloud based services utilized by us, whether temporary, regular, or prolonged, would negatively impact our operations and our business would be seriously harmed.

As we increase the amount of personal and user data we store and process, we may become subject to complex and evolving laws, regulations, executive actions, rules, contractual obligations, policies, and other obligations regarding privacy, data protection, content, and other matters. Many of these obligations are subject to change and uncertain interpretations.

Currently, we collect, store, and use limited amounts of personal data and other sensitive information. As our business grows and we increase the amount of such data collect, store and use, we will become subject to a variety of laws, regulations, industry standards, policies, contractual requirements, executive actions, and other obligations relating to privacy, security, and data protection which are becoming increasingly stringent and subject to rapid change and uncertain interpretation. Preparing for and complying with these obligations could require us to devote significant resources. These obligations may necessitate changes to our services, information technologies, systems, and practices. In addition, these obligations may require us to change our business model.

Cyber-attacks could have a disruptive effect on our business.

From time to time we and our third-party service providers experience cyber-attacks, attempted and actual breaches of our or their information technology systems and networks or similar events, which could result in a loss of sensitive business or customer information, systems interruption or the disruption of our operations. The techniques that are used to obtain unauthorized access, disable or degrade service or sabotage systems change frequently and may be difficult to detect for long periods of time, we are accordingly unable to anticipate and prevent all data security incidents.

Even if we are fully compliant with legal standards and contractual or other requirements, we still may not be able to prevent security breaches involving sensitive data. The sophistication of efforts by hackers to gain unauthorized access to information systems has continued to increase in recent years and may continue to do so. Breaches, thefts, losses or fraudulent uses of customer, employee or company data could cause consumers to lose confidence in the security of our websites, mobile applications, point of sale systems and other information technology systems and, as a result of this loss in confidence, choose not to purchase from us. Such security breaches also could expose us to risks of data loss, business disruption, litigation, fines, regulatory charges and other costs or liabilities, any of which could adversely affect our business.

Our business may be materially adversely affected by global geopolitical conditions resulting from the ongoing Russia-Ukraine conflict and the Israel-Hamas conflict.

Global markets are experiencing volatility and disruption as a result of the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the Israel-Hamas conflict. The invasion of Ukraine by Russia and the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.

15

Any of the abovementioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect our business. The extent and duration of the ongoing conflicts, resulting sanctions and any related market disruptions are impossible to predict, but could be substantial, particularly if current or new sanctions continue for an extended period of time or if geopolitical tensions result in expanded military operations on a global scale. Any such disruptions may also have the effect of heightening many of the other risks described in this section. If these disruptions or other matters of global concern continue for an extensive period of time, our business may be materially adversely affected.

We may be impacted by our ability to attract, develop and retain qualified associates and manage labor-related costs.

We believe one of our competitive advantages is providing a positive, engaging and satisfying experience for each customer, which requires us to have highly trained and engaged associates. Our success depends in part upon our ability to attract, develop and retain a sufficient number of qualified associates to enable us to grow our customer base. The turnover rate in the health and wellness industry is generally high, and qualified individuals of the requisite caliber and number needed may be in short supply. Competition for such qualified individuals or changes in labor laws could require us to incur higher labor costs. Our inability to recruit a sufficient number of qualified individuals may delay the expansion of our customer base and our growth. Significant increases in associate turnover rates or significant increases in labor-related costs could have a material adverse effect on our results of operations, financial condition and cash flows.

Large and similar sized competitors could steal our market share by offering lower prices.

We endeavor to provide high quality service to our clients at the best possible price, however, large and similar sized competitors might steal some of our market share by offering lower prices, causing us to lose some of our clients which could have a material adverse effect on our results of operations, financial condition and cash flows.

Our insurance may not be sufficient.

We carry insurance that we consider adequate in regard to the nature of the covered risks and the costs of coverage. We are not fully insured against all possible risks, nor are all such risks insurable.

Our business depends on the continued contributions made by Mr. Quanzhong Lin, our key executive officer. The loss of his services may result in a severe impediment to our business.

Our success is dependent upon the continued contributions made by our CEO and President, Mr. Quanzhong Lin. The Company has no “Key Man” insurance to cover the resulting losses in the event that any of our officer or directors should die or resign.

If Mr. Lin cannot serve the Company or is no longer willing to do so, the Company may not be able to find alternatives in a timely manner or at all. This would likely result in a severe damage to our business operations and would have an adverse material impact on our financial position and operational results. To continue as a viable operation, the Company may have to recruit and train replacement personnel at a higher cost.

Our key executive does not devote his full business time to our operationsoperations..

 

Mr. Quanzhong Lin, ourOur President and Chief Executive Officer, Mr. Quanzhong Lin, is involved in a number of businesses and does not devote all of his working time to our operations.business. Our positive reputation in Chengdu is derived from the standing of Mr. Lin’s business success and standingLin in the Chengdu business community. If Mr. Lin does not devote sufficient attentiontime to our business, our operations could suffer andwhich would have an adverse material impact on our financial conditionsposition and results of operations may be materially and adversely affected. If Mr. Lin’s other businesses should fail or if his reputation in the community should be impaired, our business could suffer and our financial conditions and results of operations may be materially and adversely affected.operational results.

 

1216

 

Some of the other businesses operatedengaged in by Mr. Lin or his affiliates maycould be deemed competitorscompetitive with aspects of ours.

Mr. Quanzhong Lin is engaged in other businesses.our business. Should such other businesses prove more successful than ours, Mr. Lin could choose to focus his attention on such businesses which could cause him to fail to devote sufficient attention to our business and our operations could suffer and our financial conditions and results of operations may be materially and adversely affected

Our principal shareholder is not familiar with American business practices.

 

Mr. Quanzhong Lin, our founder and principal shareholder, is a citizen of the PRC and an active entrepreneur in Chengdu. Mr. Lin is not familiar with American business practices and is heavily influenced by the business culture in the PRC. Certain governmental entities pay bonuses or subsidies to individuals in China whose companies become publicly traded in America and thereThere is a certain level of respect and prestige associated with being the Chinese principal of a company which is publicly traded in the U.S. Mr. Lin’s motivation for causing the business of AiXinZhongdong to become a part of a U.S. publicly-traded company may differ from those of American entrepreneurs and his values may cause him to operate the business differently than would an American entrepreneur.entrepreneur which could have a material adverse effect on our results of operations, financial condition and cash flows

 

We may be adversely impacted by certain compliance or legal matters.

We, along with third parties with which we do business, are subject to complex compliance and litigation risks. The cost of defending against claims that might be brought against us or the ultimate resolution of such claims, whether by settlement or adverse court decision, may harm our business. Further, potential claimants may be encouraged to bring lawsuits based on a settlement from us or adverse court decisions against us. We cannot currently assess the likely outcome of such suits, but if the outcome were negative, it could have a material adverse effect on our reputation, results of operations, financial condition and cash flows.

In addition, we may be impacted by litigation trends, including class action lawsuits involving consumers and shareholders, that could have a material adverse effect on our reputation, the market price of our common stock, results of operations, financial condition and cash flows.

Failure to make adequate contributions to various employee benefits plans as required by PRC regulations may subject us to penalties.

Companies operating in China are required to participate in various government sponsored employee benefit plans, including certain social insurance, housing funds and other welfare-oriented payment obligations, and contribute to the plans in amounts equal to certain percentage of salaries, including bonuses and allowances, of employees up to a maximum amount specified by the local government from time to time at locations where they operate their businesses. The requirement of employee benefit plans has not been implemented consistently by the local governments in China given the different levels of economic development in different locations. Employers that fail to make adequate social insurance and housing provident fund contributions may be subject to late payment fees, fines and sanctions. If the relevant PRC authorities determine that we need to make supplemental contributions or that we are subject to late payment fees, fines or other legal sanctions, such as order of timely rectification, in relation to our failure to make social insurance and housing fund contributions in full for our employees, our business and financial condition may be adversely affected.

17

Our common stock may be delisted under the Holding Foreign Companies Accountable Act if the PCAOB is unable to attract, train and retain qualified personnel,inspect our businessauditors. The delisting of our common stock or the threat of their being delisted, may be materially and adversely affected.affect the value of your investment.

The HFCAA was enacted on December 18, 2020. The HFCAA, as amended, states if the SEC determines that a company has filed audit reports issued by a registered public accounting firm that has not been subject to inspection by the PCAOB for two consecutive years beginning in 2021, the SEC shall prohibit the securities of such company from being traded on a national securities exchange or in the over the counter trading market in the U.S. On June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act which, if enacted, would amend the HFCAA and require the SEC to prohibit an issuer’s securities from trading on any U.S. stock exchange if its auditor is not subject to PCAOB inspections for two consecutive years instead of three.

On March 24, 2021, the SEC adopted interim final rules relating to the implementation of certain disclosure and documentation requirements of the HFCAA. A company will be required to comply with these rules if the SEC identifies it as having a “non-inspection” year under a process to be subsequently established by the SEC. The SEC is assessing how to implement other requirements of the HFCAA, including the listing and trading prohibition requirements described above. On September 22, 2021, the PCAOB adopted a final rule implementing the HFCAA, which provides a framework for the PCAOB to use when determining whether the PCAOB is unable to inspect or investigate completely registered public accounting firms located in a foreign jurisdiction because of a position taken by one or more authorities in that jurisdiction.

On December 2, 2021, the SEC issued amendments to finalize rules implementing the submission and disclosure requirements in the HFCAA. The rules apply to registrants that the SEC identifies as having filed an annual report with an audit report issued by a registered public accounting firm that is located in a foreign jurisdiction and that PCAOB is unable to inspect or investigate completely because of a position taken by an authority in foreign jurisdictions. On December 16, 2021, the PCAOB issued a Determination Report which found that the PCAOB is unable to inspect or investigate completely registered public accounting firms headquartered in: (i) China, and (ii) Hong Kong. On August 26, 2022, the CSRC, the Ministry of Finance of the PRC, and the PCAOB signed a Statement of Protocol, or the Protocol, governing inspections and investigations of audit firms based in China and Hong Kong. Pursuant to the Protocol, the PCAOB shall have independent discretion to select any issuer audits for inspection or investigation and has the unfettered ability to transfer information to the SEC. Notwithstanding the foregoing, if the PCAOB is not able to inspect and investigate completely our auditor’s work papers in China, you may be deprived of the benefits of such inspection which could result in limitation or restriction to our access to the U.S. capital markets and trading of our securities may be prohibited under the HFCAA and the Nasdaq may determine to delist our securities if the PCAOB determines that it cannot inspect or investigate completely our auditor under the HFCAA.

 

Our future success depends,auditor is not headquartered in China or Hong Kong and was not identified in this report as a firm subject to the PCAOB’s determination.

The SEC may propose additional rules or guidance that could impact us if our auditor is not subject to PCAOB inspection. For example, on August 6, 2020, the President’s Working Group on Financial Markets, or the PWG, issued the Report on Protecting United States Investors from Significant Risks from Chinese Companies to the then President of the United States. This report recommended the SEC implement five recommendations to address companies from jurisdictions that do not provide the PCAOB with sufficient access to fulfil its statutory mandate. Some of the concepts of these recommendations were implemented with the enactment of the HFCAA. However, some of the recommendations were more stringent than the HFCAA. For example, if a significant extent,company’s auditor was not subject to PCAOB inspection, the report recommended that the transition period before a company would be delisted would end on our abilityJanuary 1, 2022.

The SEC has announced that the SEC staff is preparing a consolidated proposal for the rules regarding the implementation of the HFCAA and to attract, trainaddress the recommendations in the PWG report. The implications of possible additional regulation in addition to the requirements of the HFCAA and retain qualified personnel, particularly management, technicalwhat was recently adopted on December 2, 2021 are uncertain. While we understand that there has been dialogue among the CSRC, the SEC and marketing personnelthe PCAOB regarding the inspection of PCAOB-registered accounting firms in China, there can be no assurance that we will be able to comply with expertise in nutritional products. Our sales and customer service teams are critical to maintainingrequirements imposed by U.S. regulators. Such uncertainty could cause the qualitymarket price of our services as they frequently interact with our clients. We must continuecommon stock to attract qualified personnel at a fast pace to increase the number of our clients and products we distribute. As we are still a relatively young company, our ability to train and integrate new employees into our operations may not meet the growing demands of our business. If we are unable to attract, train, and retain qualified personnel, our business may be materially and adversely affected.

 

18

Our business, financial condition and results of operations, as well as our ability to obtain financing, may be adversely affectedA joint statement by the downturn inSEC and the globalPublic Company Accounting Oversight Board (United States), or Chinese economy.the “PCAOB,” the newly enacted “Holding Foreign Companies Accountable Act” and the Accelerating Holding Foreign Companies Accountable Actall call for additional and more stringent criteria to be applied to emerging market companies upon assessing the qualification of their auditors, especially the non-U.S. auditors who are not inspected by the PCAOB. These developments could add uncertainties to the market for our common stock.

 

It is unclear whetherOn April 21, 2020, the Chinese economy will resume its high growth rate afterSEC and the impactPCAOB released a joint statement highlighting the risks associated with investing in companies based in or having substantial operations in emerging markets including China. The joint statement emphasized the risks associated with lack of Covid-19 dissipates. There is considerable uncertainty overaccess for the long-term effects of the expansionary monetaryPCAOB to inspect auditors and fiscal policies that have been adopted by the central banks and financial authorities of some of the world’s leading economies, including the United States. Economic conditionsaudit work papers in China are sensitive to global economic conditions, as well as changesand higher risks of fraud in domestic economic and political policies and the expected or perceived overall economic growth rate in China.emerging markets.

 

The saleOn December 18, 2020, the HFCAA was signed and became law. This legislation requires certain issuers of nutritional productssecurities to establish that they are not owned or controlled by a foreign government. Specifically, an issuer must make this certification if the PCAOB is unable to audit specified reports because the issuer has retained a foreign public accounting firm not subject to inspection by the PCAOB. Furthermore, if the PCAOB is unable to inspect the issuer’s public accounting firm for three consecutive years, the issuer’s securities are banned from trading on a national exchange or through other methods. On December 29, 2022, the AHFCAA was enacted, which amended the HFCAA by decreasing the number of non-inspection years from three years to two, thus reducing the time period before our common stock may be affectedprohibited from trading or delisted if the PCAOB were to determine that it could not inspect our auditor.

On March 24, 2021, the SEC announced that it had adopted interim final amendments to implement congressionally mandated submission and disclosure requirements of the HFCAA. The interim final amendments will apply to registrants that the SEC identifies as having filed an annual report on Forms 10-K, 20-F, 40-F or N-CSR with an audit report issued by economic downturns. Our productsa registered public accounting firm that is located in a foreign jurisdiction and that the PCAOB has determined it is unable to inspect or investigate completely because of a position taken by an authority in that jurisdiction. The SEC will implement a process for identifying such a registrant and any such identified registrant will be required to submit documentation to the SEC establishing that it is not owned or controlled by a governmental entity in that foreign jurisdiction, and will also require disclosure in the registrant’s annual report regarding the audit arrangements of, and governmental influence on, such a registrant.

On September 22, 2021, the PCAOB adopted rules to create a framework for the PCAOB to use when determining, as contemplated under the HFCAA, whether it is unable to inspect or investigate completely registered public accounting firms located in a foreign jurisdiction because of a position taken by one or more authorities in that jurisdiction.

On December 2, 2021, the SEC issued amendments to finalize the interim final rules previously adopted in March 2021 to implement the submission and disclosure requirements in the HFCAA. The rules apply to registrants that the SEC identifies as having filed an annual report with an audit report issued by a registered public accounting firm that is located in a foreign jurisdiction and that the PCAOB is unable to inspect or investigate completely because of a position taken by an authority in a foreign jurisdiction.

On December 16, 2021, the PCAOB issued a Determination Report which found that the PCAOB was then unable to inspect or investigate completely registered public accounting firms headquartered in: (1) mainland China of the People’s Republic of China, because of a position taken by one or more authorities in mainland China; and (2) Hong Kong, a Special Administrative Region and dependency of the PRC, because of a position taken by one or more authorities in Hong Kong. The PCAOB has made such designations as mandated under the HFCAA. Pursuant to each annual determination by the PCAOB, the SEC will, on an annual basis, identify issuers that have used non-inspected audit firms and thus are at risk of such suspensions in the future.

On August 26, 2022, the CSRC, the Ministry of Finance of the PRC, and the PCAOB signed a Statement of Protocol, or the Protocol, governing inspections and investigations of audit firms based in China and Hong Kong. Pursuant to the Protocol, the PCAOB shall have independent discretion to select any issuer audits for inspection or investigation and has the unfettered ability to transfer information to the SEC. On December 15, 2022, the PCAOB determined that the PCAOB was able to secure complete access to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong and voted to vacate its previous determinations to the contrary. However, should PRC authorities obstruct or otherwise fail to facilitate the PCAOB’s access in the future, the PCAOB will consider the need to issue a new determination. Notwithstanding the foregoing, if the PCAOB is not able to inspect and investigate completely our auditor’s work papers in China, you may be vieweddeprived of the benefits of such inspection which could result in limitation or restriction to our access to the U.S. capital markets and trading of our securities may be prohibited under the HFCAA.

19

Our auditor, KCCW Accountancy Corp. (“KCCW CPA”), an independent public accounting firm registered with the PCAOB, and an auditor of publicly traded companies in the U.S., is subject to laws in the U.S. pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable professional standards. Our auditor is based in the United States and has been inspected by the PCAOB on a regular basis, with the last inspection in 2022. Our auditor is not headquartered in mainland China or Hong Kong and was not identified as discretionarya firm subject to the determinations announced by the PCAOB on December 16, 2021. Nevertheless, should the PCAOB be unable to fully conduct inspection of our clients, whoauditor’s work papers in China, it will make it difficult to evaluate the effectiveness of our auditor’s audit procedures or equity control procedures. Investors may chooseconsequently lose confidence in our reported financial information and procedures or quality of the financial statements, which would adversely affect us and our securities. Moreover, if trading in our securities is prohibited under the HFCAA in the future because the PCAOB determines that it cannot inspect or fully investigate our auditor at such future time, if our securities were then traded on an exchange, that exchange may determine to discontinuedelist our securities.

There are uncertainties under the PRC Securities Law relating to the procedures and requisite timing for the U.S. securities regulatory agencies to conduct investigations and collect evidence within the territory of the PRC.

On December 28, 2019, the newly amended Securities Law of the PRC (the “PRC Securities Law”) was promulgated, which became effective on March 1, 2020. According to Article 177 of the PRC Securities Law (“Article 177”), the securities regulatory authority of the State Council may establish a regulatory cooperation mechanism with securities regulatory authorities of another country or reduce spendingregion for the implementation of cross-border supervision and administration. Article 177 further provides that overseas securities regulatory authorities shall not engage in activities pertaining to investigations or evidence collection directly conducted within the territories of the PRC, and that no Chinese entities or individuals shall provide documents and information in connection with securities business activities to any organizations and/or persons aboard without the prior consent of the securities regulatory authority of the State Council and the competent departments of the State Council. As of the date of this prospectus, we are not aware of any implementing rules or regulations which have been published regarding application of Article 177.

Article 177 is only applicable where the activities of overseas authorities constitute a direct investigation or evidence collection by such authorities within the territory of the PRC. Our principal business operation is conducted in the PRC. In the event that the U.S. securities regulatory agencies carry out an investigation on us such products duringas an economic downturn.enforcement action by the Department of Justice, the SEC or other authorities, such agencies’ activities will constitute conducting an investigation or collecting evidence directly within the territory of the PRC and accordingly fall within the scope of Article 177. In that case, the U.S. securities regulatory agencies may have to consider establishing cross-border cooperation with the securities regulatory authority of the PRC by way of judicial assistance, diplomatic channels or establishing a regulatory cooperation mechanism with the securities regulatory authority of the PRC. However, there is no assurance that the U.S. securities regulatory agencies will succeed in establishing such an event, our abilitycross-border cooperation in this particular case and/or establish such cooperation in a timely manner.

Furthermore, there have not been implementing rules or regulations regarding the application of Article 177, and it remains unclear as to retain existing clients and increase or maintain our saleshow it will be adversely affected,interpreted, implemented or applied by the Chinese Securities Regulatory Commission or other relevant government authorities. As such, there are uncertainties as to the procedures and requisite timing for the U.S. securities regulatory agencies to conduct investigations and collect evidence within the territory of the PRC. If the U.S. securities regulatory agencies are unable to conduct such investigations, there exists a risk that they may determine to suspend or de-register our registration with the SEC and may also delist our securities from any applicable trading market within the US.

We could be subject to conflicting demands placed upon us by regulatory authorities in the United States and the PRC which could result in disciplinary actions if not resolved.

Article 26 of the Trial Measures issued by the CSRC on February 17, 2023 came into effect on March 31, 2023. Article 26 provides that if an overseas securities regulatory agency intends to conduct an investigation and collect evidence regarding an overseas offering or listing activities by a domestic company, and request assistance of the CSRC under relevant cross-border securities regulatory cooperation agreements, the CSRC may provide necessary assistance in accordance with the laws of the PRC. Any domestic entity or individual intending to provide documents and materials requested by an overseas securities regulatory agency in connection with an investigation may not provide such information without prior approval from the CSRC and competent authorities under the State Council. In addition, Article 11 of the Provisions on Strengthening Confidentiality and Archives Administration in Respect of Overseas Issuance and Listing of Securities by Domestic Enterprises which was jointly issued by the CSRC, the Ministry of Finance, the State Secrecy Administration and the State Archives Bureau on February 24, 2023 came into effect on March 31, 2023, and provides that, when an overseas securities regulator and the relevant competent authorities intends to conduct inspections or investigations to collect evidence from a domestic enterprise and any domestic securities firms and securities service agencies providing services regarding the overseas offering and listing activities of the domestic enterprise, the inspection or investigation shall be carried out under the appropriate cross-border regulatory cooperation agreement, and the CSRC or the relevant authorities shall provide the requisite assistance pursuant to the bilateral and multilateral cooperation mechanism. Further, any domestic company, securities firm and securities service agency shall obtain the consent of the CSRC or the relevant administrative authorities prior to cooperating in an inspection or investigation carried out by an overseas securities regulator or relevant administrative authorities or providing documents and materials for cooperating in the inspection or investigation.

20

As this regulation has recently been adopted, clarifying regulations have not been issued and companies in China and their counsel generally have little experience in assessing when permission must be obtained before releasing information to a foreign regulatory agency. If the Company were to provide information to any securities regulatory agency in violation of Article 26 or Article 11, it would be subject to fines and, if the information were deemed a state secret, government work secret or might jeopardize the national security of China or the public interest, as provided in turn negatively impactthe Confidentiality and Archives Provisions, it could cause the Company or the individuals responsible for the disclosure to be subject to criminal investigation. Likewise, if the Company refuses to provide information requested by any U.S. securities regulatory agency in circumstances that the Company believes would have caused it to violate Article 26 or Article 11, it will be subject in the United States to fines, penalties. While detailed interpretation of or implementation rules under Article 177, of Article 26 and Article 11 have yet to be promulgated, the inability of an overseas securities regulator to directly conduct an investigation or evidence collection activities within China may further increase difficulties that you may face in protecting your interests.

We are exposed to liabilities relating to environmental protection and safety laws and regulations.

Our operations are subject to comprehensive and frequently changing laws and regulations relating to environmental protection and health and safety. The discharge of waste and pollutants from our manufacturing operations into the environment may give rise to liabilities that may require us to incur costs to remedy such discharge. If we violate such laws or regulations, we may be required to implement corrective actions and could be subject to civil or criminal fines or penalties or other sanctions.

However, we cannot assure you that any environmental laws adopted in the future will not materially increase our operating costs and other expenses. We cannot assure you that we will not have to make significant capital or operating expenditures in the future in order to comply with existing or new laws and regulations or that we will comply with applicable environmental laws at all times. Such violations or liability could have a material adverse effect on our business, financial condition and results of operations.

 

Moreover, a slowdown or disruption in the global or China’s economyWe may have a materialrequire additional financing and adverse impact onour operations could be curtailed if we are unable to obtain required additional financing available to us. There is a risk that our business, results of operations and prospects would be materially and adversely affected by any global economic downturn or disruption or slowdown of China’s economy.

Future strategic alliances or acquisitions may have a material and adverse effect on our business, reputation and results of operations.when needed.

 

We may need to obtain additional debt or equity financing to fund the immediate development of Yunnan Runcangsheng and future capital expenditures. While we do not anticipate seeking additional financing in the immediate future, enter into strategic alliances with various third partiesany the issuance of additional equity securities may result in dilution to furtherthe holders of our outstanding shares of capital stock. Additional debt financing may include conditions that would restrict our freedom to operate our business, purposes from time to time. Strategic alliances with third parties could subject us to a number of risks, including risks associated with sharing proprietary information, non-performance by the counter-party, and an increase in expenses incurred in establishing new strategic alliances, any of which may materially and adversely affect our business. In addition, to the extent the strategic partner suffers negative publicity or harm to their reputation from events relating to their business, we may also suffer negative publicity or harm to our reputation by virtue of our association with such third parties, and we may have little ability to control or monitor their actions.as conditions that:

limit our ability to pay dividends or require us to seek consent for the payment of dividends;
increase our vulnerability to general adverse economic and industry conditions;
require us to dedicate a portion of our cash flow from operations to payments on our debt, thereby reducing the availability of our cash flow to fund capital expenditures, working capital and other general corporate purposes; and
limit our flexibility in planning for, or reacting to, changes in our business and our industry.

 

1321

 

In addition, althoughWe cannot guarantee that we have no current acquisition plans, if we are presented with appropriate opportunities, we may acquirewill be able to obtain any additional assets, products, technologies or businessesfinancing on terms that are complementaryacceptable to our existing business, including businesses that are ownedus, or controlled by Mr. Lin or his affiliates. Future acquisitions and the subsequent integration of new assets and businesses into our own would require significant attention from our management and could result in a diversion of resources from our existing business, which in turn could have an adverse effect on our business operations. Acquired assets or businesses may not generate the financial results we expect. Furthermore, acquisitions could result in the use of substantial amounts of cash, potentially dilutive issuances of equity securities, the occurrence of significant goodwill impairment charges, amortization expenses for other intangible assets and exposure to potential unknown liabilities of the acquired business. Moreover, the costs of identifying and consummating acquisitions may be significant. In addition to possible shareholders’ approval, we may also have to obtain approvals and licenses from the relevant government authorities in the PRC for the acquisitions and to comply with any applicable PRC laws and regulations, which could result in increased costs and delay.

If we or our PRC subsidiaries acquire any domestic companies in China, such acquisition will be subject to PRC laws and regulations on foreign investment. We and our PRC subsidiaries are restricted or prohibited from directly acquiring interests in companies in certain industries under PRC laws and regulations. Our consolidated affiliated entities outside of the PRC are not subject to PRC laws and regulations on foreign investment and may acquire PRC companies operating in industries where foreign investments are restricted or prohibited. However, there are uncertainties with respect to the interpretation and application of PRC laws and regulations regarding indirect foreign investments in such industries.

We have limited business insurance coverage.

Insurance companies in China currently do not offer as extensive an array of insurance products as insurance companies do in more developed economies. We do not have any business liability or disruption insurance to cover our operations. We have determined that the costs of insuring for these risks and the difficulties associated with acquiring such insurance on commercially reasonable terms make it impractical for us to have such insurance. Any uninsured occurrence of business disruption may result in our incurring substantial costs and the diversion of resources, which could have an adverse effect on our results of operations and financial condition.at all.

 

General Risks Related to DoingAssociated with Business Operations in China

 

The PRC government exerts substantial influencehas significant oversight and discretion over the mannerconduct of a PRC company’s business operations or to exert control over any offering of securities conducted overseas and/or foreign investment in which we must conductChina-based issuers, and may intervene with or influence our business activities.operations, may limit or completely hinder our ability to offer or continue to offer securities to investors, and may cause the value of such securities to significantly decline or become worthless, as the government deems appropriate to further regulatory, political and societal goals.

 

The PRC government may intervene or influence our operations at any time, which could result in a material change in our operations and/or the value of our common stock. For example, the PRC government has exercisedrecently published new policies that significantly affected certain industries such as the education and continuesinternet industries, and we cannot rule out the possibility that the PRC government will release regulations or policies regarding any industry that could adversely affect the business, financial condition and results of operations of our company. Furthermore, the PRC government has also recently indicated an intent to exercise substantialexert more oversight and control over virtually every sector ofsecurities offerings and other capital markets activities that are conducted overseas and foreign investment in China-based companies. Any such action, once taken by the Chinese economy through regulation and state ownership. OurPRC government, could significantly limit or completely hinder our ability to operate in China may be harmed by changes in its laws and regulations, including those relating to taxation, import and export tariffs, environmental regulations, land use rights, property and other matters. We believe our operations in China are in material compliance with all applicable legal and regulatory requirements. However, the centraloffer or local governments of the jurisdictions in which we operate may impose new, stricter regulations or interpretations of existing regulations that would require additional expenditures and efforts on our part to ensure our compliance with such regulations or interpretations. Accordingly, government actions in the future, including any decision not to continue to support recent economic reformsoffer securities to investors and cause the value of such securities to return to a more centrally planned economysignificantly decline or regional or local variations in the implementation of economic policies, could have a significant effect on economic conditions in China or particular regions thereof.extreme cases, become worthless.

 

In addition, theThe PRC government through its variousinitiated a series of regulatory actions and statements to regulate business operations in China with little advance notice, including cracking down on illegal activities in the securities market, enhancing supervision over China-based companies listed overseas using variable interest entity (“VIE”) structures, adopting new measures to extend the scope of cybersecurity reviews and expanding anti-monopoly enforcement efforts. These statements and regulatory actions have yet to have an impact on our daily business operations, the ability to accept foreign investments or list our securities on a U.S. or other foreign exchange. Since these statements and regulatory actions are new, it is highly uncertain how soon legislative or administrative regulation making bodies will respond and what existing or new laws or regulations or detailed implementations and interpretations will be modified or promulgated, if any, and the potential impact such modified or new laws and regulations will have on our daily business operation, the ability to accept foreign investments and list our securities on an U.S. or other foreign exchange.

The CSRC has released draft rules for China-based companies seeking to conduct initial public offerings in foreign markets. The Chinese government agenciesmay exert more oversight and industry associations, is accumulating vast amounts of data into huge data bases intended to enable it to tighten control over its residents. As a resultofferings that are conducted overseas and foreign investment in China-based issuers, which could significantly limit or completely hinder our ability to offer or continue to offer our common stock to investors and could cause the value of a social credit system designedour common stock to significantly decline or become worthless.

On December 24, 2021, the CSRC released the Administrative Provisions of the State Council Regarding the Overseas Issuance and Listing of Securities by Domestic Enterprises (Draft for Comments) (the “Administrative Provisions”) and the PRC governmentMeasures for the Overseas Issuance of Securities and Listing Record-Filings by Domestic Enterprises (Draft for Comments) (the “Measures”). The Administrative Provisions and Measures lay out the filing regulation arrangement for both direct and indirect overseas listing and clarify the determination criteria for indirect overseas listing in overseas markets. The Administrative Provisions and Measures, if enacted, may subject us to reward or punish business enterprises, foreign and domestic,additional compliance requirement in the conductfuture. Any failure of their activities within the PRC, the PRC government is capable of exerting enormous influence over thoseus to fully comply with new regulatory requirements may significantly limit or completely hinder our ability to offer or continue to offer our common stock, cause significant disruption to our business enterprises,operations, and severely damage our reputation, which couldwould materially and adversely affect theirour financial condition and results of operations and financial condition.cause our common stock shares to significantly decline in value or become worthless.

 

1422

 

UncertaintiesThe CSRC has released the Trial Measures requiring Chinese domestic companies to complete filings with the CSRC if they complete an overseas offering and listing of their securities.

The Trial Measures, regulations for the filing-based administration of direct and indirect overseas securities offerings and listings by domestic companies incorporated in Mainland China went into effect on March 31, 2023. We anticipate that as a domestic Chinese operating company with securities listed in the U. S., we will be required to make filings pursuant to the Trial Measures. Any filings we make in accordance with the Trial Measures will provide the Chinese Government with information regarding our operations. Reviewing information we provide may cause the PRC government to exert oversight and control over our operations, securities offerings and other capital markets activities. Any such action could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or in extreme cases, become worthless.

The CSRC has released Provisions on Strengthening the Confidentiality and Archives Administration Related to the Overseas Securities Offering and Listing by Domestic Enterprises which may limit the activities of or disclosures made by companies in the PRC which, directly or indirectly, list their securities overseas.

The Confidentiality and Archives Provisions, which went into effect March 31, 2023, require, among other items, that PRC domestic enterprises seeking to offer and list securities in overseas markets, establish an archival system which will maintain the confidentiality of information in accordance with applicable laws and regulations. Further, if a PRC domestic enterprise plans, directly or indirectly, to release documents or provide material that contain state secrets or government work secrets, or that will jeopardize national security or the public interest, it must strictly comply with all relevant governmental procedures and obtain approval of the appropriate regulatory before doing so. Although we are subject to the Confidentiality and Archives Provisions, we believe that none of the documents or materials we intend to provide to parties outside of the PRC contains materials that would require us to make any filing or obtain any approval of a Chinese regulatory authority. Nevertheless, the determination of whether information contains state secrets, government work secrets or jeopardizes national security or the public interest is subjective and any failure or perceived failure by us or our subsidiaries to comply with the confidentiality and archive administration requirements under the Confidentiality and Archives Provisions could cause us to be referred for criminal investigation and held liable for such violations by the authorities in China. Further, PRC regulatory authorities could use these regulations to limit our disclosures or interfere with our operations. Any determination that we have violated the Confidentiality and Archives Provisions or use of these provisions to limit our disclosures could cause the value of our common stock to significantly decline in value or become worthless.

You may have difficulty in effecting service of legal process or bringing actions in China against us or our management based on foreign laws.

We are a Colorado holding company which conducts our operations in China through wholly owned subsidiaries with direct equity ownership and most of our assets are and will be located outside the United States. Almost all of our operations will be conducted in China. In addition, nearly all of our officers and directors, including Quanzhong Lin, Huiliang Jiao and Tianfeng Li are PRC nationals and residents of China and all of their assets are located outside the United States. In addition, Yao-Te Wang is a resident of Taiwan and resides in Taiwan. Christopher Lee, our remaining director, resides outside of the United States for a significant portion of time. As a result, it may be difficult for you to effect service of process upon us or our directors and officers inside China or to bring actions against us or our management in China.

Shareholder claims that are common in the United States, including securities law class actions and fraud claims, generally are difficult to pursue as a matter of law or practicality in China. For example, in China, there are significant legal and other obstacles to obtaining information needed for shareholder investigations or litigation outside China or otherwise with respect to foreign entities. Although the local authorities in China may establish a regulatory cooperation mechanism with the securities regulatory authorities of another country or region to implement cross-border supervision and administration, such regulatory cooperation with the securities regulatory authorities in the Unities States have not been efficient in the absence of mutual and practical cooperation mechanism. According to Article 177 of the PRC Securities Law which became effective in March 2020, no overseas securities regulator is allowed to directly conduct an investigation or evidence collection activities within the territory of the PRC. Accordingly, without the consent of the competent PRC securities regulators and relevant authorities, no organization or individual may provide the documents and materials relating to securities business activities to overseas parties outside of the PRC.

23

You may have difficulty in enforcing foreign judgements in China against us or our management.

China does not have treaties providing for the reciprocal recognition and enforcement of judgments of courts with the United States and many other countries and regions. Even judgements from countries that have an enforcement treaty with China are often not enforceable in China. Therefore, recognition and enforcement in China of judgments of a court in any non-PRC jurisdiction in relation to any matter not subject to a binding arbitration provision may be difficult or impossible. It may also be difficult for you to enforce U.S. courts judgments based on violations of the civil liability provisions of the U.S. federal securities laws against us and our officers and directors, since most of them are residents of the PRC and those who are not residents of the PRC reside outside of the United States for all or a significant portion of time. In addition, there is uncertainty as to whether the courts of China would recognize or enforce judgments of U.S. courts.

Foreign exchange fluctuations may affect our business.

The functional currency utilized by our PRC Subsidiaries is the RMB and we accept payment for our products in RMB. Therefore, foreign exchange fluctuations may influence our business in unpredictable ways.

The value of the Renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political and economic conditions and the foreign exchange policy adopted by the PRC government. For instance, in August 2015, the People’s Bank of China, or PBOC, changed the way it calculates the mid-point price of Renminbi against the U.S. dollar, requiring the market-makers who submit for reference rates to consider the previous day’s closing spot rate, foreign-exchange demand and supply as well as changes in major currency rates. In fiscal year 2019 and 2020, the value of the Renminbi depreciated by approximately 6.9% and 5.5% against the U.S. dollar, respectively. In fiscal year 2021 and 2022 the value of the Renminbi appreciated by approximately 7.4% and 3.2% against the U.S. dollar. It is difficult to predict how market forces or PRC or U.S. government policy, including any interest rate increases by the Federal Reserve, may impact the exchange rate between the Renminbi and the U.S. dollar in the future. There remains significant international pressure on the PRC government to adopt a more flexible currency policy, including from the U.S. government, which has threatened to label China as a “currency manipulator,” which could result in greater fluctuation of the Renminbi against the U.S. dollar.

A substantial percentage of our revenues and costs are denominated in Renminbi, and a significant portion of our assets are also denominated in Renminbi. We are a holding company and we rely on dividends, loans and other distributions on equity paid by our operating subsidiaries in China. Any significant fluctuations in the value of the Renminbi may materially and adversely affect our liquidity and cash flows. Appreciation of the U.S. dollar against the Renminbi would have a negative effect on the U.S. dollar amount we would receive. Conversely, to the extent that we need to convert U.S. dollars into Renminbi for our operations, appreciation of the Renminbi against the U.S. dollar would have an adverse effect on the Renminbi amount we would receive.

Inflation could pose a risk to our business.

Inflation is an important factor that must be considered as we move forward. A change in the rate of inflation could influence the profits that we generate from our business. When the rate of inflation rises, the operational costs of running our company would increase, such as labor costs, raw materials and public utilities, affecting our ability to provide our services at competitive prices. An increase in the rate of inflation would force our clients to search for other service providers, causing us to lose business and revenue.

Changes in the policies, regulations, rules and the enforcement of laws of the PRC government may be quick with little advance notice and could have a significant impact upon the business we may be able to conduct in the PRC and the profitability of such business.

The PRC’s economy is in a transition from a planned economy to a market oriented economy subject to five-year and annual plans adopted by the central government that set national economic development goals. Policies of the PRC government can have significant effects on the economic conditions of the PRC. The PRC government has confirmed that economic development will follow the model of a market economy. Under this direction, we believe that the PRC will continue to strengthen its economic and trading relationships with foreign countries and business development in the PRC will follow market forces. While we believe that this trend will continue, we cannot assure you that this will be the case. Changes in policies, regulations, rules and the enforcement of laws by the PRC government, which changes may be quick with little advance notice, could adversely affect our interests by. Although the PRC government has been pursuing economic reform policies for more than two decades, we cannot assure you that the government will continue to pursue such policies or that such policies may not be significantly altered, especially in the event of a change in leadership, social or political disruption, or other circumstances affecting the PRC’s political, economic and social environment.

24

There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulations could limit the legal protections available to you and us.regulations.

 

Most of our operations are conducted in the PRC and are governed by PRC laws, rules and regulations. Our PRC Subsidiaries are subject to laws, rules and regulations applicable to foreign investment in China. The PRC legal system is a civil law system based on written statutes. Unlike the common law systems, it is a system, in which legal casesprior court decisions may be cited for reference but have limited value as precedents. precedential value.

In the late 1970s,1979, the PRC government began to promulgate a comprehensive system of laws, rules and regulations governing economic matters in general. The overall effectHowever, China has not developed a fully integrated legal system, and recently enacted laws, rules and regulations may not sufficiently cover all aspects of legislation over the past three decades has significantly increased the protections afforded to various forms of foreigneconomic activities in China or private-sector investment in China. Our PRC subsidiary ismay be subject to lawssignificant degree of interpretation by PRC regulatory agencies and regulations applicable to various PRC laws and regulations generally applicable to companies in China. However, sincecourts. In particular, because these laws, rules and regulations are relatively new, and because of the PRC legal system continueslimited number of published decisions and the non-precedential nature of these decisions, and because the laws, rules and regulations often give the relevant regulator significant discretion in how to rapidly evolve,enforce them, the interpretations of many laws, regulations and rules are not always uniforminterpretation and enforcement of these laws, rules and regulations involve uncertainties and can be inconsistent and unpredictable. Therefore, it is possible that our existing operations may be found not to be in full compliance with relevant laws and regulations. In addition, the PRC legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules involve uncertainties.until after the occurrence of the violation.

 

From time to time, we may have to resort toAny administrative and court proceedings to enforce our legal rights. However, sincein China may be protracted, resulting in substantial costs and diversion of resources and management attention. Since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. Furthermore,These uncertainties may impede our ability to enforce the PRC legal system is based in part on government policiescontracts we have entered into and internal rules (some of which are not published in a timely manner or at all) that may have retroactive effect. As a result, we may not be aware of our violation of these policies and rules until sometime after the violation. Such uncertainties, including uncertainty over the scope and effect of our contractual, property (including intellectual property) and procedural rights, and any failure to respond to changes in the regulatory environment in China could materially and adversely affect our business, financial condition and impede our ability to continue ourresults of operations.

 

ChangesPRC regulations regarding acquisitions impose significant regulatory approval and review requirements, which could make it more difficult for us to pursue growth through acquisitions.

Under the PRC Anti-Monopoly Law, companies undertaking acquisitions relating to businesses in China’s economic, politicalChina must notify the anti-monopoly enforcement agency in advance of any transaction where the parties’ revenues in the China market exceed certain thresholds and the buyer would obtain control of, or social conditionsdecisive influence over, the other party. In addition, on August 8, 2006, six PRC regulatory agencies, including the MOFCOM, the State-Owned Assets Supervision and Administration Commission, the State Administration of Taxation, the SAIC, the China Securities Regulatory Commission, or the CSRC, and the State Administration of Foreign Exchange, or SAFE, jointly adopted Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the M&A Rules, which came into effect on September 8, 2006 and was amended on June 22, 2009. Under the M&A Rules, the approval of MOFCOM must be obtained in circumstances where overseas companies established or controlled by PRC enterprises or residents acquire domestic companies affiliated with such PRC enterprises or residents. Applicable PRC laws, rules and regulations also require certain merger and acquisition transactions to be subject to security review.

Our business may be subject to a variety of PRC laws and other obligations regarding cybersecurity and data protection.

Our business may be subject to PRC laws relating to the collection, use, sharing, retention, security, and transfer of confidential and private information, such as personal information and other data. These laws continue to develop, and the PRC government policiesmay adopt other rules and regulations in the future. Non-compliance could result in penalties or other significant legal liabilities.

25

Pursuant to the PRC Cybersecurity Law, which was promulgated by the Standing Committee of the National People’s Congress on November 7, 2016 and took effect on June 1, 2017, personal information and important data collected and generated by a critical information infrastructure operator in the course of its operations in China must be stored in China, and if a critical information infrastructure operator purchases internet products and services that affects or may affect national security, it should be subject to cybersecurity review by the Cyberspace Administration of China (“CAC”). Due to the lack of further interpretations, the exact scope of “critical information infrastructure operator” remains unclear.

On December 28, 2021, twelve Chinese government agencies jointly promulgated the Measures for Cybersecurity Review, which became effective February 15, 2022, set forth the cybersecurity review mechanism for critical information infrastructure operators, and provided that critical information infrastructure operators who intend to purchase internet products and services that affect or may affect national security shall be subject to a cybersecurity review. On June 10, 2021, the Standing Committee of the National People’s Congress promulgated the PRC Data Security Law, which took effect in September 2021. The Data Security Law provides for a security review procedure for data activities that may affect national security. Moreover, the State Internet Information Office issued the Measures of Cybersecurity Review (Revised Draft for Comments, not yet effective) on July 10, 2021, which requires operators with personal information of more than 1 million users who want to list abroad to file a cybersecurity review with the CAC. Furthermore, the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the Opinions on Severe and Lawful Crackdown on Illegal Securities Activities, which was available to the public on July 6, 2021. These opinions emphasized the need to strengthen the administration over illegal securities activities and the supervision of overseas listings by China-based companies. These opinions proposed to take effective measures, such as promoting the construction of relevant regulatory systems, to deal with the risks and incidents facing China-based overseas-listed companies and the demand for cybersecurity and data privacy protection. As these laws, opinions and the draft measures were recently issued, official guidance and interpretation of these remain unclear in several respects at this time, and the PRC government authorities have wide discretion in the interpretation and enforcement of these laws, opinions and draft measures. Therefore, it is uncertain whether the future regulatory changes would impose additional restrictions on our business

The Data Security Law also sets forth the data security protection obligations for entities and individuals handling personal data, including that no entity or individual may acquire such data by stealing or other illegal means, and the collection and use of such data should not exceed the necessary limits. The costs of compliance with, and other burdens imposed by, PRC Cybersecurity Law and any other cybersecurity and related laws may limit the utility of our internet sales channel of distribution and could have an adverse impact on our business. Further, if the enacted version of the Measures for Cybersecurity Review mandates clearance of cybersecurity review and other specific actions to be completed by companies like us, we face uncertainties as to whether such clearance can be timely obtained, or at all.

There remains uncertainty as to how the Draft Measures will be interpreted or implemented and whether the PRC regulatory agencies, including the CAC, may adopt new laws, regulations, rules, or detailed implementation and interpretation related to the Draft Measures. If any such new laws, regulations, rules, or implementation and interpretation comes into effect, we will take all reasonable measures and actions to comply and to minimize the adverse effect of such laws on us.

We cannot assure you that PRC regulatory agencies, including the CAC, would take the same view as we do, and there is no assurance that we can fully or timely comply with such laws. In the event that we are subject to any mandatory cybersecurity review and other specific actions required by the CAC, we face uncertainty as to whether any clearance or other required actions can be timely completed, or at all. Given such uncertainty, we may be further required to shut down our website, or face other penalties, which could materially and adversely affect our business, financial condition, and results of operations.

PRC regulations relating to investments in offshore companies by PRC residents may subject our PRC-resident beneficial owners or our PRC Subsidiaries to liability or penalties, limit our ability to inject capital into our PRC Subsidiaries or limit our PRC Subsidiaries’ ability to increase their registered capital or distribute profits.

SAFE promulgated the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents’ Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles, or SAFE Circular 37, on July 4, 2014, which replaced the former circular commonly known as “SAFE Circular 75.” SAFE Circular 37 requires PRC residents to register with local branches of SAFE in connection with their direct establishment or indirect control of an offshore entity, for the purpose of overseas investment and financing, with such PRC residents’ legally owned assets or equity interests in domestic enterprises or offshore assets or interests, referred to in SAFE Circular 37 as a “special purpose vehicle.” SAFE Circular 37 further requires amendment to the registration in the event of any significant changes with respect to the special purpose vehicle, such as changes in capital contributed by PRC individuals, share transfers or exchanges, mergers, divisions or other material events. In the event that a PRC shareholder holding interests in a special purpose vehicle fails to fulfill the required SAFE registration, the PRC Subsidiaries of that special purpose vehicle may be prohibited from making profit distributions to the offshore parent and from carrying out subsequent cross-border foreign exchange activities, and the special purpose vehicle may be restricted in its ability to contribute additional capital into its PRC Subsidiaries. Moreover, failure to comply with the various SAFE registration requirements could result in liability under PRC law for evasion of foreign exchange controls.

26

As we have little control over the registration procedures, we cannot assure you of the outcome of such registration, and we cannot assure you that any of our shareholders who are PRC residents will submit the required registration or amend or update their registration as required under Circular 37 and the Notice of the State Administration of Foreign Exchange on Further Simplifying and Improving the Foreign Exchange Administration Policies for Direct Investment [Hui Fa (2015) No.13] issued by SAFE with effect from June 1, 2015, or SAFE Notice 13, in a timely manner or at all. In addition, we may not be aware of the identities of all of our beneficial owners who are PRC residents. We do not have control over our beneficial owners and cannot assure you that all of our PRC-resident beneficial owners will comply with SAFE Circular 37 and subsequent implementation rules. The failure of our current and future beneficial owners who are PRC residents to register or amend their SAFE registrations in a timely manner pursuant to SAFE Circular 37 and subsequent implementation rules, may subject the beneficial owners or our PRC Subsidiaries to fines and legal sanctions. On February 13, 2015, SAFE promulgated a Notice on Further Simplifying and Improving Foreign Exchange Administration Policy on Direct Investment, or SAFE Notice 13, which became effective on June 1, 2015. Pursuant to SAFE Notice 13, entities and individuals are required to apply for foreign exchange registration of foreign direct investment and overseas direct investment, including those required under the SAFE Circular 37, with designated domestic banks, instead of SAFE. The designated domestic banks will directly review the applications and conduct the registration.

Furthermore, since it is unclear how the new SAFE regulations, and any future regulation concerning offshore or cross-border transactions, will be interpreted, amended and implemented by the relevant PRC government authorities, we cannot predict how these regulations will affect our business operations or future strategy. Failure to register or comply with relevant requirements may also limit our ability to contribute additional capital to our PRC Subsidiaries and limit our PRC Subsidiaries’ ability to distribute dividends to our company. These risks may have a material adverse effect on our business, and operations.

All of our assets and clients are in China. Accordingly, our business, financial condition, results of operations and prospects may be influenced to a significant degree by political, economic and social conditions in China generally and by continued economic growth in China as a whole.

China’s economy differs from the economies of most developed countries in many respects, including the level of government involvement, level of development, growth rate, control of foreign exchange and allocation of resources. Although the PRC government has implemented measures since the late 1970s emphasizing the utilization of market forces for economic reform, the reduction of state ownership of productive assets, and the establishment of improved corporate governance in business enterprises, a substantial portion of productive assets in China is still owned by the PRC government. In addition, the PRC government continues to play a significant role in regulating industry development by imposing industrial policies. The PRC government also exercises significant control over the PRC economic growth through allocating resources, controlling payment of foreign currency-denominated obligations, setting monetary policy, and providing preferential treatment to particular industries or companies.

While China’s economy has experienced significant growth over the past decades, growth has been uneven, both geographically and among various sectors of the economy, and may slow down in the future. Some of the government measures may benefit the overall Chinese economy but, may have a negative effect on us. For example, our financial condition and results of operations may be adversely affected by government control over capital investments or changes in tax regulations. Any stimulus measures designed to boost the Chinese economy may contribute to higher inflation, which could adversely affect our results of operations and financial condition. For example, certain operating costs and expenses, such as employee compensation and office operating expenses, may increase as a result of higher inflation.

15

As exemplified by the outbreak of Covid-19, natural disasters, public health crises, political crises, and other catastrophic events or other events outside of our control may adversely impact our business, the welfare of our customers or the operations of third parties on which we depend and could impact consumer spending.

Our business and operating results are subject to, and can suffer from, the adverse effects of natural disasters, such as earthquakes, tsunamis, power shortages or outages, floods or monsoons, public health crises, such as pandemics and epidemics, political crises, such as terrorism, war, political instability or other conflict, or other events outside of our control. Such conditions can also impact the facilities and business operations of our suppliers, third-party service providers or customers which, in turn, could adversely affect our business operations. Moreover, these types of events could negatively impact consumer spending in the impacted regions or depending upon the severity, globally, which could adversely impact our operating results. For example, in December 2019, an outbreak of a new strain of coronavirus, COVID-19, emerged in Wuhan, China. Within weeks, despite efforts to contain the virus in China that included widespread shutdowns of cities and businesses, the number of those infected grew significantly, and beyond China’s borders. The spread of the virus has adversely affected businesses, supply chains, business travel, commodity prices, consumer confidence and business sentiment throughout China and elsewhere. At this point, the full extent to which the coronavirus may impact our results remains uncertain.

 

If relations between the United States and China worsen, investorsWe may be unwilling to hold or buy our stock and our stock price may decrease, and the Chinese economy may be negatively impacted.

At various times during recent years, the United States (“U.S.”) and China have had significant disagreements over political and economic issues. Most recently, a dispute has erupted over the outbreak of COVID-19 in Wuhan, China, and the initial disclosures made by the Chinese government with respect to the outbreak. Controversies may arise in the future between these two countries. Any political or trade controversies between the United States and China, whether or not directly related to our business, could reduce the price of our common stock.

The outbreak of Covid-19 has caused many politicians in the United States to question its dependence upon Chinatreated as a source of certain products. Wereresident enterprise for PRC tax purposes under the United StatesPRC Enterprise Income Tax Law, and we may therefore be subject to adopt a policy intended to establish sources for certain products in the United States or otherwise outside of China, it could negatively impact the Chinese economy and demand for our products.

The slowing economic growth in China may assert a negative impactPRC income tax on our operation and financial results.

After experiencing rapid growth for more than a decade, China’s economy has been hit by shrinking foreign and domestic demand, weak investment, factory overcapacity and oversupply in the property market, and has experienced a painful slowdown in the last two years, exacerbated by the outbreak of Covid-19. As the government tries to shift the growth engine away from manufacturing and debt-fueled investment toward the services sector and consumer spending, the outlook of the Chinese economy is uncertain.

Under the EIT Law, we may be classified as a PRC “resident enterprise” for PRC enterprise income tax purposes. Such classification would likely result in unfavorable tax consequences to us and our non-PRC shareholders and have a material adverse effect on our results of operations and the value of your investment.global income.

 

Under the PRC Enterprise Income Tax Law or the EIT Law, that became effectiveand its implementing rules, both of which came into effect on January 1, 2008, an enterpriseenterprises established under the laws of jurisdictions outside the PRCof China with “de facto management bodies” withinlocated in China may be considered PRC tax resident enterprises for tax purposes and may be subject to the PRC is considered a “resident enterprise” for PRC enterprise income tax purposes and is generally subject to a uniformat the rate of 25% enterprise income tax rate on its worldwidetheir global income. Under the implementation rules to the EIT Law, a “de“De facto management body” is defined asrefers to a managing body that has materialexercises substantive and overall management and control over the manufacturingproduction and business, operations, personnel, accounting books and human resources, finances and propertiesassets of an enterprise. In addition, a circular, known as SAT Circular 82, issued in April 2009 and amended in January 2014 by theThe State Administration of Taxation orissued the SAT, specifies that certain offshore incorporated enterprises controlled by PRC enterprises or PRC enterprise groups will be classifiedNotice Regarding the Determination of Chinese-Controlled Offshore-Incorporated Enterprises as PRC resident enterprises ifTax Resident Enterprises on the following are locatedbasis of de facto management bodies, or resident in the PRC: senior management personnel and departments that are responsible for daily production, operation and management; financial and personnel decision making bodies; key properties, accounting books, company seal, and minutes of board meetings and shareholders’ meetings; and half or more of the senior management or directors having voting rights. Further to SAT Circular 82, the SAT issued a bulletin, known as SAT Bulletin 45, which took effect in September 2011, to provide more guidance on the implementation of SATApril 22, 2009. Circular 82 and clarifyprovides certain specific criteria for determining whether the reporting and filing obligations“de facto management body” of such “Chinese-controlled offshore incorporated resident enterprises.” SAT Bulletin 45 provides procedures and administrative details for the determination of resident status and administration on post-determination matters.a Chinese-controlled offshore-incorporated enterprise is located in China. Although both SAT Circular 82 and SAT Bulletin 45 only applyapplies to offshore enterprises controlled by PRC enterprises, or PRC enterprise groups, not those controlled by PRC individualsforeign enterprises or foreign individuals, the determining criteria set forth in SAT Circular 82 and SAT Bulletin 45 may reflect the SAT’sState Administration of Taxation’s general position on how the “de facto management body” test should be applied in determining the tax resident status of offshore enterprises, regardless of whether they are controlled by PRC enterprises, PRC enterprise groups or by PRC or foreign individuals.

16

We are subject to the 25% enterprise income tax. However, since all of our activities are in China,enterprises. If we, do not believe AiXinZhonghong or our Company meet all of the conditionsAiXin Colorado and AiXin BVI, were to be classified as a PRC resident enterprise., However, if we engage in activities outside of Mainland China, the PRC tax authorities may classify AiXinZhonghong or our company asconsidered a PRC resident enterprise, whichwe would result in a number of unfavorable PRC tax consequences. First, we or our offshore subsidiaries will be subject to the uniform 25% enterprise income tax on our world-wide income, which could materially reduce our net income. In addition, we will also be subject to PRC enterprise income tax reporting obligations.

Furthermore, although dividends paid by one PRC tax resident enterprise to an offshore incorporatedat the rate of 25% on our global income. In such case, our profitability and cash flow may be materially reduced as a result of our global income being taxed under the Enterprise Income Tax Law. We believe that none of our entities outside of China is a PRC resident enterprise controlled byfor PRC enterprises or PRCtax purposes. However, the tax resident status of an enterprise groups should qualify as “tax-exempt income” under the EIT Law and Bulletin 45, we cannot assure you that dividends paid by our PRC subsidiary to AiXin HK will not beis subject to a 10% withholding tax, as the PRC foreign exchange control authorities, which enforce the withholding tax on dividends, anddetermination by the PRC tax authorities have not yet issued guidanceand uncertainties remain with respect to the processinginterpretation of outbound remittances to entities that are treated as resident enterprises for PRC enterprise income tax purposes but not controlled by PRC enterprises or PRC enterprise groups.the term “de facto management body.”

 

Finally, dividends payable by us to our investors and gains on the sale of our shares may be become subject to PRC withholding tax.

27

 

WeRestrictions on currency exchange may not be ablelimit our ability to obtain certain benefits under the relevant tax treaty on dividends paid byutilize our PRC subsidiaries to us through AiXin HK.revenue effectively.

 

We are a holding company incorporatedwith no material operations of our own. We conduct substantially all of our operations through the operating companies established in the PRC. Substantially all of our revenue is denominated in Renminbi. The Renminbi is currently convertible under the laws of Colorado“current account,” which includes dividends, trade and as such rely on dividendsservice-related foreign exchange transactions, but requires approval from or registration with appropriate government authorities or designated banks under the “capital account,” which includes foreign direct investment and other distributions on equityloans, including loans we may secure from our onshore subsidiaries. The relevant PRC subsidiaries to satisfy part of our liquidity requirements. Pursuant to the EIT Law, a withholding tax rate of 10% currently applies to dividends paid by a PRC “resident enterprise” to a foreign enterprise investor, unless any such foreign investor’s jurisdiction of incorporation has a tax treaty with China that provides for preferential tax treatment. Pursuant to a Notice 112 issued by the SAT in January 2008 and the Arrangement between the Mainland China and the Hong Kong Special Administrative Region on the Avoidance of Double Taxation and Prevention of Fiscal Evasion,governmental authorities or the Double Taxation Arrangement (Hong Kong), such withholding tax ratelocal bank may be loweredlimit or eliminate our ability to 5% if the PRC enterprise is at least 25% held by a Hong Kong enterprise at all times within the 12-month period immediately prior to distribution of the dividends and is determined by the relevant PRC tax authority to have satisfied other conditions and requirements under the Double Tax Avoidance Arrangement (Hong Kong) and other applicable PRC laws. Pursuant to a SAT Circular 601 issued by the SAT in October 2009, non-resident enterprises that cannot provide valid supporting documents as “beneficial owners” may not be approved to enjoy tax treaty benefits, and “beneficial owners” refers to individuals, enterprises or other organizations which are normally engaged in substantive operations. These rules also set forth certain adverse factors on the recognition of a “beneficial owner”. Specifically, they expressly exclude a “conduit company,” or any company established for the purposes of avoiding or reducing tax obligations or transferring or accumulating profits and not engaged in actual operations such as manufacturing, sales or management, from being a “beneficial owner.” Whether a non-resident company may obtain tax benefits under the relevant tax treaty will be subject to approval of the relevant PRC tax authority and will be determined by the PRC tax authority on a case-by-case basis. In June 2012, the SAT further provides in an announcement that a comprehensive analysis should be made when determining the beneficial owner status based on various factors supported by documents including the articles of association, financial statements, records of cash movements, board meeting minutes, board resolutions, staffing and materials, relevant expenditures, functions and risk assumption as well as relevant contracts and other information. Our Hong Kong subsidiary has not applied for the approval for a withholding tax rate of 5% from the local tax authority as our PRC subsidiaries have not paid dividends due to their loss-making status in the past and will not be able to pay dividendspurchase foreign currencies in the future until they have achieved accumulated profits.We plan to have our Hong Kong subsidiary assume some managerial and administrative functions, as well as conduct other business functions in the future. Once we implement such a plan, we do not believe that our Hong Kong subsidiary will be considered a conduit company as defined under SAT Circular 601. However, our Hong Kong subsidiary as currently situated may be considered a conduit company and we cannot assure you that the relevant PRC tax authority will agree with our view when our Hong Kong subsidiary applies to obtain tax benefits under the relevant tax treaty in the future. As a result, although our PRC subsidiary is currently wholly owned by our Hong Kong subsidiary, we may not be able to enjoy the preferential withholding tax rate of 5% under the Double Taxation Arrangement (Hong Kong) and therefore be subject to withholding tax at a rate of 10% with respect to dividends to be paid by our PRC subsidiary to AiXin HK.

17

Enhanced scrutiny over acquisition transactions by the PRC tax authorities may have a negative impact on potential acquisitions we may pursue in the future.for current account transactions.

 

In connection with the EIT Law, the MinistrySince 2016, PRC governmental authorities have imposed more stringent restrictions on outbound capital flows, including heightened scrutiny over “irrational” overseas investments for certain industries, as well as over four kinds of Finance and the SAT jointly issued a SAT Circular 59 in April 2009, and the SAT issued a SAT Circular 698 in December 2009. Both SAT Circular 59 and Circular 698 became effective retroactively on January 1, 2008.“abnormal” offshore investments, which are:

 

According to SAT Circular 698, where a non-resident enterprise transfers the equity interests of a PRC “resident enterprise” indirectly by disposition of the equity interests of an overseas holding company, or an Indirect Transfer, and the overseas holding company is located in a tax jurisdiction that: (1) has an effective tax rate less than 12.5% or (2) does not tax foreign income of its residents, the non-resident enterprise, being the transferor, must report to the relevant tax authority of the PRC “resident enterprise” this Indirect Transfer. Using a “substance over form” principle, the PRC tax authority may disregard the existence of the overseas holding company if it lacks a reasonable commercial purpose and was● investments through enterprises established for the purpose of reducing, avoiding or deferring PRC tax. Asonly a result, gains derived from such Indirect Transfer may be subject to PRC withholding tax at up to 10%. SAT Circular 698 also provides that, where a non-PRC resident enterprise transfers its equity interests in a PRC “resident enterprise” to its related parties at a price lower than the fair market value, the relevant tax authority has the power to make a reasonable adjustment to the taxable income of the transaction. In addition, the PRC “resident enterprise” is supposed to provide necessary assistance to support the enforcement of SAT Circular 698.few months without substantive operation;

 

There is little guidance● investments with amounts far exceeding the registered capital of the onshore parent and practical experience as to the application of SAT Circular 698, and it is possible that the PRC tax authorities would pursue our offshore shareholders to conduct a filing regarding our offshore restructuring transactions where non-resident investors were involved and would request our PRC subsidiary to assist in providing such disclosures. In addition, if our offshore subsidiaries are deemed to lack substance they could be disregardednot supported by the PRC tax authorities. As a result, we and our non-resident investors may become at risk of being taxed under SAT Circular 698 and may be required to expend valuable resources to comply with SAT Circular 698 or to establish that we should not be taxed under SAT Circular 698, which may have a material adverse effectits business performance shown on our financial condition and results of operations or the non-resident investors’ investments in us.statements;

 

By promulgating● investments in targets which are unrelated to an onshore parent’s main business; and implementing these circulars, the PRC tax authorities have enhanced their scrutiny over the direct or indirect transfer of equity interests in a PRC resident enterprise by a non-resident enterprise. The PRC tax authorities have the discretion under SAT Circular 59 and SAT Circular 698 to make adjustments to the taxable capital gains based on the difference between the fair value of the equity interests transferred and the cost of investment. Although we currently have no confirmed plans to pursue any acquisitions in China or elsewhere in the world, we may pursue acquisitions in the future that may involve complex corporate structures. If we are considered a non-resident enterprise under the EIT Law and if the PRC tax authorities make adjustments under SAT Circular 59 or SAT Circular 698, our income tax costs associated with such potential acquisitions will be increased, which may have an adverse effect on our financial condition and results of operations.

18

PRC regulations establish complex procedures for some acquisitions of PRC companies by foreign investors, which could make it more difficult for us to pursue growth through acquisitions in China.

 

Six PRC regulatory agencies promulgated regulations effective on September 8, 2006 that are commonly referred to as the M&A Rules. The M&A Rules establish procedures and requirements that could make some acquisitions● investments with abnormal sources of PRC companies by foreign investors more time-consuming and complex, including requirements in some instances that the Ministry of Commerce be notified in advance of any change-of-control transaction in which a foreign investor takes control of a PRC domestic enterprise. In addition, national security review rules issued by the PRC governmental authorities in 2011 require acquisitions by foreign investors of domestic companies engaged in military-related or certain other industries that are crucial to national securityRenminbi funding suspected to be subject to prior security review. Moreover, the Anti-Monopoly Law requires that the Ministryinvolved in illegal transfer of Commerce shall be notified in advanceassets or illegal operation of any concentration of undertaking if certain thresholds are triggered. We may expand our business in part by acquiring complementary businesses. Complying with the requirements of the M&A Rules, security review rules and other PRC regulations to complete such transactions could be time-consuming, and any required approval processes, including obtaining approval from the Ministry of Commerce, may delay or inhibit our ability to complete such transactions, which could affect our ability to expand our business or maintain our market share.underground banking.

 

PRC regulations relatingOn January 26, 2017, SAFE promulgated the Circular on Further Improving Reform of Foreign Exchange Administration and Optimizing Genuineness and Compliance Verification, which tightened the authenticity and compliance verification of cross-border transactions and cross-border capital flow, including requiring banks to verify board resolutions, tax filing forms and audited financial statements before wiring foreign invested enterprises’ foreign exchange dividend distribution of over US$50,000. In addition, the Outbound Investment Sensitive Industry Catalogue (2018) lists certain sensitive industries that are subject to NDRC pre-approval requirements prior to remitting investment funds offshore, investment activities by PRC residents may limitwhich subjects us to increased approval requirements and restrictions should we have overseas investments. Since a significant amount of our PRC subsidiaries’ ability to increase their registered capital or distribute profits to us,revenue is denominated in Renminbi, any existing and future restrictions on currency exchange may limit our ability to inject capital intoutilize revenue generated in Renminbi to fund our PRC subsidiaries, or otherwise expose us to liability and penalties under PRC law.

The PRC State Administrationbusiness activities outside of Foreign Exchange, or the SAFE, promulgated in October 2005 a SAFE Circular 75 that requires PRC citizens or residents to register with SAFE or its local branch in connection with their establishment or control of an offshore entity established for the purpose of overseas equity financing involving a roundtrip investment whereby the offshore entity acquires or controls onshore assets or equity interests held by the PRC, citizens or residents. In addition, such PRC citizens or residents must update their SAFE registrations when the offshore special purpose vehicle undergoes material events relating to increases or decreases in investment amount, transfers or exchanges of shares, mergers or divisions, long-term equity ormake investments, service any debt investments, external guarantees, or other material events that do not involve roundtrip investments. Subsequent regulations further clarified that PRC subsidiaries of an offshore company governed by the SAFE regulations are required to coordinate and supervise the filing of SAFE registrations in a timely manner by the offshore holding company’s shareholders who are PRC citizens or residents. If these shareholders fail to comply, the PRC subsidiaries are required to report to the local SAFE branches. If our shareholders who are PRC citizens or residents do not complete their registration with the local SAFE branches, our PRC subsidiary may be prohibited from distributing its profits and proceeds from any reduction in capital, share transfer or liquidation to us, and we may be restricted in our ability to contribute additional capital to our PRC subsidiary. Moreover, failure to comply with the various SAFE registration requirements described above could result in liabilities for our PRC subsidiary under PRC laws for evasionincur outside of applicable foreign exchange restrictions, including (1) the requirement by SAFE to return the foreign exchange remitted overseas within a period specified by SAFE, with a fine of up to 30% of the total amount of foreign exchange remitted overseas and deemed to have been evasive and (2) in circumstances involving serious violations, a fine of no less than 30% of and up to the total amount of remitted foreign exchange deemed evasive. Furthermore, the persons-in-charge and other persons at our PRC subsidiary who are held directly liable for the violations may be subject to criminal sanctions.

These foreign exchange regulations provide that PRC residents include both PRC citizens, meaning any individual who holds a PRC passport or resident identification card, and individuals who are non-PRC citizens but primarily reside in the PRC due to their economic ties to the PRC. We have requested PRC residents holding direct or indirect interest in our company to our knowledge to make the necessary applications, filings and amendments as required under SAFE Circular 75 and other related rules. However, we cannot assure you that all of our shareholders who are PRC citizens and hold interests in us have registered with the local SAFE branch as required under SAFE Circular 75. In addition, we may not be informed of the identities of all the PRC residents holding direct or indirect interest in our company, and we cannot provide any assurances that these PRC residents will comply with our request to make or obtain any applicable registrations or comply with other requirements required by SAFE Circular 75 or other related rules. A failure by our PRC resident shareholders or future PRC resident shareholders to comply with the SAFE regulations, if SAFE requires it, could subject us to fines or other legal sanctions, restrict our cross-border investment activities, limit our PRC subsidiary’s ability to make distributionsChina or pay dividends or affect our ownership structure, which could adversely affect our business and prospects.

19

Furthermore, it is unclear how these regulations, and any future regulation concerning offshore or cross-border transactions, will be interpreted, amended and implemented by the relevant government authorities. We cannot predict how these regulations will affect our business operations or future strategy. For example, we may be subject to a more stringent review and approval process with respect to our foreign exchange activities, such as remittance of dividends and foreign-currency-denominated borrowings, which may adversely affect our financial condition and results of operations. In addition, if we decide to acquire a PRC domestic company, either we or the owners of such company, as the case may be, may not be able to obtain the necessary approvals or complete the necessary filings and registrations required by the foreign exchange regulations. This may restrict our ability to implement our acquisition strategy and could adversely affect our business and prospects.

Fluctuations in exchange rates could have a material adverse effect on our results of operations and the value of your investment.

Substantially all of our revenues and expenditures are denominated in RMB. As the functional currency for our PRC subsidiary and consolidated affiliated entities is RMB, fluctuations in the exchange rate may cause us to incur foreign exchange losses on any foreign currency holdings they may have. If we decide to convert our RMB into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or for other business purposes, appreciation of the U.S. dollar against the RMB would have a negative effect on the U.S. dollar amount available to us.

The value of the Renminbi against the U.S. dollar and other currencies is affected by, among other things, changes in China’s political and economic conditions and China’s foreign exchange policies. On July 21, 2005, the PRC government changed its decade-old policy of pegging the value of the RMB to the U.S. dollar, and the Renminbi appreciated more than 20% against the U.S. dollar over the following three years. It is difficult to predict how long the current situation may last and when and how it may change again. There remains significant international pressure on the PRC government to adopt a substantial liberalization of its currency policy, which could result in a further and more significant appreciation in the value of the Renminbi against the U.S. dollar. Significant revaluation of the Renminbi may have a material and adverse effect on your investment. For example, to the extent that we need to convert U.S. dollars we receive from securities offerings outside of China into Renminbi for our operations, appreciation of the Renminbi against the U.S. dollar would have an adverse effect on the Renminbi amount we would receive from the conversion. Conversely, if we decide to convert our Renminbi into U.S. dollars for the purpose of making payments for dividends on our common stock or for other business purposes, appreciation of the U.S. dollar against the Renminbi would have a negative effect on the U.S. dollar amount available to us. In August 2015, the PRC Government devalued its currency by approximately 3%, representing the largest yuan depreciation in 20 years. Concerns remain that China’s slowing economy, and in particular its exports, will need a stimulus that can only come from further cuts in the exchange rate.

Recently, as part of the trade war between the two countries, the United States imposed tariffs on a large number of products exported from China to the United States. Subsequently, the RMB depreciated relative to the U. S. dollar causing the United States to consider what further actions it could take to address the situation.

Appreciation or depreciation in the value of the Renminbi relative to the U.S. dollar would affect our financial results reported in U.S. dollar terms without giving effect to any underlying change in our business or results of operations. The income statements of our operations are translated into U.S. dollars at the average exchange rates in each applicable period. To the extent the U.S. dollar strengthens against foreign currencies, the translation of these foreign currencies denominated transactions results in reduced revenue, operating expenses and net income for our international operations. Similarly, to the extent the U.S. dollar weakens against foreign currencies, the translation of these foreign currency denominated transactions results in increased revenue, operating expenses and net income for our international operations. We are also exposed to foreign exchange rate fluctuations as we convert the financial statements of our foreign subsidiaries into U.S. dollars in consolidation. If there is a change in foreign currency exchange rates, the conversion of the foreign subsidiaries’ financial statements into U.S. dollars will lead to a translation gain or loss, which is recorded as a component of other comprehensive income. Very limited hedging transactions are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not entered into any hedging transactions. While we may enter into hedging transactions in the future, the availability and effectiveness of these transactions may be limited, and we may not be able to successfully hedge our exposure at all.

20

Fluctuation in the value of RMB may have a material adverse effect on your investment.

The value of RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political and economic conditions. Our revenues, costs, and financial assets are denominated in RMB, while our reporting currency is the U.S. dollar. Accordingly, this may result in gains or losses from currency translation on our financial statements. We rely entirely on dividends from our operating subsidiary in China. Therefore, any significant fluctuation in the value of RMB may materially and adversely affect our cash flows, revenues, earnings, financial position, and the value of, and any dividends payable on, our stock in U.S. dollars. For example, an appreciation of RMB against the U.S. dollar would, to the extent that we need to convert U.S. dollars into RMB for such purposes, make any new RMB denominated investments or expenditures more costly to us. An appreciation of RMB against the U.S. dollar would result in foreign currency translation gains for financial reporting purposes when we translate our RMB denominated financial assets into U.S. dollars, as the U.S. dollar is our reporting currency.

Dividends we receive from our subsidiaries located in the PRC may be subject to PRC withholding tax.

The EIT Law provides that a maximum income tax of 20% is applicable to dividends payable to non-PRC investors that are “non-resident enterprises,” to the extent such dividends are derived from sources within the PRC. However, the State Council has reduced such rate to ten percent (10%) through the implementation regulations. We are a Colorado holding company and all of our income is derived from our AiXinZhonghong subsidiary located in the PRC. Therefore, dividends paid to us from China may be subject to the 10% income tax if we are considered a “non-resident enterprise” under the EIT Law. If we are required under the EIT Law and its implementation regulations to pay income tax for any dividends we receive from our PRC subsidiaries, it may have a material and adverse effect on our net income and materially reduce the amount of dividends, if any, we may pay to our shareholders.

 

WeFluctuations in foreign exchange rates will impact our reported results.

The functional currency utilized by our PRC Subsidiaries is the RMB. Our financial results are reported in U.S. Dollars. Therefore, foreign exchange fluctuations will impact the reporting of our financial results and significant fluctuations in the value of the RMB relative to the U.S. Dollar may be exposedmaterially and adversely affect our financial results as reported in our filings with the SEC. Such variations in our perceived operating results may increase the volatility in the market for our common stock.

The disclosures in our reports and other filings with the SEC and our other public pronouncements are not subject to liabilities under the Foreign Corrupt Practices Act and Chinese anti-corruption laws, andscrutiny of any determination that we violated these laws could have a material adverse effect on our business.regulatory bodies in the PRC.

 

We are subject to the Foreign Corrupt Practice Act, or FCPA,regulations of the SEC and our reports and other laws that prohibit improper payments or offers of paymentsfilings with the SEC are subject to foreign governmentsSEC review in accordance with the rules and their officials and political parties by U.S. persons and issuers as definedregulations promulgated by the statute,SEC under the Securities Act and the Exchange Act. Our SEC reports and other disclosure and public pronouncements are not subject to the review or scrutiny of any PRC regulatory authority. For example, the disclosure in our SEC reports and other filings are not subject to the review by China Securities Regulatory Commission, a PRC regulator that is responsible for oversight of the purposecapital markets in China. Accordingly, you should review our SEC reports, filings and our other public pronouncements with the understanding that no local regulator has done any review of obtainingus, our SEC reports, other filings or retaining business. We have operations, agreements with third parties and we make the majorityany of our sales in China. PRC also strictly prohibits bribery of government officials. Our activities in China create the risk of unauthorized payments or offers of payments by the employees, consultants, sales agents or distributors of our Company, even though they may not always be subject to our control. It is our policy to implement safeguards to discourage these practices by our employees. However, our existing safeguards and any future improvements may prove to be less than effective, and the employees, consultants, sales agents or distributors of our Company may engage in conduct for which we might be held responsible. Violations of the FCPA or Chinese anti-corruption laws may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could negatively affect our business, operating results and financial condition. In addition, the U.S. government may seek to hold our Company liable for successor liability FCPA violations committed by companies in which we invest or that we acquire.public pronouncements.

 

Uncertainties with respectIntroduction of new laws or changes to existing laws by the PRC legal system could limit the legal protections available to you and us.government may adversely affect our business.

 

We conduct all of our business through AiXinZhonghong, our subsidiary in the PRC. AiXinZhonghong is subject to laws and regulations applicable to foreign investments in China and, in particular, laws applicable to foreign-invested enterprises. The PRC legal system is based ona codified legal system made up of written statutes,laws, regulations, circulars, administrative directives and prior court decisionsinternal guidelines. Unlike common law jurisdictions like the U.S., decided cases (which may be cited for reference buttaken as reference) do not form part of the legal structure of the PRC and thus have limited precedential value. Since 1979,no binding effect on subsequent cases with similar issues and fact patterns. Furthermore, in line with its transformation from a seriescentrally-planned economy to a more free market-oriented economy, the PRC government is still in the process of newdeveloping a comprehensive set of laws and regulations. As the legal system in the PRC is still evolving, laws and regulations have significantly enhancedor the protections affordedinterpretation of the same may be subject to various formsfurther changes. For example, the PRC government may impose more stringent environmental regulations which would affect our ability to comply with, or our costs to comply with, such regulations. Such changes, if implemented, may adversely affect our business operations and may reduce our profitability.

Risks Relating to Our Holding Company Structure

Substantial uncertainties exist with respect to the interpretation and implementation of the newly enacted Foreign Investment Law and how it may impact the viability of our current corporate structure, corporate governance and business operations.

On March 15, 2019, the PRC National People’s Congress approved the Foreign Investment Law, which came into effect on January 1, 2020 and replaced existing laws regulating foreign investment in the PRC and become the legal foundation for foreign investment in the PRC. Meanwhile, the Implementation Regulation of the Foreign Investment Law and the Measures for Reporting of Information on Foreign Investment came into effect as of January 1, 2020, which clarified and elaborated the relevant provisions of the Foreign Investment Law. The Foreign Investment Law sets out the basic regulatory framework for foreign investments and proposes to implement a system of pre-entry national treatment with a restricted list for foreign investments, pursuant to which (i) foreign entities and individuals are prohibited from investing in the areas that are not open to foreign investments, (ii) foreign investments in China. However, since the PRCrestricted industries must satisfy certain requirements under the law, and (iii) foreign investments in business sectors outside of the restricted list will be treated equally with domestic investments. The Foreign Investment Law also sets forth necessary mechanisms to facilitate, protect and manage foreign investments and proposes to establish a foreign investment information reporting system, through which foreign investors or foreign-invested enterprises are required to submit initial report, report of changes, report of deregistration and annual report relating to their investments to the Ministry of Commerce, or MOFCOM, or its local branches.

Although our operating structure is legal system continues to evolve rapidly,and permissible under the interpretations of many laws,current Chinese law and regulations, and rules are not always uniform and enforcement of these laws, regulations and rules involves uncertainties,including the Foreign Investment Law, Chinese regulatory authorities could disallow our operating structure, which may limit legal protections available to you and us. In addition, any litigation in China may be protracted andwould likely result in substantial costs and diversion of resources and management attention. In addition, alla material change in our operations and/or could cause the value of our executive officers and all of our directors are residents of China and not of the U.S., and substantially all the assets of these persons are located outside the U.S. As a result, it could be difficult for investorscommon stock to effect service of process in the U.S.significantly decline or to enforce a judgment obtained in the U.S. against our Chinese operations, subsidiary and affiliate.become worthless.

 

2128

 

YouWe may rely on dividends and other distributions on equity paid by our PRC Subsidiaries to fund any cash and financing requirements we may have, difficulty enforcing judgments against us.and any limitation on the ability of our PRC Subsidiaries to make payments to us could have a material and adverse effect on our ability to conduct our business.

 

We are a Colorado holding company but AiXin BVI is a British Virgin Islands corporation, AiXin HK is a Hong Kong company, and we rely on dividends and other distributions on equity paid by our operating subsidiary AiXinZhonghong, is located in the PRC. Virtually all of our assets are located outside the U.S.PRC Subsidiaries and all of our current operations are conducted in the PRC. In addition, all of our directors and officers, with the exception of our newest director, Christopher Lee, are residents of China. Substantially all of the assets of these persons are located outside the U.S. As a result, it may be difficult for you to effect service of process within the U.S. upon these persons. It may also be difficult for you to enforce in U.S. courts judgments predicated on the civil liability provisions of the U.S. federal securities laws againstloans between us and our officersPRC Subsidiaries to fund any cash and directors. In addition, there is uncertainty as to whether the courtsfinancing requirements we or any of theour PRC would recognize or enforce judgments of U.S. courts. The recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. Courts in ChinaSubsidiaries may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based on treaties between China and the country where the judgment is made or on reciprocity between jurisdictions. China does not have, any treaties or other arrangements that provideincluding for the reciprocal recognition and enforcementpayment of foreign judgments withdividends to our investors, the U.S. In addition, accordingshareholders of AiXin Colorado. Any limitation on the ability of our PRC Subsidiaries to the PRC Civil Procedures Law, courts in the PRC will not enforce a foreign judgment againstmake payments to or transfer funds to us or our directorsother PRC Subsidiaries could have a material and officers if they decide that the judgment violates basic principles of PRC law or national sovereignty, security or the public interest. So it is uncertain whether a PRC court would enforce a judgment rendered by a court in the U.S.

Future inflation in China may inhibitadverse effect on our ability to conduct our business in China.

In recent years,and the Chinese economy has experienced periods of rapid expansion and highly fluctuating rates of inflation. During the past ten years, the rate of inflation in China has been as high as 20.7% and as low as -2.2%. These factors have led to the adoption by the Chinese government, from time to time, of various corrective measures designed to restrict the availability of credit or regulate growth and contain inflation. High inflation may in the future cause the Chinese government to impose controls on credit and/or prices, or to take other action, which could inhibit economic activity in China, and thereby harm the market for our products and our company.

Risks Relating to Our Common Stock and Our Status as a Public Company

Our common stock is quoted on OTCQX which may have an unfavorable impact on our stock price and liquidity.

Our common stock is quoted on OTCQX under the symbol “AXIN”. The trading market for securities of companies quoted on OTCQX or other quotation systems is substantially less liquid than the average trading market for companies listed on a national securities exchange. The quotationability of our shares on OTCQXPRC Subsidiaries to conduct their respective businesses. If our PRC Subsidiaries incur debt, the instruments governing the debt may result in a less liquid market available for existing and potential stockholders to trade shares of our common stock, could depress the market price of our common stock and could have a long-term adverse impact on ourrestrict their ability to raise capital in the future.

Our Chief Executive Officer who is our principal stockholder has substantial influence over our Company, and his interests may not be aligned with the interests of ourpay dividends or make other stockholders.

Quanzhong Lin, our President and Chief Executive Officer, owns substantially in excess of a majority of our outstanding shares. As a result, Mr. Lin has significant influence over our business, including decisions regarding acquisitions, mergers, consolidations, the sale of all or substantially all of our assets, election of directors and other significant corporate actions, including potential transactions in which he may have a conflict of interest. As a result of this concentration of ownership, you and our other stockholders, acting alone, may not have the abilitydistributions to determine the outcome of matters requiring stockholder approval, including the election of our directors or significant corporate transactions. In addition, this concentration of ownership, which is not subject to any voting restrictions, may discourage, delay or thwart efforts by third parties to take-over or effect a change in control of our company which could deprive our stockholders of an opportunity to receive a premium for their shares as part of a sale of our company, and may limit the price that investors are willing to pay for our common stock.

22

Our management is not familiar with the United States securities laws.

Our management, with the exception of our newest Director, Christopher Lee, is generally unfamiliar with the requirements of the U.S. securitiesus. Under PRC laws and regulations, our PRC Subsidiaries may not appreciate the need to devote the resources necessary to comply with such laws. A failure to adequately respond to applicable securities laws could lead to investigations by the SEC and other regulatory authorities that could be costly, divert management’s attention and disrupt our business.

Our accounting personnel who are primarily responsible for the preparation and supervisionpay dividends only out of the preparation of our financial statements under generally accepted accounting principles in the U.S. have had no education or training in U.S. GAAP and SEC rules and regulations pertaining to financial reporting, which could impact our ability to prepare our financial statements and convert our books and records to U.S. GAAP.

We maintain our books and recordstheir respective accumulated profits as determined in accordance with generally acceptedPRC accounting principles in the PRC, or PRC GAAP. Our accounting personnel in the PRC who have the primary responsibilities of preparing and supervising the preparation of financial statements under U.S. GAAP have had no education or training in U.S. GAAP and related SEC rulesstandards and regulations. As such, they may be unable to identify potential accounting and disclosure issues that may arise upon the conversionIn addition each of our books and records from PRC GAAPSubsidiaries is required to U.S. GAAP, which could affect our abilityset aside at least 10% of its accumulated after-tax profits each year, if any, to prepare our financial statements in accordance with U.S. GAAP. We have taken stepsfund a certain statutory reserve fund, until the aggregate amount of such fund reaches 50% of its registered capital. Such reserve funds cannot be distributed to ensure that our financial statements are in accordance with U.S. GAAP, including our hiringus as dividends. At its discretion, each of a U.S. accounting firm to work with our PRC Subsidiaries may allocate a portion of its after-tax profits based on PRC accounting personnel and managementstandards to convert our books and records to U.S. GAAP and prepare our financial statements. However, the measures we have taken may not be sufficient to mitigate the foregoing risks. Furthermore, the need to comply with U.S. GAAP may require us to expend substantial amounts of resources and time that could divert our management’s attention and disrupt our business.

We will incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance requirements, including establishing and maintaining internal controls over financial reporting, and we may be exposed to potential risks if we are unable to comply with these requirements.

As a public company we will incur significant legal, accounting and other expenses under the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), together with rules implemented by the Securities and Exchange Commission and applicable market regulators. These rules impose various requirements on public companies, including requiring certain corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these requirements. These rules will increase our legal and financial costs and will make some activities more time-consuming and costly.

PRC companies have historically not adopted a Western style of management and financial reporting concepts and practices, which include strong corporate governance, internal controls and, computer, financial and other control systems. Most of our middle and top management staff are not educated and trained in the Western system, and we may have difficulty hiring new employees in the PRC with such training. As a result of these factors, we may experience difficulty in establishing management, legal and financial controls, collecting financial data and preparing financial statements, books of account and corporate records and instituting business practices that meet Western standards.

23

The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluations and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Compliance with Section 404 may require that we incur substantial accounting expenses and expend significant management efforts. When we completed the acquisition of AiXin BVI, we adopted the financial reporting controls and disclosure controls and procedures of AiXinZhonghong. The financial controls and disclosure controls and procedures of AiXinZhonghong are not adequate for a public company. Among others weaknesses, the lack of familiarity of our accounting staff with U.S. GAAP constitutes a material weakness in our controls for financial reporting. We have taken steps to rectify this weakness, including hiring a U.S. accounting firm to work with our management and accounting personnel. There is no assurance, however, that the steps taken to date will be sufficient to rectify this material weakness. In the event that we fail to remedy the weaknesses in our controls over financial reporting and adopt appropriate disclosure controls and procedures, our financial reporting may be deficient and we may fail to comply with the reporting requirements of the Securities Exchange Act and other U.S. securities laws, in which event, the market price of our common stock could decline if investors and others lose confidence in the reliability of our financial statements and we could be subject to sanctions or investigations by the SEC or other applicable regulatory authorities.

If we become directly subject to the scrutiny, criticism and negative publicity involving U.S. publicly-traded Chinese companies, we may have to expend significant resources to investigate and resolve the matter which could harm our business operations, stock price and reputation and could result in a loss of your investment in our stock, especially if such matter cannot be addressed and resolved favorably.

U.S. public companies that have substantially all of their operations in China, particularly companies that completed reverse merger transactions, have been the subject of intense scrutiny, criticism and negative publicity by investors, financial commentators and regulatory agencies, such as the SEC. Much of the scrutiny, criticism and negative publicity have focused on financial and accounting irregularities and mistakes, a lack of effective internal controls over financial accounting, inadequate corporate governance policiesan enterprise expansion fund, or a lack of adherence theretostaff welfare and in many cases, allegations of fraud. As a result of the scrutiny, criticism and negative publicity, the publicly traded stock of many Chinese companies has sharply decreased in value and, in some cases, has become virtually worthless. Many of these companies are now subject to stockholder lawsuits, SEC enforcement actions and are conducting internal and external investigations into the allegations. It is not clear what affect this sector-wide scrutiny, criticism and negative publicity will have on our company, our business and our stock price. If we become the subject of any unfavorable allegations, whether such allegations are proven to be true or untrue, we will have to expend significant resources to investigate such allegations and/or defend our company. This situation will be costly and time consuming and distract our management from growing our company. If such allegations are not proven to be groundless, our company and business operations will be severely impacted and your investment in our stock could be rendered worthless.

Techniques employed by manipulative short sellers in Chinese small-cap stocks may drive down the market price of our common stock.

Short selling is the practice of selling securities that the seller does not own but rather has borrowed from a third party with the intention of buying identical securities back at a later date to return to the lender. The short seller hopes to profit from the difference in the sale price of the borrowed securities and the purchase price of the replacement shares. As it is therefore in the short seller’s best interests for the price of the stock to decline, there have been incidents of short sellers publishing, or arranging to publish negative opinions in order to create negative market momentum. While traditionally these disclosed shorts have been limited in their ability to access mainstream business media or to otherwise create negative market rumors, the rise of the Internet and technological advancements regarding document creation, videotaping and publication by weblog (“blogging”) have allowed many disclosed shorts to publicly attack a company’s credibility, strategy and veracity by means of so-called research reports that mimic the type of investment analysis performed by large Wall Street firms and independent research analysts. These short attacks have, in the past, resulted in the selling of shares in the market, on occasion on a large scale and broad base. Issuers with business operations based in the PRC, that have limited trading volumes and that are susceptible to higher volatility levels than U.S. domestic large-cap stocks can be particularly vulnerable to such short attacks.

These short seller publications are not regulated by any governmental, self-regulatory organization or other official authority in the U.S., are not subject to the certification requirements imposed by the SEC in Regulation Analyst Certification and, accordingly, the opinions they express may be based on distortion of the actual facts or, in some cases, fabrication of the facts. In light of the limited risks involved in publishing such information, and the enormous profit that can be made from running just one successful short attack, unless the short sellers become subject to significant penalties, it is more likely than not that disclosed shorts will continue to issue such reports.

24

While we intend to strongly defend our public filings against any such short seller attacks, oftentimes we are constrained, either by principles of freedom of speech, applicable state law (often called Anti-SLAPP statutes), or issues of commercial confidentiality, in the manner in which we can proceed against the relevant short seller. You should be aware that in light of the relative freedom to operate that such persons enjoy – oftentimes blogging from outside the U.S. with little or no assets or identity requirements – should we be targeted for such an attack and the rumors not dismissed by market participants, our stock will likely suffer from a temporary, or possibly long term, decline in market price.

Because we do not intend to pay any cash dividends on our common stock, our stockholders will not be able to receive a return on their shares unless they sell them.bonus fund.

 

We have not declaredhad no transactions that involved the transfer of cash or paidassets throughout our corporate structure. None of our Chinese Operating Companies has distributed any cash or other assets to AiXin HK, including by way of dividends onor interest payments and AiXin Colorado has not transferred any cash or other assets to any of our common stock nor do we anticipate paying anyPRC Subsidiaries. No transfers, dividends or distributions have been made to our investors. To the extent our cash or other assets is in one of our Chinese Operating Companies or AiXin HK, the foreseeable future. Furthermore, we expectfunds or assets may not be available to retain any future earnings to finance ourfund operations and expansion. Theor for use outside of mainland China or Hong Kong including for the payment of dividends to the shareholders of AiXin Life, due to interventions by the governments of PRC or Hong Kong, or the imposition of restrictions and limitations on the ability of the PRC Subsidiaries to use such cash dividends inor assets imposed by the future will be at the discretiongovernment of our Board of Directors and will depend upon our earnings levels, capital requirements, any restrictive loan covenants and other factors the Board considers relevant.mainland China or Hong Kong.

 

Unless weThe PRC government may continue to strengthen its capital controls, and more restrictions and substantial vetting processes may be put forward by SAFE for cross-border transactions falling under both the current account and the capital account. Any limitation on the ability of our PRC Subsidiaries to pay dividends or make other kinds of payments to us could materially and adversely limit our stockholdersability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business.

Except for such limitations on our Company’s ability to transfer cash and other assets among our entities currently or hereafter imposed by the governments of the PRC and Hong Kong, there are no limitations on our Company’s ability to transfer cash and other assets through our corporate structure. Our Company does not have any cash management policies with respect to the transfer of cash among our entities other than requirements for the approval of management for transfers in excess of specified amounts and none of our entities is currently party to any debenture, loan or other agreement which imposes restrictions or otherwise limits our Company’s ability to transfer our cash and other assets and we have not adopted any policies that dictate how funds are transferred other than as necessary to comply with applicable laws.

In addition, the Enterprise Income Tax Law and its implementation rules provide that a withholding tax rate of up to 10% will be applicable to dividends payable by Chinese companies to non-PRC-resident enterprises unless otherwise exempted or reduced according to treaties or arrangements between the PRC central government and governments of other countries or regions where the non-PRC-resident enterprises are incorporated.

PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from making loans or additional capital contributions to our PRC Subsidiaries, which could materially and adversely affect our liquidity and our ability to fund and expand our business.

We are an offshore holding company conducting our operations in China through our PRC Subsidiaries. We may make loans or provide guarantees for the benefit of our PRC Subsidiaries subject to the approval of or registration with governmental authorities and limitations of the amount, or we may make additional capital contributions to our PRC Subsidiaries. Any loans to our PRC Subsidiaries, which are treated as foreign-invested enterprises under PRC law, are subject to foreign exchange loan registrations. In addition, a foreign-invested enterprise, or FIE, shall use its capital pursuant to the principle of authenticity and self-use within its business scope. The capital of an FIE shall not be used for the following purposes: (i) directly or indirectly for payments beyond the business scope of the enterprise or payments prohibited by relevant laws and regulations; (ii) directly or indirectly for investments in securities or investments other than in banks’ principal-secured products unless otherwise provided by relevant laws and regulations; (iii) the granting of loans to non-affiliated enterprises, except where it is expressly permitted in the business license; and (iv) paying the expenses related to the purchase of real estate that is not for self-use (except for foreign-invested real estate enterprises).

In light of the requirements imposed by PRC regulations on loans to and direct investments in PRC entities by offshore holding companies, we cannot assure you that we will be able to complete the necessary government registrations or obtain the necessary government approvals on a timely basis, if at all, with respect to future loans by us to our PRC Subsidiaries or with respect to future capital contributions by us to our PRC Subsidiaries. If we fail to complete such registrations or obtain such approvals, our ability to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially and adversely affect our liquidity and our ability to fund and expand our business.

29

Risks Related to our Common Stock

There is a limited public market for our common stock and you may not be able to receiveresell our shares at or above the price you paid or at all.

There is a return on theirlimited public market for our common stock in the OTCQB. On many days during the years ended December 31, 2022, and 2023, and to date in 2024, no shares unless they sell them.were traded. We cannot assure you that an active public market for our common stock will develop or that you will be able to sell shares when you desire to do so.

Chinese companies are undergoing heightened scrutiny by US regulatory authorities.

It appears that US regulatory authorities, including the SEC and the exchanges on which our common stock might trade, are subjecting Chinese companies to heightened scrutiny and review. This had made it more difficult for certain Chinese companies to complete public offerings of their securities or list their shares for trading on securities markets in the US. Such activities could impact our ability to uplistresell our shares at or raise capital inabove the public markets which may materially impact our business and our consolidated financial position, results of operations, and cash flows.

price you paid or at all.

The market price of our common stock can becomeshares is likely to be highly volatile, leadingwhich could result in substantial losses to the possibility of its value being depressed at a time when you may want to sell your holdings.investors.

 

The markettrading price of our common stock can become volatile. Numerousmay be volatile and could fluctuate widely due to factors many of which are beyond our control,control. The trading price for our common stock varied during the twelve-month period ended December 31, 2023, between a high of $11.00 on April 13, 2023 and a low of $1.00 on November 20, 2023. The last reported trade in our common stock on March 21, 2024, was $0.27. Our stock price is likely to continue to be volatile and subject to significant price and volume fluctuations. This may causehappen because of the broad market and industry factors, like the performance and fluctuation of the market prices of other companies with business operations located mainly in China that have securities publicly traded in the United States. The securities of some companies with operations in China and securities publicly traded in the United States have experienced significant volatility, including price declines in connection with their initial public offerings. The trading performance of these Chinese companies’ securities after their offerings may affect the attitudes of investors toward Chinese companies publicly traded in the United States, including those of investors based in China, in general and consequently may impact the trading performance of our common stock, regardless of our actual operating performance. Such volatility in the price of our common stock including any stock-run up, may be unrelated to fluctuate significantly. Theseour actual or expected operating performance and financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our common stock.

In addition to market and industry factors, include:the trading price and volume of our common stock may be highly volatile due to factors specific to our operations, including the following:

 

our earnings releases, actual or anticipated changesvariations in our earnings, fluctuations in ouractual and perceived operating results or our failure to meet the expectations of financial market analysts and investors;results;
  
changes in financial estimatesnews regarding gains or losses of customers or partners by us or by any securities analysts who might cover our stock;competitors;
  
speculation aboutnews regarding gains or losses of key personnel by us or our business in the press or the investment community;competitors;
  
significantannouncements of competitive developments, relating toacquisitions or strategic alliances in our relationships withindustry by us or our customers or suppliers;competitors;
  
stock market price and volume fluctuations of other publicly traded companies and,changes in particular, those that are in our industry;earnings estimates or buy/sell recommendations by financial analysts;
  
customer demand for our products;potential litigation;
  
investor perceptionsthe imposition of fines or penalties related to our industryactivities in generalthe PRC and our Company in particular;failure to comply with applicable rules and regulations;
  
general market conditions or other developments affecting us or our industry; and
 
the operating and stock price performance of comparable companies;
general economic conditionsother companies, other industries and trends;

25

announcements by usother events or factors beyond our competitors of new products, significant acquisitions, strategic partnerships or divestitures;
changes in accounting standards, policies, guidance, interpretation or principles;
loss of external funding sources; and
sales of our common stock, including sales by our directors, officers or significant stockholders; and departures of key personnel.control.

 

Securities class action litigation is often instituted against companies following periods of volatility in their stock price. Should this type of litigation be instituted against us, it could result in substantial costs to us and divert our management’s attention and resources.

Moreover, securities markets may from time-to-time experience significant price and volume fluctuations for reasons unrelated to the operating performance of particular companies. These market fluctuations may adversely affect the price of our common stock and other interests in our Company at a time when you want to sell your interest in us.

If we fail to develop and maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud, as a result, current and potential stockholders could lose confidence in our financial reports, which could harm our business and the trading price of our common stock.

Effective internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud. Section 404 of the Sarbanes-Oxley Act of 2002 requires us to evaluate and report on our internal controls over financial reporting. Compliance with Section 404 requires that we strengthen, assess and test our system of internal controls to provide the basis for our report. The process of strengthening our internal controls and complying with Section 404 is expensive and time consuming and requires significant management attention. We cannot be certain that the measures we undertake will ensure that we will maintain adequate controls over our financial processes and reporting in the future. Furthermore, if we are able to rapidly grow our business, the internal controls that we will need will become more complex, and significantly more resources will be required to ensure our internal controls remain effective. Failure to implement required controls, or difficulties encountered in their implementation, could harm our operating results or cause us to fail to meet our reporting obligations. If we discover a material weakness in our internal controls, the disclosure of that fact, even if the weakness is quickly remedied, could diminish investors’ confidence in our financial statements and harm our stock price. In addition, non-compliance with Section 404 could subject us to a variety of administrative sanctions, including the suspension of trading, ineligibility for listing on the OTC Markets, and the inability of registered broker-dealers to make a market in our common stock, which would further reduce our stock price.

There is no active trading market for our shares of common stock.

There is no active trading market for our common stock. There can be no assurance that a regular trading market for our securities will develop, or that if one develops, that it will be sustained. The trading price of our securities could be subject to wide fluctuations, in response to announcements by us or others, developments affecting us, and other events or factors. In addition, the stock market has experienced extreme price and volume fluctuations in recent years. These fluctuationsthat have had a substantial effect on the market prices for many companies, often been unrelated or disproportionate to the operating performance of suchparticular companies. Securities class action litigation has often been instituted against companies following periods of volatility in the overall market and in the market price of a company’s securities. This litigation, if instituted against us, could result in very substantial costs, divert our management’s attention and resources, and harm our business, operating results and financial condition. In addition, recent fluctuations in the financial and capital markets have resulted in volatility in securities prices.

Military or other conflicts in Ukraine, the Middle East or elsewhere may lead to increased volume and price volatility for publicly traded securities which could adversely impact the price of our common stock.

Military or other conflicts in Ukraine, the Middle East or elsewhere may lead to increased volume and price volatility for publicly traded securities, or affect the operations or financial condition of companies, and maylead to national, regional or international economic disruptions and economic uncertainty, any of which could adversely impact the price of our common stock.

The sale or availability for sale of substantial amounts of our common stock could adversely affect its market price.

Sales of substantial amounts of our common stock in the public market or the perception that these sales could occur, could adversely affect the market pricesprice of our common stock and could materially impair our ability to raise capital through equity offerings in the securities. Such risks couldfuture. Shares held by our existing shareholders may be sold in the public market in the future subject to the restrictions in Rule 144 under the Securities Act. We cannot predict what effect, if any, market sales of securities held by our significant shareholders or any other shareholder or the availability of these securities for future sale will have an adverse effect on the stock’s future liquidity.market price of our common stock.

26

 

OurIf securities or industry analysts do not publish research or reports about our business, or if they adversely change their recommendations regarding our common stock, is subject to the “Penny Stock” Rules of the SECmarket price for our common stock and the trading market in our securities is limited, which makes transactions in our stock cumbersome and may reduce the value of an investment in our stock.volume could decline.

 

The SEC has adopted Rule 15g-9 which establishestrading market for our common stock will be influenced by research or reports that industry or securities analysts publish about our business. If one or more analysts who cover us downgrade our common stock, the definition of a “penny stock,” for the purposes relevant to us, as any equity security that has a market price for our common stock would likely decline. If one or more of less than $5.00 per sharethese analysts cease to cover us or with an exercisefail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the market price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: (a) that a broker or dealer approve a person’s accounttrading volume for transactions in penny stocks; and (b) the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the pennyour common stock to be purchased.decline.

Because we do not expect to pay dividends in the foreseeable future, you must rely on price appreciation of our common stock for return on your investment.

 

In orderTo date, we have not paid dividends on our common stock. We currently intend to approve a person’s account for transactions in penny stocks, the broker or dealer must: (a) obtain financial information and investment experience and objectives of the person; and (b) make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the Commission relating to the penny stock market, which, in highlight form: (a) sets forth the basis on which the broker or dealer made the suitability determination; and (b) that the broker or dealer received a signed, written agreement from the investor prior to the transaction. Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors to disposeretain all of our common sharesavailable funds and causeany future earnings to fund the development and growth of our business. As a declineresult, we do not expect to pay any cash dividends in the market value offoreseeable future. Therefore, you should not rely on an investment in our stock.

Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotationscommon stock as a source for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

Under our Articles of Incorporation, our Board of Directors has the authority, without stockholder approval, to issue preferred stock with terms that may not be beneficial to common stockholders and with the ability to adversely affect stockholder voting power and perpetuate the board’s control over our company.dividend income.

 

Our Boardboard of Directorsdirectors has complete discretion as to whether to distribute dividends. The timing, amount and form of future dividends, if any, will depend on, among other things, our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by resolutionus from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors. Accordingly, the return on your investment in our common stock will likely depend entirely upon any future price appreciation of our common stock. There is no guarantee that our common stock will appreciate in value or even maintain the price at which you purchased our common stock and you may authorize the issuance of preferred stock in one or more series with such limitations and restrictions as it may determine, in its sole discretion, with no further authorization by security holders required for the issuance of such shares. The Board may determine the specific terms of the preferred stock, including: designations; preferences; conversions rights; cumulative, relative; participating; and optional or other rights, including: voting rights; qualifications; limitations; or restrictions of the preferred stock.even lose your entire investment.

 

30

The issuance

Our CEO has substantial influence over our company. His interests may not be aligned with the interests of preferred stock may adversely affect the voting powerour other shareholders, and other rights of the holders of common stock. Preferred stock may be issued quickly with terms calculated to discourage, make more difficult, delayhe could prevent or preventcause a change inof control of our company or make removal of management more difficult. As a result, the Board of Directors’ ability to issue preferred stock may discourage the potential hostile acquirer, possibly resulting in beneficial negotiations. Negotiating with an unfriendly acquirer may result in terms more favorable to us and our stockholders. Conversely, the issuance of preferred stock may adversely affect the market price of, and the voting and other rights of the holders of the common stock. We presently have no plans to issue any preferred stock.

We may, in the future, issue additional shares of common stock, which would reduce investors’ percent of ownership and may dilute our share value.transactions.

 

Our ArticlesQuanzhong Lin, our Chairman of Incorporation authorizes the issuanceBoard of 500 million sharesDirectors and Chief Executive Officer, beneficially owns an aggregate of approximately 58% of our outstanding common stock. We currentlyAccordingly, Mr. Lin could have outstanding 49,999,891 sharessignificant influence in determining the outcome of common stock.any corporate transaction or other matter submitted to the shareholders for approval, including mergers, consolidations, the appointment of directors and other significant corporate actions. Mr. Lin will also have the power to prevent or cause a change in control. Without the consent of Mr. Lin, we may be prevented from entering into transactions that could be beneficial to us or our minority shareholders. In addition, Mr. Lin could violate his fiduciary duties by diverting business opportunities from us to himself or others. The future issuanceinterests of common stockMr. Lin may result in substantial dilutiondiffer from the interests of our other shareholders. The concentration in the percentageownership of our common stock held by our then existing stockholders. Weshares may value any common stock issuedcause a material decline in the future on an arbitrary basis. The issuance of common stock for future services or acquisitions or other corporate actions may have the effect of diluting the value of the shares held by our investors and might have an adverse effect on any trading market for our common stock.

 

27

Item 1B.Unresolved Staff Comments

 

No disclosure is required pursuant to this item.

 

Item 1C.

Cybersecurity Policy

We regularly review our cybersecurity defenses to assess our vulnerability to cybersecurity attacks from viruses, malware and more sophisticated and targeted cyber-related attacks such as hackers looking to demand ransomware or access our systems to obtain information and data, as well as our vulnerability to cybersecurity failures resulting from human error and technological errors. We rely upon internal IT personnel working in conjunction with specialized outside security consultants on a day to day basis to conduct reviews and upgrade our systems when determined to be necessary.

Our overall strategy in combatting cybersecurity risks includes a variety of measures, including:

the use of antivirus software, virtual private networks, email security, as well as other software and system-wide measures such as multi-factor authorization to prevent and detect data intrusions;

deployment of updates and patches as they become available from our software suppliers and consultants and maintaining the current versions of major software to reduce the exposure to vulnerabilities;

the use of third-party services to conduct mandatory online training for all employees regarding identifying and avoiding cyber-security risks;

the review of the security procedures used by third parties that may host or otherwise have access to our systems;

the deployment of third-party cyber-security experts to perform penetration testing on our internal and external networks and systems in an effort to identify potential vulnerabilities; and

consideration of the cybersecurity risks posed by interacting with current and potential third-party service providers, suppliers and customers..

We are not aware of any existent weakness in our systems or malware embedded in our systems that are likely to would materially affect, or are reasonably likely to materially affect, our operations.

Day-to day management of cybersecurity threats is conducted by our Information Technology department in conjunction with outside service providers, which is charged with identifying and reporting threats to senior management. On a quarterly basis, cybersecurity is reviewed by our Chief Executive Officer and Chief Financial Officer, who are expected to report to the Audit Committee.

Board Oversight

The Audit Committee of our Board of Directors, which is composed of all non-employee directors, is responsible for oversight of our efforts to eliminate cybersecurity risks. The Audit Committee meets regularly with our Chief Executive Officer and Chief Financial Officer and, in turn, reports its finding to the Board of Directors.

31

Item 22.Properties.

 

No disclosure is required pursuantWe currently operate 25 retail pharmacies in Chengdu. The pharmacies are operated subject to this item.short term leases at market rate rents. In addition to the pharmacies, we maintain our administrative offices in Chengdu.

 

Yunnan Runcangsheng operates a 13,000 square meter production facility, including, R&D centers, extraction facilities, preparation workshops and a warehouse. Yunnan Runcangsheng operates planting facilities where it grows some of the key ingredients used in its products. Runcangsheng acquired the right to use the production facility pursuant to a Development Agreement with the People’s Government of Luquan Li and Miao Autonomous County. The Development Agreement grants Ruuncangsheng the rights to use the facility for a period of five years ending November 25, 2025, provided Runcangsheng invests certain amounts in the development of the property and its business, including the construction of office space, manufacturing facilities and workshops. The governmental authorities appear to be satisfied with the progress Runcangsheng has made in the development of the property to date and have not expressed any intent to terminate the Agreement.

Effective March 31, 2024, we terminated our lease for the Shangyan Hotel. In the termination agreement we and the landlord agreed to release each other from any claims and the landlord agreed to return the security deposit.

On February 6, 2024, we entered into a lease with respect to a hotel located in Bandzhuyuan Town, Xindu District, Chengdu City. The term of the lease commenced February 29, 2024 and expires April 15, 2034. The lease provides for an annual rent of 1.2 million RMB and an annual property management fee of 400,000 RMB, which remains unchanged for the initial five-year term and are subject to a 5% annual increase thereafter. We have remitted to the landlord a deposit equal to two months’ rent and property management fee, refundable upon lease expiration or termination, less deductions for any outstanding payments, damages, or breaches of contract. The Lease grants us the right to occupy various areas within the hotel, covering approximately 18,000 square meters, including the first-floor lobby, external shops (subject to the rights of the current occupants), second to fourth floors, fifth to eighteenth floors (inclusive of meeting rooms and part of the dining rooms), underground and ground parking lots, and all hotel facilities and equipment.

Item 3Legal Proceedings.

 

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

 

In December 2020, Jian Yiao (the “Plaintiff”) filed a complaint against Chengdu Aixintang Pharmacy Co., Ltd. (“Aixintang Pharmacy”) in Zhangjiagang People’s Court in Jiangsu Province. The complaint alleges that Mr. Yiao is entitled to $392,305 (RMB2,500,000) from Aixintang Pharmacy for breaching a purchase agreement entered in March 2020 (the “Purchase Agreement”). Aixintang Pharmacy claimed that the Purchase Agreement was the result of a forgery by an employee, and that Aixintang Pharmacy did not enter the Purchase Agreement. The Court determined that Aixintang Pharmacy breached the Purchase Agreement by not delivering the products ordered and ordered Aixintang Pharmacy to pay $392,305 (RMB2,500,000) to the Plaintiff. In December 2020, Aixintang Pharmacy filed a motion in the Jiangsu Suzhou Intermediate People’s Court against the verdict.

In February 2021, the judge in the Jiangsu Suzhou Intermediate People’s Court denied Aixintang Pharmacy’s motion and upheld the judgment from the first trial. In March 2021, Aixintang Pharmacy filed another motion to the Jiangsu High People’s Court on the basis that the Purchase Agreement was forged. In February 2022, Aixintang Pharmacy filed an appeal in Jiangsu High People’s Court against the judgment reached by Jiangsu Suzhou Intermediate People’s Court in February 2021. To date, this legal proceeding remains pending.

The incident which is the subject to the above lawsuit occurred before Aixintang Pharmacy was acquired by the Company. In November 2021, Mr. Lin agreed to indemnify the Company against any losses arising from this legal proceeding.

The Company believes that current pending litigation will not have a material adverse effect on its consolidated financial position, results of operations or cash flows.

32

Item 4Mine Safety Disclosures.

 

Not applicable

 

PART II

 

Item 5Market For Registrant’s Common Equity, Related Stockholder Matters And Issuer Purchases Of Equity Securities.

 

Market Information

 

Our common stock is quoted on OTCQX Best MarketOTCQB under the symbol “AIXN.” From February 6, 2019 until January 22, 2021 until June 5, 2023, our common stock was quoted on the OTCQBOTCQX under the symbol “AIXN.”

 

There exists onlyTrading in stocks on the OTCQX and OTCQB is often thin and is characterized by wide fluctuations in trading prices due to many factors that may have little to do with a limited tradingcompany’s operations or business prospects. We cannot assure you that there will be a market for our common stock onin the OTCQX Best Market tier offuture.

The following table sets forth the OTC Markets (www.otcmarkets.com) with limited or no volume. The below table indicates, with respect to our common stock, the range of high and low trading prices of one share of our common stock for each full quarterly period withinfiscal quarter during the two most recent fiscal years. Over-the-counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions. Our common stock trades on a limited, sporadic and volatile basis. These high and low bid prices per share of common stock have been adjusted to give effect to the 1-for-2 reverse stock split of our common stock effected on February 17, 2023.

 

Year ended December 31, 2020 Low  High 
Year ended December 31, 2023 Low  High 
First Quarter $2.40  $8.20  $1.60  $6.86 
Second Quarter  2.49   4.38   1.17   11.01 
Third Quarter  3.01   4.00   2.25   4.50 
Fourth Quarter  3.05   6.45   1.00   2.25 

 

Year ended December 31, 2021 Low  High 
Year ended December 31, 2022 Low High 
First Quarter $4.80  $6.13  $3.22  $6.98 
Second Quarter  7.00   7.00  3.32 5.49 
Third Quarter  4.00   6.79  3.32 4.00 
Fourth Quarter  4.40   6.98  3.35 6.80 

 

Holders

 

As of March 31, 2022, we had in excess of 70029, 2024, there were approximately 635 record holders of our common stock.

28

 

Dividends

 

Since inception we have not paid any dividends on our common stock. We currently do not anticipate paying any cash dividends in the foreseeable future on our common stock. Although we intend to retain our earnings, if any, to finance the exploration and growth of our business, our board of directors will have the discretion to declare and pay dividends in the future.

 

Payment of dividends in the future will depend upon our earnings, growth, capital requirements, and other factors, which our board of directors may deem relevant.

 

Issuer Purchases of Equity Securities

 

None.

33

Securities Authorized for Issuance under Equity Compensation Plans

 

The following table sets forth information about the common stock available for issuance under compensatory plans and arrangements as of December 31, 2021.2023.

 

Plan Category (a)
Number of securities to be issued upon exercise of outstanding options
 (b)
Weighted-average exercise price of outstanding options under equity compensation plans
  (c)
Number of securities remaining available for future issuance under equity Compensation plans (excluding securities reflected in
column (a))
 
         
Equity compensation plan approved by security holders None     662,500 
           
Equity compensation plans not approved by security holders None     None 
           
Total None     662,500 

 

On January 10, 2019, we adopted the 2019 Equity Incentive Plan (the “2019 Plan”) pursuant to which we registered up to 5,000,000625,000 shares of our common stock for issuance and delivery to employees, directors and consultants of the Company as additional incentives to attract and retain the best available personnel.

 

Penny Stock Regulations

 

The SEC has regulations which generally define so-called “penny stocks” to be equity securities that have a market price less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exemptions. Our common stock is a “penny stock” and is subject to Rule 15g-9 under the Exchange Act, or the Penny Stock Rule. This rule imposes additional sales practice requirements on broker-dealers that sell such securities to persons other than established customers and “accredited investors” (generally, individuals with a net worth in excess of $1,000,000 or annual incomes exceeding $200,000, or $300,000 together with their spouses). For transactions covered by Rule 15g-9, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser’s written consent to the transaction prior to sale. As a result, this rule may affect the ability of broker-dealers to sell our securities and may affect the ability of purchasers to sell any of our securities in the secondary market, thus possibly making it more difficult for us to raise additional capital.

 

For any transaction involving a penny stock, unless exempt, the rules require delivery, prior to any transaction in penny stock, of a disclosure schedule required by the SEC relating to the penny stock market. Disclosure is also required to be made about sales commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements are required to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stock.

 

There can be no assurance that our common stock will qualify for exemption from the Penny Stock Rule. In any event, even if our common stock were exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person from participating in a distribution of penny stock, if the SEC finds that such a restriction would be in the public interest.

 

Recent Sales of Unregistered Equity Securities

 

During 2020 and 2021,the fourth quarter of 2023, we did not have any sales of equity securities in transactions that were not registered under the Securities Act of 1933, as amended, that have not been previously reported in a report filed pursuant to the Exchange Act.

 

2934

 

Item7Management’s Discussion andAnd Analysis ofOf Financial Condition andAnd Results ofOf Operations.

 

The following discussion should be read in conjunction with our consolidated audited financial statements and related notes thereto and other financial information appearing elsewhere in this report. In addition to historical information, the following discussion contains forward-looking statements. Where possible, we have tried to identify these forward-looking statements by using words such as “anticipate,” “believe,” “intends,” or similar expressions. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot assure you that these expectations will prove to be correct. As a result of many factors, including those factors set forth in the “Risk Factors” section of this report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in this report.

Overview

In December 2017, we completed a “reverse” acquisition whereby we acquired all of the outstanding shares of AiXin (BVI) International Group Co., Ltd. a British Virgin Islands corporation (“AiXin BVI”). As a result, AiXin BVI became our wholly-owned subsidiary, and through AiXin BVI we now own all of the outstanding shares of HK AiXin International Group Co., Limited, a Hong Kong limited company (“AiXin HK”), which in turn owns all of the outstanding shares of Chengdu AiXinZhonghong Biological Technology Co., Ltd., a Chinese limited company (“AiXinZhonghong”), which began distributing nutritional products in 2013.

In September 2021, we completed the acquisition of nine pharmacies located in Chengdu by acquiring the entities which owned the pharmacies for an aggregate purchase price of RMB 34,635,845, or approximately US$5.31 million. Since that time, the number of our pharmacies has increased to 13.

Pursuant to an Equity Transfer Agreement (the “Transfer Agreement”), on September 30, 2022, we acquired all of the outstanding equity of Yunnan Runcangsheng Technology Co., Ltd (“Runcangsheng”) for RMB 31,557,820 (approximately USD$4.4 million), reduced by $116,802 the excess of the estimated net worth of Runcangsheng over its audited net worth as of December 31, 2021. In addition to transferring their respective equity interest in Runcangsheng, both Sellers agreed to forgive any loans due to them from Runcangsheng. Runcangsheng operates a 13,000 square meter production facility, which houses R&D centers, extraction facilities, preparation workshops and a warehouse. Runcangsheng has more than 30 sub brands and operates planting facilities where it grows some of the key ingredients used in its products. Many of the products it has developed are specifically targeted to alleviate symptoms associated with the increasingly competitive and pressured lifestyle of the Chinese middle class.

Runcangsheng. was established in April 2020, and is headquartered in Luquan Yi and Miao Autonomous County, Kunming City, Yunnan Province. It is focused on promoting a healthy lifestyle through the use of foods believed to promote well-being, health foods, modernized versions of traditional Chinese medical products and plant extracts. Runcangsheng cultivates many of the raw materials used in its products, compounds the materials into easy to transport and use pre-packaged foods and distributes the products at the wholesale level. As life-styles in China evolve, work pressures increase and the ingestion of meats and other western style foods increases, Runcangsheng seeks to design and market products intended to combat the increase in obesity, hypertension, insomnia and physical ailments associated with such changes. The acquisition of Runcangsheng will enable us to operate as a vertically integrated company, capable of formulating the kinds of health foods and other nutritional products and supplements suitable for our clients and marketing those products through our distribution channels.

In addition to our acquisitions in the health and nutritional sector, in July 2021, we completed the acquisition of Aixin Shangyan Hotel through which we owned and operated a hotel located in the Jinniu District, Chengdu City. Effective March 31, 2024, we terminated our lease for the Shangyan Hotel. In the termination agreement we and the landlord agreed to release each other from any claims and the landlord agreed to return the security deposit.

On February 6, 2024, we entered into a lease with respect to a hotel located in Bandzhuyuan Town, Xindu District, Chengdu City. The term of the lease commenced February 29, 2024 and expires April 15, 2034. The Lease grants us the right to occupy various areas within the hotel, covering approximately 18,000 square meters, including the first-floor lobby, external shops (subject to the rights of the current occupants), second to fourth floors, fifth to eighteenth floors (inclusive of meeting rooms and part of the dining rooms), underground and ground parking lots, and all hotel facilities and equipment. References to hotel revenues and operating costs below are with respect to the hotel we previously occupied in the Jinniu District of Chengdu.

We intend to look for additional opportunities to profit from the growing healthcare market in China. Though currently we are not party to any agreements, we will explore, among other opportunities, expanding our product line through internal research and acquiring complementary products from third parties, acquiring additional pharmacies and other retail outlets and operating nursing homes and possibly clinics which provide medical care to clients.

Our Business

 

We are focused on providing health and wellness products to the growing middle class in China. We currently develop, manufacture, market and sell consumerpremium-quality healthcare, nutritional products in China by offering premium-quality nutritional products.and wellness supplements, including herbs and greens, traditional Chinese remedies, functional products, such as weight management tools, probiotics, foods and drinks. We also offer products purchased from third parties and provide advertising and marketing services to clients which engage us to market and distribute their products. We offer our nutritional products and those of our clients for which we provide marketing services, through oura diversified, omni-channel business model which generates revenues through retail and wholesale product sales, offices, exhibition events we organizethrough company-owned pharmacies, direct marketing and sponsor, and person-to-person marketing.e-commerce. Our marketing business mainly focuses onapproach emphasizes proactively approaching customers such as by hosting marketing events for clients, which we believe is ideally suited to marketing ourthe products and those of our clients for which we perform advertising servicesoffer because sales of healthcare, nutritional products and supplements are strengthened by ongoing personal contact and support, coaching and education among the Company and our clients towards how to achieve a healthy and active lifestyle.

 

In September 2021,

35

We believe the competitive strengths that will enable us to grow in the health and wellness market include our ability to design and manufacture products that are responsive to consumers’ needs as the life style of China’s middle class evolves, our coordinated omni-channel distribution network where we completedenable consumers to obtain the acquisition of nineinformation they need to improve their lifestyle on our website, at our pharmacies located in Chengdu by acquiring the entities which owned the pharmacies for an aggregate purchase price of RMB 34,635,845, or approximately US$5.31 million (“Transfer Price”). The Transfer Price will be reduced by an amount equal to any amounts paid or distributed by any of the entities to its shareholders after December 31, 2020 and increased by an amount contributed to any of the entities by its shareholders after such date. The pharmacies will be used to supplementthrough individual meetings with our efforts to distribute our nutritional products.team members.

 

In July we completed the acquisition of Aixin Shangyan Hotel. Shangyan Hotel Company ownsOur ability to operate profitably and operates a hotel located in the Jinniu District, Chengdu City. The hotel covers more than 8,000 square meters and hasgenerate positive cash flow will be determined by our ability to attract a large restaurantand loyal customer base and provide the information and products they need cost effectively. Our revenue will largely be determined by our ability to achieve and maintain a strong brand name and company image, the volume of products we sell and the prices we can charge for such products, which will require that can accommodate 600 people, 6 luxury dining rooms, a 200 square meter music tea house, 13 private tea rooms, 108 guest rooms and other supporting facilities. We acquired the hotel through an acquisition of the outstanding equity of Aixin Shangyan Hotel for a purchase price of RMB 7,598,887, or approximately $1.16 million (“Transfer Price”). The Transfer Pricewe compete effectively. Our costs will largely be reduced by an amount equal to any amounts paid or distributeddetermined by the hotelcost of raw materials and acquired inventory, the labor used to its shareholders after December 31, 2020design and will be increased by an amount equalmanufacture products, and the costs incurred to any amounts contributeddeliver these products to the hotel by its equity owners after December 31, 2020.

In March 2020, the World Health Organization announced that infections caused by the coronavirus disease of 2019 (“COVID-19”) had become pandemic and national, provincial and local authorities, including those whose jurisdictions include Chengdu, where our offices, hotel and pharmacies are located, adopted various regulations and orders, including “shelter in place” rules, restrictions on travel, mandates on the number of people that may gather in one location and closing non-essential businesses. Many of these measures have been relaxed due to the decrease in the prevalence of Covid-19 in China. However, since February 2022 to date, COVID-19 cases have increased again in many cities of China. There has been only a slight increase in the number of cases in Sichuan Province, the Province in which we are located, and we do not expect that the recent increase will materially impact our operations. During the years ended December 31, 2021 and 2020, the ongoing operations of our advertising and marketing business were not materially adversely impacted by the measures taken to limit the spread of the disease in China. Our hotel and pharmacies, however, experienced adverse impacts due to travel and work restrictions imposed on a temporary basis in Chengdu to limit the spread of COVID-19. We implemented procedures to promote employee and customer safety. These measures will not significantly increase our operating costs. However, we cannot predict with certainty what measures may be taken by our suppliers and customers and the impact these measures may have on our financial results for 2022.consumer.

 

In additionWe intend to build a reputation as a provider of premium health and wellness products that seeks to improve our ongoing operations,customers health and well-being. Our objective is to offer a broad and deep mix of products for consumers interested in living well, whether they are looking to treat a health-related issue or simply maintain their overall wellness, Our premium, value-added offerings include both proprietary products developed and manufactured by us as well as products acquired from or sold on behalf of third parties. We believe our range of products and ability to develop new products, combined with the customer support and service we seekoffer, differentiate us and allow us to acquire interests in additional businesses through opportunities found by our management or presented by persons or firms which desire to take advantage of the perceived advantages of an Exchange Act registered corporation. We do not restrict our search to any specific business, industry, or geographical locationeffectively compete against food, drug and may participate in a business venture of virtually any kind or nature.

Itmass channel players, specialty stores, independent vitamin, supplement and natural food shops and online retailers. There is the goal of our management, in particular, our Chairman, Quanzhong Lin to growno assurance that we will achieve our business and to modify its capital structure in order to qualify for a listing on NASDAQ or the NYSE-American exchange. As part of this effort, we will continue to seek to acquire more businesses and to modify our capital structure as necessary to meet the requirements of the exchange to which we apply for a listing. As part of this effort. on June 8, 2020, Mr. Lin transferred to our Company35,049,685 shares of our common stock for cancellation.objectives.

30

 

Results of Operations

 

Years ended December 31, 2023 and 2022

The following table sets forth the results of our operations for the periods indicated as a percentage of net revenue, certainrevenue. Certain columns may not add due to rounding (In reviewing the tables below, please note that the operations of our pharmacies and our hotel are reflected in our financial results from August 2022, the dates as of which the acquisitions were completed):rounding:

 

 Years Ended December 31,  Years Ended December 31, 
 2021  2020  2023  2022 
 $  % of Revenue  $  % of Revenue  $  

% of

Revenue

  $  

% of

Revenue

 
Revenue $3,066,233   100% $2,451,055   100% $4,089,799   100% $2,708,560   100%
Operating costs and expenses  3,093,171   101%  1,656,595   68%  6,588,606   161%  5,278,019   195%
Income (Loss) from operations  (26,938)  (1)%  794,460   32%
Non-operating income (expenses), net  34,023   1%  563,178   23%
Loss from operations  (2,498,807)  (61)%  (2,569,459)  (95)%
Non-operating income (expense), net  427,632   10%  (3,798,689)  (140)%
Loss before income tax  (2,071,175)  (51)%  (6,368,148)  (235)%
Income tax expense  274,321   9%  340,127   14%  19,519   0.5%  1,097   0.04%
Net income(loss) $(267,236)  (9)% $1,017,511   42%
Net loss $(2,090,694)  (51)% $(6,369,245)  (235)%

 

The following table shows our operations by business segment for the years ended December 31, 20212023 and 2020.2022.

 

  2021  2020 
Net revenue        
Advertising and products $2,406,988  $2,451,055 
Pharmacies  280,447   - 
Hotel  378,798   - 
Total revenues, net $3,066,233  $2,451,055 
         
Operating costs and expenses        
Advertising and products        
Cost of goods sold $316,750  $224,675 
Operating expenses  1,344,543   1,431,920 
Pharmacies        
Cost of goods sold  218,735   - 
Operating expenses  252,513   - 
Hotel        
Hotel operating costs  744,594   - 
Operating expenses  216,036   - 
Total operating costs and expenses $3,093,171  $1,656,595 
         
Income (loss) from operations        
Advertising and products $745,695  $794,460 
Pharmacies  (190,801)  - 
Hotel  (581,832)  - 
Income (loss) from operations $(26,938) $794,460 

  For the Years Ended December 31, 
  2023  2022 
Net revenue        
Products $1,159,134  $823,930 
Pharmacies  937,655   789,347 
Hotel  1,194,829   856,884 
Manufacture and sale  798,181   238,399 
Total revenues, net $4,089,799  $2,708,560 
         
Operating costs and expenses        
Products        
Cost of goods sold $393,862  $171,345 
Operating expenses  1,790,747   1,526,246 
Pharmacies        
Cost of goods sold  531,890   578,092 
Operating expenses  455,906   622,835 
Hotel        
Hotel operating costs  1,811,065   1,739,948 
Operating expenses  192,963   310,902 
Manufacture and sale        
Cost of goods sold  688,198   353,723 
Operating expenses  723,975   (25,072)
Total operating costs and expenses $6,588,606  $5,278,019 
         
Loss from operations        
Products $(1,025,475) $(873,661)
Pharmacies  (50,141)  (411,580)
Hotel  (809,199)  (1,193,966)
Manufacture and sale  (613,992)  (90,252)
Loss from operations $(2,498,807) $(2,569,459)

 

31

Revenue

 

Revenue was $3,066,233$4,089,799 in the year ending December 31, 2021,2023, compared to $2,451,055 in the same period of 2020,$2,708,560 for 2022, an increase of $615,178$1,381,239 or 25%51%. The increase in revenue was mainly due to increases in direct sales of our nutritional products, increases in revenues from our hotel and pharmacies, and the generation of revenue by Runcangsheng which we acquired in September 2022. For the year ended December 31, 2023, we had $2,894,970 in product revenues (of which $1,159,134 were from direct sales, $937,655 were from sales at our pharmacies and $798,181 from sales by Runcangsheng) and hotel revenue of $1,194,829. For 2022, we had $1,851,676 product revenues (of which $823,930 were from direct sales, $789,347 represented sales at our pharmacies, $238,399 represented sales from Runcangsheng), and hotel revenue of $856,884.

Direct products sales

Our direct products sales revenue was $1,159,134 for the year ended December 31, 2023, compared with $823,930 for 2022, representing an increase of $335,204 or 41%. Our direct products sales revenue as a percentage to total revenue was 28% for the year ended December 31, 2023, compared to 30% for 2022. The increase in direct sales revenue was mainly due to our heightened promotional activities in 2023 and the cessation of the Covid-19 policy in China.

Pharmacies Revenue

Our pharmacies revenue was $937,655 for the year ended December 31, 2023, compared with $789,347 for 2022, representing an increase of $148,308 or 19%. Our pharmacies revenue as a percentage to total revenue was 23% for the year ended December 31, 2023, compared to 29% for 2022. The increase in pharmacies revenue was a result of our introduction of new products in the second half year of 2022. Specifically, we started to sell Chinese medicinal herbs, considered by some to be a treatment and prevention supplements for Covid-19.

Hotel Revenue

Our hotel revenue was $1,194,829 for the year ended December 31, 2023, compared with $856,884 for 2022, representing an increase of $337,945 or 39%. Our hotel revenue as a percentage of total revenue was 29% for the year ended December 31, 2023, compared to 32% for 2022. The increase in hotel revenue was a result of increased advertisingtravel and consumption activities in China after the pandemic.

Manufacture and sales

Our manufacture and sales revenues were $798,181 for the year ended December 31, 2023, compared with $238,399 for 2022, representing an increase of $559,782 or 235%. Our manufacture and sales revenue as a percentage of total revenue was 20% for the year ended December 31, 2023, compared to 9% for 2022. The primary reason for the increase in manufacture and sales revenue was the inclusion of revenue from our hotel and pharmacies, partly offset by a declineRuncangsheng. which we acquired in product revenues of the Advertising and products segment. For 2021, we had advertising and product revenues of $2,406,988, pharmacies revenue of $280,447, and hotel revenue of $378,798. For 2020, we had $2,451,055 in advertising and products revenue and no revenues from the hotel and pharmacies as the acquisitions were not completed until 2021.September 2022.

 

Operation Costs and Expenses

 

Cost of Goods Sold

 

Cost of goods sold was $535,485 in $1,613,950 for the year ended December 31, 2021,2023, compared to $224,675$1,103,160 for 2020,2022, an increase of $310,810$510,790 or 138%46%. The increase in our cost of goods sold is attributable to the increase in product sales due to the acquisition of the pharmacies as well as an increase in cost of goods sold from our traditional products. sales.

Direct products sales

The cost of goods sold for our nutritionaldirect products was $393,862 for the year ended December 31, 2023, compared with $171,345 for 2022, representing an increase of $222,517 or 130%. The cost of goods sold for our direct product sales as a percentage of sales was 69%34% in 2021,2023, compared to 39%21% for 2020. 2022. The increase in cost of goods sold was primarily driven by the increased commission payouts to our sales personnel in 2023.

Pharmacies Revenue

The cost of goods sold at our pharmacies was $531,890 for the year ended December 31, 2023, compared with $578,092 for 2022, representing a decrease of $46,202 or 8%. The cost of goods sold at our pharmacies as a percentage of pharmacy product sales was 57% in 2023, compared to 73% in 2022. The decrease in cost of goods sold was mainly due to the low cost of Chinese medicinal herbs which were acquired by subsidiary Runcangsheng and distributed by our pharmacies; our coordination of activities at our pharmacies, such as the implementation of bulk inventory purchasing which reduced our purchasing costs; and cost reduction measures undertaken in 2023, including reviewing our list of vendors and replacing those vendors with higher purchasing costs.

Manufacture and sales

The cost of goods sold for our manufacture and sales was $688,198 for the year ended December 31, 2023, compared with $353,723 for, representing an increase of $334,475 or 95%. The cost of goods sold as a percentage of nutritional productsales by our manufacture and sales was higher86% in 2021 than 20202023, compared to 148% in 2022. The primary reason for the increase in cost of goods sold was due to increased sales volumeour acquisition of lower profit margin productsRuncangsheng in 2021.September 2022, which resulted in our recording twelve months of revenues and costs in 2023 compared with three months in 2022.

 

Hotel Operating Costs

 

Hotel Operatingoperating costs were $744,594$1,811,065 and $1,739,948 for the yearyears ended December 31, 2021. There were no comparable2023 and 2022, representing an increase of $71,117 or 4%. The increase in hotel operating costs was mainly due to the increase in 2020 ashotel sales but was partly offset by decreases in the acquisition was completed in 2021.cost of foods and fruits.

 

Operating Expenses

 

Operating costs and expenses were $2,557,688$3,163,591 for the year ended December 31, 2021,2023, compared to $1,431,920$2,434,911 for 2020,the same period of 2022, an increase of $1,125,766.$728,680 or 30%. The increase in operating expenses was mainly due to the inclusion of theincrease in operating expenses of the hotel and pharmacies since their respective dates of acquisitions.reported for Runcangsheng which was acquired on September 30, 2022.

 

Income (loss)Loss from Operations

 

Loss from operations was $(26,938)$2,498,807 in the year ended December 31, 2021,2023, compared to income of $794,460$2,569,459 in 2020,2022, a decrease of $821,398$70,652 or 103%3%. The decrease in our incomeloss from operations for 20212023 was mainly due to the inclusion of the losses occurred byincreases in our revenues at our pharmacies and hotel along with a slight decrease insegments, partly offset by the losses incurred by direct sales activities and our income from advertising services and product sales.new subsidiary, Runcangsheng.

37

 

Non-operating Income

 

Non-operating income was $34,023$427,632 for the year ended December 31, 2021,2023, compared to $563,178non-operating expenses of $3,798,689 for 2020.the year ended December 31, 2022. For 2021,2023, we had interest income of $4,113$838 and other income $438,348, partly offset by other expenses of $11,554. For 2023, other income mainly consisted of a government grant of $369,857. For 2022, we had an impairment loss of goodwill of $3,823,770 arising from the acquisition of Runcangsheng, and other expenses of $31,651, partly offset by interest income of $4,876 and other income of $63,064 and other expenses of $33,154. For 2020, we had interest income of $537,580 and other income $28,924 and other expense $3,326. The interest income in 2020 was primarily due to the interest income from a loan to third party in 2020, which was repaid in full during the year ended December 31, 2020.$51,856.

 

Income tax expenseTax Expense

 

Income tax expense was $274,321$19,519 and $340,127$1,097 for the years ended December 31, 20212023 and 2020, a decrease2022, respectively, an increase of $65,806$18,422 or 19%1,679% for 2021the year ended December 31, 2023 compared with 2020.2022.

 

Net Income (Loss)Loss

 

Our net income (loss)loss for the yearsyear ended December 31, 2021 and 20202023 was $2,090,694, compared to a net loss of $(267,236) and income of $1,017,511, respectively,$6,369,245 for 2022, a decrease in net income of $1,284,747$4,278,551 or 126%for 2021 compared with 202061%. The decrease in our net income in 2021loss was mainly due to a decrease in interest incomeincreased sales and the absence of an impairment loss, partly offset by increased operating losses incurred by our hotelcosts and pharmacies.expenses as explained above.

32

 

Liquidity and Capital Resources

During the year ended of December 31, 2021,2023, we used $57,804$1,392,259 in operations. As of December 31, 2021,2023, cash and cash equivalents were $8,556,642$443,758 (excluding $44,211$23,208 of restricted cash), compared to $7,676,689$510,128 (excluding $109,772 of restricted cash) as of December 31, 2020.2022. At December 31, 2021,2023, we had a working capital deficit of $4,753,390$4,467,006 compared to $6,753,486$3,346,358 at December 31, 2020.2022.

 

The following is a summary of cash provided by or used in each of the indicated types of activities during the years ended December 31, 20212023 and 2020,2022, respectively.

 

  December 31, 2021  December 31, 2020 
Net cash (used in) provided by operating activities $(57,804) $1,613,207 
Net cash (used in) provided by investing activities $(4,431,513) $4,085,236 
Net cash (used in) provided by financing activities $5,221,864  $1,546,854 
  December 31, 2023  December 31, 2022 
Net cash used in operating activities $(1,392,259) $(1,624,565)
Net cash (used in) provided by investing activities $(302,838) $(3,522,369)
Net cash provided by (used in) financing activities $1,560,466  $(2,389,593)

 

Net cash provided byused in operating activities

 

For the year ended December 31, 2021,2023, net cash used in operating activities was $57,804.$1,392,259. This reflects our net loss of $267,236,$2,090,694, adjusted by non-cash related expenses including depreciation and amortization expense of $96,106,$410,690, a change in deferred tax of $18,570,$15,152, a bad debt reversal of $47,762, an inventory impairment of $7,770, operating lease expenseexpenses of $411,607$817,179, government grant income of $369,857 and stock-based compensation of $371,540, and then decreased by changes in working capital of $651,251.$506,639. The cash outflow from changes in working capital mainly resulted from unearned revenueincreases in other receivables and prepaid expense, including related party receivables of $122,897, payments$11,649, in accounts payable from related party of $159,843, in accrued liabilities and other payables of $161,393, in taxes payable of $57,467,$52,010 and payments of lease liabilities of $473,508 and payments of accrued liabilities of $142,027,$779,599, partly offset by cash inflows from accounts receivable, including from related parties in the amount of $477,951, cash inflows from advances to suppliers of $133,513, cash inflows from inventory of $36,240, cash inflows from accounts payable of $93,682, and cash inflow from other receivables and prepaid expenses $94,992 and inventoryunearned revenue of $69,738.$37,275.

 

For the year ended December 31, 2020,2022, net cash provided byused in operating activities was $1,613,207.$1,624,565. This was primarily due toreflects our net incomeloss of $1,017,511, adjusted$6,369,245, increased by non-cash related expenses including depreciation and amortization expense of $43,462, provision for bad debt$185,565, the change in deferred tax of $13,624, and$1,858, operating lease expense of $837,425, stock-based compensation of $371,540, inventory impairment of $54,899 and then increased by favorablean impairment loss of goodwill of $3,823,770, less changes in working capital of $15,340.$576,330. The favorablecash outflow from changes in working capital mainly resulted from a decrease in advance to suppliers of $136,479, a decrease in other receivables and prepaid expenses of $20,003, a decrease in inventory of $6,866, and an increase in outstanding accounts receivable of $425,961, payments of lease liabilities of $710,865, a change in accounts payable of $71,153, unearned revenue of $24,401 and taxes payable of $169,734,$137,711, which was partly offset by a decrease incash inflows from accrued liabilities and other payables of $166,012.$289,868, other receivable and prepaid expense of $109,439, inventory of $150,872, accounts payable to related party of $140,608, and advances to suppliers of $103,016.

 

Net cash (used in) provided byused in investing activities

 

For the year ended December 31, 2021,2023 and 2022, net cash used in investing activities was $4,431,513, mainly$302,838 including $295,487 for the acquisitionpurchase of fixed assets, $4,032 for the purchase of intangible assets, and $3,319 cash disposed of at the termination of a hotel and pharmacies.

non-operating subsidiary. For the year ended December 31, 2020,2022, net cash provided byused in investing activities was $4,085,236, which was$3,522,369, mainly due toas a result of $3,812,027 paid for the returnacquisition of prepayments for acquisitions of $4,087,409, partly offset byRuncangsheng, and purchases of property and equipment of $2,173.$156,723, partly offset by cash acquired in connection with the acquisition of Runcangsheng of $446,381.

Net cash (used in) provided by financing activities

 

For the year ended December 31, 2021,2023, net cash provided by financing activities reflectedwere the result of capital contributions of $142,200 and proceeds from a capital contributiongovernment grant of $4,386,070$369,857, and the proceeds from advances from related parties of $1,204,442, partially offset by the repayment of loans from third parties of $368,648.

$1,048,409. For the year ended in December 31, 2020,2022, net cash provided byused in financing activities werewas $2,389,593 as a result of payments made against advances from related parties of $1,546,854.$2,389,593.

 

38

We substantially depleted our available cash and working capital during 2023 supporting our operations which generated a $2,498,807 loss in 2023 and completing the acquisition of Runcangsheng. It is likely that Runcangsheng will require additional capital to achieve its short term operational goals and long range business plans. Further, we may need additional capital to maintain our other businesses. We may also have to raise additional financing as our working capital requirements are expected to increase in line with the growth of our business. In the past we have funded our operations through proceeds from private placements of equity and advances from our principal shareholder. Should we require capital to fund our business, we intend to finance our business by raising additional capital or, when available, borrowing additional funds. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders and could cause the price of our common stock to decrease. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

We are subject to all of the substantial risks inherent in the development of a new business enterprise within an extremely competitive industry. Due to the absence of a long-standing operating history and the emerging nature of the markets in which we compete, we anticipate operating losses until we can successfully implement our business strategy. Our revenue model is new and evolving, and we cannot be certain that it will be successful. The potential profitability of our business model is unproven. We may never achieve profitable operations. Our future operating results depend on many factors, including demand for our products, the level of competition, and the ability of our officers to manage our business and growth. As a result of the emerging nature of the market in which we compete, we may incur operating losses until such time as we can develop a substantial and stable revenue base. Additional development expenses may delay or negatively impact our ability to generate profits. Accordingly, we cannot assure you that our business model will be successful or that we can sustain revenue growth, achieve or sustain profitability, or continue as a going concern.

Our ability to obtain funds through the issuance of debt or equity is dependent upon the state of the financial markets at such time as we may seek to raise funds. The state of the capital market markets may be adversely impacted by various risks and uncertainties, including, but not limited to future and current impacts of global events such as COVID-19, the war in the Ukraine and the conflict in Palestine, increases in inflation and other risks detailed herein.

Impact of Inflation

 

Our results of operations may be affected by inflation, particularly rising prices for products and other operating costs if we cannot pass such increases along to our customers in the form of higher prices for our products and services. Generally, we are not party to long term contracts and our inventory turns multiple times per year and we anticipate that we will be able to increase prices on products to reflect increases in the cost of inventory.

 

33

Contractual Obligations

 

We have no long-term fixed contractual obligations or commitments.commitments other than leases that are disclosed in Note 12 in the notes to our consolidated financial statements.

 

Contingencies

 

Our operations are conducted in the PRC and are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environments in China and foreign currency exchange rates. Our results may be adversely affected by changes in PRC government policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad and rates and methods of taxation, among other things.

 

Our sales, purchases and expense transactions in China are denominated in RMB and all of our assets and liabilities in China are also denominated in RMB. The RMB is not freely convertible into foreign currencies under the current PRC law. In China, foreign exchange transactions are required by law to be transacted only by authorized financial institutions. Remittances in currencies other than RMB may require certain supporting documentation in order to affect the remittance.

 

Significant Accounting Policies

 

Our management’s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which were prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported net sales and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and assumptions. We base our estimates on historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements, we believe the following accounting policies are the most critical to assist you in fully understanding and evaluating this management discussion and analysis.

 

39

Basis of Presentation

 

The accompanying financial statements are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”). The functional currency of AiXinZhonghong, Aixin Shangyan Hotel, Aixintang Pharmacies, and Runcangsheng is the Chinese Renminbi (‘‘RMB’’(“RMB”). The accompanying financial statements are translated from RMB and presented in U.S. dollars (“USD”).

 

Use of Estimates

 

In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

 

Significant estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.

 

34

Accounts Receivable

 

We maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of December 31, 20212023 and 2020,2022, the bad debt allowance was $213,787$80,640 and $148,520,$272,550, respectively.

 

Revenue Recognition

ASU No. 2014-09, Revenue from Contracts with Customers (“Topic 606”), became effective for us on January 1, 2018. Our revenue recognition disclosure reflects updated accounting policies that are affected by this new standard. We applied the “modified retrospective” transition method for open contracts for the implementation of Topic 606. As revenues are and have been primarily from the delivery of products and the performance of services, and we have no significant post-delivery obligations, this did not result in a material recognition of revenue on the accompanying consolidated financial statements for the cumulative impact of applying this new standard. We made no adjustments to previously-reported total revenues, as those periods continue to be presented in accordance with our historical accounting practices under Topic 605, Revenue Recognition.

 

Revenue from sale of goods under Topic 606 is recognized in a manner that reasonably reflects the delivery of our products and services to customers in return for expected consideration and includes the following elements:

 

 executed contract(s) with customers that we believe are legally enforceable;
 identification of performance obligation in the respective contract;
   
 determination of the transaction price for each performance obligation in the respective contract;
 allocation of the transaction price to each performance obligation; and
 recognition of revenue only when we satisfy each performance obligation.

 

Our revenue recognition policies for our operating segments are as follows:

 

Advertising and Products

Advertising Revenue

Commencing in the third quarter of 2019 we began to provide advertising services to our clients. Advertising contracts are signed to establish the price and advertising services to be provided. Pursuant to the advertising contracts, we provided advertising and marketing services to clients through exhibition events, conferences, and person-to-person marketing. We perform a credit assessment of each customer to assess the collectability of the contract price prior to entering into contracts.

Most of the advertisement contracts designated that we perform advertising services for the client through exhibition events, conferences, and person-to-person marketing during the contracted period, regardless of the number of such events. As such, we determined that the performance obligation is satisfied over time during the contracted period and revenue is recognized accordingly. Such advertising revenue amounted to $1,944,811 and $1,863,785 for the years ended December 31, 2021 and 2020, respectively.

A smaller proportion of our advertising revenue is generated from services to clients through exhibition events, conferences, and person-to-person marketing, and our compensation is based on the number of products sold. Such advertising revenue amounted to $0 and $6,558 for the years ended December 31, 2021 and 2020, respectively.

All of the advertising revenue is subject to the PRC VAT of 6%. This VAT may be offset by VAT paid by us for raw materials and other materials purchased in China.

35

Products Revenue

 

Our revenue from sales of products is recognized when goods are delivered to the customer and no other obligation exists. We do not provide unconditional return or other concessions to customers. Our sales policy allows for the return of unopened products for cash after deducting certain service and transaction fees. As an alternative to returning a product, customers may request an exchange for products with the same value.

 

Product sales revenue represents the invoiced value of goods, net of value-added taxes (“VAT”). All of our products sold in China are subject to the PRC VAT of 17% of the gross sales price prior to May 1, 2018, 16% since May 1, 2018 and 13% since April 1, 2019. This VAT may be offset by VAT paid by for raw materials and other materials purchased in China. We record VAT payables and VAT receivables net of payments in the financial statements. The VAT tax return is filed offsetting the payables against the receivables. Sales and purchases are recorded net of VAT collected and paid as we act as an agent for the government.

 

Pharmacies

Our retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation. We generally receive payment from pharmacy customers we satisfy our performance obligations. We record a receivable when we have an unconditional right to receive payment and only the passage of time is required before payment is due. Sales revenue represents the invoiced value of goods, net of VAT. All of the products sold in our pharmacies are exempt from VAT as the pharmacies qualify for a small business exemption.

Manufacture and Sale

The Company’s new subsidiary Runcangsheng recognizes revenue at the time products are shipped as this satisfies its performance obligation. The Company records a receivable for the sales when it has an unconditional right to receive payment and only the passage of time is required before payment is due. Sales revenue represents the invoiced value of goods, net of VAT. All of the Company’s products sold in China are subject to the PRC VAT of 13% unless it is a qualified small business subject to exemption.

Hotel

 

Hotel revenues are primarily derived from the rental of rooms, food and beverage sales and other ancillary goods and services, including but not limited to souvenir, parking and conference reservations. Each of these products and services represents a distinct performance obligation and, in exchange for these services, we receive fixed amounts based on published rates or negotiated contracts. Payment is due in full at the time when the services are rendered or the goods are provided. Room rental revenue is recognized on a daily basis when rooms are occupied. Food and beverage revenue and other goods and services revenue are recognized when they have been delivered or rendered to the guests as the respective performance obligations are satisfied. All of the hotel’s goods sold in China are subject to the PRC VAT of 6%. This VAT may be offset by VAT paid by on raw materials and other materials purchased in China.

 

Pharmacies

Our retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation. We generally receive payment from pharmacy customers we satisfy our performance obligations. We record a receivable when we have an unconditional right to receive payment and only the passage of time is required before payment is due. Sales revenue represents the invoiced value of goods, net of VAT. All of the products sold in our pharmacies are exempt from VAT as the pharmacies qualify for a small business exemption.

Foreign Currency Translation and Comprehensive Income (Loss)

The functional currency of our business operations is RMB. For financial reporting purposes, RMB is translated into USD as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet dates. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period.

Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity as “Accumulated other comprehensive income”. Gains and losses resulting from foreign currency transactions are included in income. There was no significant fluctuation in the exchange rate for the conversion of RMB to USD after the balance sheet date.

We use FASB ASC Topic 220, “Comprehensive Income”. Comprehensive income (loss) is comprised of net income (loss) and all changes to the statements of stockholders’ equity, except those due to investments by stockholders, changes in paid-in capital and distributions to stockholders. Comprehensive loss for years ended December 31, 2021 and 2020 consisted of net loss and foreign currency translation adjustments.

3640

 

Item 7AQuantitative And Qualitative Disclosures About Market Risk.

 

This item does not apply to smaller reporting companies.

 

Item 8Financial Statements And Supplementary Data.

 

Our financial statements appear beginning on page F-1, immediately following the signature page of this report.

 

Item 9Changes In And Disagreements With Accountants On Accounting And Financial Disclosure.

 

Not applicable.

 

Item 9AControls And Procedures.

 

Disclosure Controls and Procedures

 

Management of AiXin Life International, Inc. is responsible for maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. In addition, the disclosure controls and procedures must ensure that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial and other required disclosures.

 

At December 31, 2021,2023, an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13(a)-15(e) and 15(d)-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”)) was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based on their evaluation of our disclosure controls and procedures, they concluded that at December 31, 2021,2023, such disclosure controls and procedures were not effective. This was due to our limited resources, including the absence of a financial staff with accounting and financial expertise and knowledge of the regulations of the Securities and Exchange Commission, and deficiencies in the design or operation of our internal control over financial reporting that adversely affected our disclosure controls and that may be considered to be “material weaknesses.”

 

We plan, if our revenues continue to increase, to seek to recruit individuals responsible for identifying reportable developments and to implement procedures designed to remediate the material weakness by focusing additional attention and resources in our internal accounting functions. However, the material weakness will not be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

37

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance to our management and board of directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

 

Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions; (ii) provide reasonable assurance that transactions are recorded as necessary for preparation of our financial statements; (iii) provide reasonable assurance that receipts and expenditures of company assets are made in accordance with management authorization; and (iv) provide reasonable assurance that unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because changes in conditions may occur or the degree of compliance with the policies or procedures may deteriorate.

 

Our management conducted an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer of the effectiveness of our internal control over financial reporting as of December 31, 2021.2023. This evaluation was based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, Internal Control-Integrated Framework. Based upon such assessment, our Chief Executive Officer and Chief Financial Officer have concluded that due to the absence of a financial staff with accounting and financial expertise and certain deficiencies in the design or operation of our internal control over financial reporting, our internal controls over financial reporting were not effective as of December 31, 2021.2023.

 

This report shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

41

 

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. The rules of the SEC do not require an attestation of the Management’s report by our registered public accounting firm in this annual report.

 

Changes in Internal Controls

 

There have been no changes in our internal control over financial reporting that occurred during our fiscal quarter and fiscal year ended December 31, 20212023 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting. Given the limitations of our accounting personnel, we need to take additional steps to ensure that our financial statements are in accordance with US GAAP.

 

Item 9B.Other Information

 

Not applicable

 

38Item 9C.Disclosure Regarding Foreign Jurisdictions That Prevent Inspections

Not applicable

 

PART III

 

Item 10Directors And Executive Officers And Corporate Governance.

 

The following table sets forth the names and ages of all directors and executive officers as of the end of the last fiscal year and on the date of this report:

 

Name Age Position
Quanzhong Lin 4346 Director, Chairman, President and Chief Executive Officer
Yao-Te Wang (1) (2) (3) 4447Director and Secretary
Christopher Lee (1) (2) (3)53 Director
Chang-Ping Lin44Director
Christopher LeeHuiliang Jiao (1) (2) (3) 50 Director
GuoluTianfeng Li 5540 Chief Financial Officer

(1)Member of the Audit Committee
(2)Member of the Compensation Committee
(3)Member of the Nominating and Corporate Governance Committee

 

Quanzhong Lin has served as a director, President and Chief Executive Officer of our company since February 2, 2017. Mr. Lin is a highly active entrepreneur in China, and currently serves as Chairman of AiXin Company Group, a diversified company which he founded in 2008. In addition to Ai XinAiXin Company Group, Mr. Lin has founded a number of companies located in Chengdu City, Sichuan Province, China, engaged in various types of business, including pharmacies, retail outlets, hotel management services and global tourism.

 

In 2009, Mr. Lin founded QingBaiJiangJinWanXiang Daily Necessities store, predecessor to AixinZhonghong Biotechnology Co., Ltd. From 2010 to 2013, Mr. Lin opened branches in Xindu and Xinjin district, officially entering the Chengdu market.

 

In September 2013, Mr. Lin founded Chengdu AixinAiXin E-Commerce Company Ltd., which in the following twelve months opened branches in cities and counties including Huayuan and Wenjiang district, and Mianyang and Jianyang city. In April 2015, AixinAiXin E-commerce Co., Ltd. changed its name to Chengdu AixinZhonghong Biotechnology Co., Ltd., whose shares became listed on the Shanghai Stock Exchange (Ticker Symbol: 207448) in October 2015; and during 2015, AixinZhonghong opened branches in Dujiangyan City, and Chongzhou City. What happened to this company?

42

Yao-Te Wang has served as a director of our company since December 12, 2017. He became our Secretary on June 20, 2023. Mr. Wang has been the Chief Executive Officer of Ivy Service Group (China), which is a transnational consultant company in China, since 2015. From January 2016 to June 2016, Mr. Wang participated in the overall operation planning for Chongqing Cultural Assets and Equity Exchange. From June 2015 to January 2016, Mr. Wang helped with the overall brand strategy development for Swire Group, who merged the biggest baking brand in Southwest China within more than 150 million RMB. From September 2014 to February 2015, Mr. Wang was the chairman special assistant for JECUI Health Science Company. From July 2012 to August 2014, Mr. Wang was the Chief Executive Officer of Ivy Service Group (Taipei). From August 2007 to June 2012, Mr. Wang was an instructor of National Defense University (Taipei), taught International Politics and Economic Analysis.

Chang-Ping Lin was elected a director of our company on January 8, 2020. Mr. Lin has more than twenty years of experience in the financial services industry in which he has held numerous management level positions. He currently serves as the Chief Executive Officer of the Taiwan Financial Development Association and operates Bo-Si International Holdings Ltd., a private consulting firm he formed in January 2018. From January 2016 to January 2018 Mr. Lin served as Marketing Director - Taiwan, for Globalink Securities. From January 2012 to January 2015 Mr. Lin was affiliated with KGI Securities, last serving as Deputy Manager, Product Management Development. Mr. Lin received an MS Degree in Public Administration and Policy from Jinan University and a BS from Ling Tung University, Department of Business Administration. Mr. Lin is an Associate Professor instructing Professional Level and Technical Personnel at Feng Chia University. He has also lectured in the Data Science Department at Providence University and the Finance Department of Da Yeh University.

 

Christopher Lee was appointed as a Member of the Board of Directors of the Company on February 5, 2021. Mr. Lee has served as Chief Financial Officer of Semileds Corporation since September 2015. Mr. Lee joined Semileds Corporation in September 2014 and from November 2014 until his appointment as Chief Financial Officer, Mr. Lee was the interim Chief Financial Officer of Semileds Corporation. Semileds develops, manufactures and sells high performance light emitting diodes and is currently listed on The Nasdaq Stock Market. Mr. Lee has over 20 years of experience in accounting and finance, including US GAAP, PCAOB standards and SEC rules and regulations. Mr. Lee was a partner of KEDP CPA Group from August 2009 to June 2011 and a self-employed accountant from July 2011 to August 2014. Mr. Lee holds a BS degree in accounting from Ohio State University and a MS degree in business taxation from Golden Gate University and is licensed as a Certified Public Accountant (CPA) in the United States.

 

39

Huiliang Jiao was elected to the Board of Directors of our company on December 1, 2022. Mr. Jiao received his degree from China Pharmaceutical University in 1997 where he majored in Pharmacy. Mr. Jiao joined Yunnan Runcangsheng Technology Co., Ltd. in April 2020, most recently serving as Chief Executive Officer. Mr. Jiao served as the general manager of Yunnan Shengshengyuan Technology Co., Ltd. from June 2016 until he joined Runcangsheng. From January 2007 until May 2016, Mr. Jiao was the general manager of Yunnan Shengcaofeng Biotechnology Co., Ltd. Throughout his career Mr. Jiao has been involved in the research and development of new products intended to improve individuals’ health and well-being, with an emphasis on functional products comprised of natural plants, foods and supplements intended to address obesity and other chronic conditions. He was named as an inventor on more than forty patents relating to the composition and manufacture of health foods. In addition to the development of health foods, Mr. Jiao has participated in the design and maintenance of production systems intended to meet the latest manufacturing standards.

 

GuoluTianfeng Li, became our Chief Financial Officer on December 12, 2017. Mr.1, 2022. Ms. Li is a CPA whoalso serves as Chief Financial Officer of the Company’s subsidiaries. Ms. Li has held various positions, most recently, Finance Manager, within the Finance Department of our subsidiary, Chengdu AiXin Pharmacy Co., Ltd., which she joined in May 2019. While serving at AiXin Pharmacy Ms. Li helped build the company’s finance team and established the development of its financial reporting and risk management systems. In addition, she presided over the preparation of the company’s financial statements, the completion of its annual audit, daily cash management, the preparation of the annual budget and the integration of newly acquired pharmacies. From May 2013 until joining AiXin Pharmacy in May 2019, Ms. Li served as managing director and Senior Accountant at Chengdu Bixin, an accounting firm, since August 2016. From October 2013 to July 2016, Mr. Li was Deputy Financial Directorthe Finance Manager of Chengdu Geeya Science and Technology Co. (Shenzhen Stock Exchange). From August 2010 to May 2013, he was Senior Auditor at Sichuan HengKun CPAJinxin Clean Energy Equipment Co., Ltd. From December 2007 to July 2010, he, where she was Managerresponsible for developing the company’s financial systems, preparing its budget and managing all aspects of the Audit Department atcash management. At Sichuan Zhonglian, an accounting firm. Mr.Jinxin Clean Energy Equipment Co Ms. Li supervised a staff of five assistants. Ms. Li received a Bachelorbachelor’s degree in Engineer Management from ChinaThe Open University of Petroleum (Beijing),China in July 1989.2017, and has received a Certificate of Honor as an Intermediate Accountant.

 

There are no family relationships among any of our officers and directors.

 

Directors hold office until the next annual meeting of shareholders and until their successors have been duly elected and qualified. Officers are elected by the board of directors and hold office until the earliest of their death, resignation or removal from office.

 

Board Meetings; Leadership Structure and Risk Oversight

 

The Board does not have a policy requiring separationMr. Quanzhong Lin holds the positions of chief executive officer and chairman of the roles of Chief Executive Officer and Chairmanboard of the Board.Company. The Board has determinedboard believes that having Mr. Lin serveLin’s services as Chairmanboth chief executive officer and chairman of the board is in the best interestsinterest of our stockholders at this time because of histhe Company and its shareholders. Mr. Lin is a well-recognized successful entrepreneur in Chengdu. He possesses detailed and in-depth knowledge of our businessesthe issues, opportunities and his familiarity with our customerschallenges facing the Company in its business and clients.is thus best positioned to develop agendas that ensure that the Board’s time and attention are focused on the most critical matters relating to the business of the Company. His combined role enables decisive leadership, ensures clear accountability, and enhances the Company’s ability to communicate its message and strategy clearly and consistently to the Company’s shareholders, employees and customers.

 

The board has not designated a lead director. Given the limited number of directors comprising the Board, the independent directors call and plan their executive sessions collaboratively and, between meetings of Directorsthe Board, communicate with management and one another directly. Under these circumstances, the directors believe designating a lead director to take on responsibility for functions in which they all currently participate might detract from rather than enhance performance of their responsibilities as a wholedirectors.

Management is responsible for considerationassessing and managing risk, subject to oversight by the board of thedirectors. The board oversees our risk management policies and risk appetite, including operational risks we face and is responsible for ensuring that material risks are identifiedrelating to our business strategy and managed appropriately. Certain risks are overseen bytransactions. Various committees of the Board of Directors and these committees make reports toboard assist the full Board of Directors, including reports on noteworthy risk-management issues. Members of the Company’s senior management team regularly report to the full Board aboutboard in this oversight responsibility in their respective areas of responsibility and a component of these reports is the risks within their areas of responsibility and the steps management has taken to monitor and control such exposures. Additional review or reporting on risks is conducted as needed or as requested by the Board or one of its committees.expertise.

 

43

Compensation of Directors

 

The following table sets forth certain information regarding the compensation paid to, earned by or accrued for, our directors during the fiscal year ended December 31, 2021.

2023.

 

  DIRECTOR COMPENSATION 
Name 

Fees Earned
or Paid

In Cash
($)

  Stock
Awards
($)
  Option
Awards
($)
  Non-Equity
Incentive Plan
Compensation
($)
  Non-Qualified
Deferred
Compensation
Earnings ($)
  All Other
Compensation
($)
  Total ($) 
Yao-Te Wang $32,000               0  $32,000 
Quanzhong Lin $24,000               0  $24,000 
Yuhua Zhu  0               0   0 
Chang-Ping Lin  0               0   0 
Christopher Lee  9,600                       9,600 

Independent Directors

  DIRECTOR COMPENSATION 
Name 

Fees Earned
or Paid

In Cash
($)

  Stock
Awards
($)
  Option
Awards
($)
  Non-Equity
Incentive Plan
Compensation
($)
  Non-Qualified
Deferred
Compensation
Earnings ($)
  All Other
Compensation
($)
  Total ($) 
Yao-Te Wang $37,000               0  $37,000 
Quanzhong Lin $0               0  $0 
Christopher Lee  9,600                0  $9,600 
Huiliang Jiao  12,000                 $12,000 

 

Our Board of Directors has determined that Yao-Te Wang, Chang-Ping Lin, Christopher Lee and Christopher LeeHuiliang Jiao are “independent directors” within the meaning of NASDAQ Marketplace Rule 5605(a)(2). and Section 10(A)(m)(3) of the Exchange Act.

40

 

Board Meetings; Committees and Membership

 

Our Board of Directors did not meet in formal session during 2020,2023 , though it regularly took action by written consent after the directors consulted with each other as to the actions to be taken.

 

We maintain the following committees of the Board of Directors: the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. Each committee is comprised entirely of directors who are “independent” within the meaning of NASDAQ Marketplace Rule 5605(a)(2). Each committee acts pursuant to a separate written charter, and each such charter has been adopted and approved by the Board of Directors. Copies of the committee charters were filed as Exhibits to our Report on Form 8-K filed on September 25, 2020.

 

Audit Committee

 

Our Audit Committee consists of Messrs. Lee, LinJiao and Wang, each of whom is independent. The Audit Committee assists the Board of Directors oversight of (i) the integrity of financial statements, (ii) our compliance with legal and regulatory requirements, (iii) the independent auditor’s qualifications and independence, and (iv) the performance of our internal audit function and independent auditor and prepares the report that the SEC requires to be included in our annual proxy statement. The audit committeeAudit Committee operates under a written charter. Mr. Lee is the Chairman of our audit committee.Audit Committee.

 

44

The Board of Directors determined that Mr. Lee possesses accounting or related financial management experience that qualifies him as financially sophisticated within the meaning of Rule 4350(d)(2)(A) of the Nasdaq Marketplace Rules and that he is an “audit committee financial expert” as defined by the rules and regulations of the SEC.

 

Nominating and Corporate Governance Committee

 

The purpose of the Nominating and Corporate Governance Committee is to assist the Board of Directors in identifying qualified individuals to become members of our Board of Directors, in determining the composition of the Board of Directors and in monitoring the process to assess Board effectiveness. Each of Messrs. Lee, LinJiao and Wang are members of the Nominating and Corporate Governance Committee. Mr. Wang serves as Chairman of the Nominating and Corporate Governance Committee. The Nominating and Corporate Governance Committee operates under a written charter.

 

 Our Nominating and Corporate Governance Committee has, among the others, the following authority and responsibilities:
   
 To determine and recommend to the Board, the criteria to be considered in selecting nominees for the director;
   
 To identify and screen candidate consistent with such criteria and consider any candidates recommended by our stockholders pursuant to the procedures described in our proxy statement or in accordance with applicable laws, rules and regulations and provisions of our charter documents.
   
 To select and approve the nominees for director to be submitted to a stockholder vote at the annual meeting of stockholders.

 

Compensation Committee

 

The Compensation Committee is responsible for overseeing and, as appropriate, making recommendations to the Board of Directors regarding the annual salaries and other compensation of our executive officers and general employees and other policies, and for providing assistance and recommendations with respect to our compensation policies and practices. Each of Messrs. Lee, LinJiao and Wang are members of the Compensation Committee. The Compensation Committee operates under a written charter. Mr. LinJiao is the Chairman of Compensation Committee.

 

Our Compensation Committee has, among the others, the following responsibilities and authority.

41

 

 The compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser.
   
 The compensation committee shall be directly responsible for the appointment, compensation and oversight of the work of any compensation consultant, legal counsel and other adviser retained by the compensation committee or said group.
   
 The Company must provide for appropriate funding, as determined by the compensation committee, for payment of reasonable compensation to a compensation consultant, legal counsel or any other adviser retained by the compensation committee or said group.

 

The compensation committee select, or receive advice from, a compensation consultant, legal counsel or other adviser to the compensation committee or said group, other than in-house legal counsel, only after conducting an independence assessment with respect to the adviser as provided for in the Exchange Act.

45

 

Code of Business Conduct and Ethics

 

Our board of directors hasWe have adopted a Code of Business Conduct and Ethics that applies to, among other persons, members of our board of directors, our Company’s officers including our Chief Executive Officer, employees, consultants and Conflicts of Interest (“Code of Ethics”) applicable to all employees, including the Company’s chief executive officer and chief financial officer.advisors. A copy of the Code of EthicsBusiness Conduct and Business ConductEthics was filed as an Exhibitexhibit to our report on Form 8_K8-K filed on September 25, 2020, and is available on the SEC’s website, www.sec.gov.www.sec.gov.

 

ShareholdersShareholder Communications

 

Shareholders may communicate with the board of directors and individual directors by submitting their communications in writing to the Company’s Corporate Secretary at Hongxing International Business Building 2, 14th FL, No. 69 Qingyun South Ave., Jinjiang District, Chengdu City, Sichuan Province, China. Any communications received that are directed to the board of directors will be processed by the Corporate Secretary and distributed promptly to the board of directors or individual directors, as appropriate. If it is unclear from the communication received whether it was intended or appropriate for the Board, the Corporate Secretary will (subject to any applicable regulatory requirements) use his business judgment to determine whether such communications should be conveyed to the board of directors.

 

Item 11Executive Compensation.

 

The following table sets forth certain information concerningabout compensation awarded to,paid, earned by or paid toaccrued for services by each individual who served as our chief executive officer orand chief financial officer for services rendered in all capacities during 2020.the year ended December 31, 2023. No other executive officer of our companyCompany or other individual received total annual salary and bonus compensation in excess of $100,000 for 2020.the year ended December 31, 2023.

 

Summary Compensation Table

 

Name and Principal Position Year  Salary ($)  Bonus ($)  Total ($) 
Quanzhong Lin, President(1)  2021  $24,000  $        $       
Guolu Li, Chief Financial Officer(2)  2021  $18,750  $  $ 

Name and Principal Position Year  Salary ($)  Bonus ($)  Total ($) 
Quanzhong Lin, President(1)  2023  $20,100  $  $20,100 
   2022   20,822       20,822 
Tiangfeng Li, Chief Financial Officer (2)  2023  $26,500  $   $26,500
   2022  $20,533  $   $20,533

 

(1) Amounts attributed to Mr. Lin represent amounts paid as President and CEO of AiXinZhonghong.

 

(2) Amounts attributed to Mr.Ms. Li represent amounts paid as CFO of AiXinZhonghong.

 

Neither Mr. Lin nor Mr.Ms. Li has an employment agreement with the Company.

 

42

Stock Option Plan; Pension, Profit-Sharing and Retirement Benefits

 

OutstandingIn 2019 we adopted the 2019 Equity Awards at Fiscal Year-EndIncentive Plan (the “2019 Plan”), which authorizes the issuance of shares of common stock for grants of stock options, stock appreciation rights, restricted stock, stock units, bonus stock, dividend equivalents, other stock related awards and performance awards that may be settled in cash, stock, or other property. The 2019 Plan authorizes the issuance of up to 625,000 shares. In October 2019, we issued an aggregate of 293,750 shares to employees and contractors under the 2019 Equity Incentive Plan.

We adopted the 2019 Plan to provide a means by which employees, directors, and consultants of our Company and those of our subsidiaries and other designated affiliates, which we refer to together as our affiliates, may be given an opportunity to purchase our common stock, to assist in retaining the services of such persons, to secure and retain the services of persons capable of filling such positions, and to provide incentives for such persons to exert maximum efforts for our success and the success of our affiliates. The material features of the 2019 Plan are outlined below. This summary is qualified in its entirety by reference to the complete text of the 2019 Plan which has been filed with the SEC.

 

None of our executive officers or directors was granted any options or equity awards during 20212023 or held any options or other equity awards at December 31, 2021.2023.

 

There are no annuity, pension or retirement benefits proposed to be paid to our officers, directors or employees in the event of retirement at normal retirement date pursuant to any presently existing plan provided or contributed to by the Company or any of its subsidiaries.

Outstanding Equity Awards

At December 31, 2023, there were no outstanding equity awards granted pursuant to the 2019 Equity Incentive Plan.

46

Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

The following table sets forth, as of March 29, 2024, certain information concerning the beneficial ownership of our common stock as of March 31, 2022, by (i) any personeach stockholder known by us to own beneficially five percent or group with more than 5% of our outstanding common stock,stock; (ii) each director,director; (iii) our chiefeach named executive officer and each other executive officer whose cash compensation for the most recent fiscal year exceeded $100,000officer; and (iv) all suchof our executive officers and directors as a group.group, and their percentage ownership and voting power. There were 24,999,945 shares of our common stock outstanding as of March 29, 2024.

 

BeneficialThe information presented below regarding beneficial ownership is determinedof our voting securities has been presented in accordance with the rules of the SECSecurities and includesExchange Commission and is not necessarily indicative of ownership for any other purpose. Under these rules, a person is deemed to be a “beneficial owner” of a security if that person has or shares the power to vote or direct the voting andof the security or the power to dispose or direct the disposition of the security. A person is deemed to own beneficially any security which such person has the right to acquire sole or shared voting or investment power with respectwithin sixty (60) days through the conversion or exercise of any convertible security, warrant, option, or other right. More than one (1) person may be deemed to be a beneficial owner of the same securities. SubjectThe percentage of beneficial ownership by any person as of a particular date is calculated by dividing the number of shares beneficially owned by such person, which includes the number of shares as to which such person has the right to acquire voting or investment power within sixty (60) days, by the sum of the number of shares outstanding as of such date including the number of such shares which such person has the right to acquire. Consequently, the denominator used for calculating such percentage may be different for each beneficial owner. Except as otherwise indicated below and under applicable community property laws, we believe that the persons named in the tablebeneficial owners of our common stock listed below have sole voting and investment power with respect to allthe shares of common stock shown as beneficially owned by them. In addition, shares of common stock issuable upon exercise of options, warrants and other convertible securities anticipated to be exercisable or convertible at or within 60 days of March 31, 2022, are deemed outstanding for the purpose of computing the percentage ownership of the person holding those securities, and the group as a whole, but are not deemed outstanding for computing the percentage ownership of any other person. As of March 31, 2022, we had outstanding 49,999,891 shares of common stock.shown.

 

To our knowledge, the persons named in the table have sole voting and investment power with respect to all shares of securities shown as beneficially owned by them.

Name of Shareholder (1) Amount and Nature of Beneficial Ownership  Percent of Common Stock 
Directors and Executive Officers:        
         
Quanzhong Lin, Chairman and CEO  14,534,676   58.14%
         
Yao-Te Wang, Director  1,884,336   7.54%
         
Christopher Lee, Director  0   - 
         
Huiliang Jiao, Director  0   - 
         
Tianfeng Li, CFO  0   - 
         
All directors and executive officers as a group (five persons)  16,419,012   65.68%

 

Name of Shareholder 

Amount and

Nature of

Beneficial

Ownership

  

Percent of

Common Stock

 
Directors and Executive Officers:        
         

Quanzhong Lin, Chairman and CEO

9 An Rong Lu Jingniu, Bldg 4 Unit 163

Chengdu, Sichuan Province, China

  29,069,353   58.14%
         

Yao-Te Wang, Director

704 No.9, Lane 14, Shijian St.

Tainan City, Taiwan, R.O.C.

  3,768,673   7.54%
         
All directors and executive officers as a group (5 persons)  32,838,026   65.68%
(1)The address of each beneficial owner is c/o AiXin Life International, Inc., Hongxing International Business Building 2, 14th FL, No. 69 Qingyun South Ave., Jinjiang District, Chengdu City, Sichuan Province, China

 

Item 13Certain Relationships And Related Transactions, And Director Independence.

 

Transactions with Related Persons

 

The following includes a summary of transactions since January 1, 2021,2023, or any currently proposed transaction, in which we were or are to be a participant and the amount involved exceeded or exceeds the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed fiscal years, and in which any related person had or will have a direct or indirect material interest (other than compensation described under “Executive Compensation”). We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, in arm’s-length transactions.

 

4347

 

Advance to/from related parties

 

AtAs of December 31, 2021,2022, the Company had accounts payable in the amount of $165,958 due to Luquan Shengcaofeng Biotechnology Co., Ltd., an affiliate of Runcangsheng, for the purchase of raw materials. This payable was satisfied during 2023.

From time to time, we have advanced certain amounts to pharmacies owned by Quanzhong Lin. The amount due from each of such entities as of December 31, 2023 and 2022 were as follows:

  

December 31,

2023

  

December 31,

2022

 
Chengdu WenJiang Aixin Nanjiang Pharmacy Co., Ltd. $563  $9,708 
Chengdu Fuxiang Tang Pharmacy Co., Ltd.  85   26,125 
Chengdu Zhiweibing Pharmacy Co., Ltd.  1,738   - 
Chengdu Wenjiang district Heneng hupu Pharmacy Co., Ltd  704   34,622 
Sichuan Aixin Investment Co. Ltd  9,310   145 
Chengdu Lisheng Huiren Tang Pharmacy Co., Ltd.  -   12,502 
Total $12,400  $83,102 

From time to time, we have received advances from a shareholders andcertain affiliates. The amounts due to such affiliates as of shareholders of $1,947,154. At December 31, 2021,2023 and 2022 were as follows:

  December 31,
2023
  December 31,
2022
 
Quanzhong Lin $

1,051,429

  $140,644 
Yirong Shen  

87,325

   89,892 
Huiliang Jiao  82,152   - 
Tianfeng Li  

780

   - 
Mianyang Aixin Cunshan Pharmacy Co. Ltd  

112

   - 
Chengdu Aixin International travel service Co, Ltd  

5,087

   6,346 
Total $

1,226,885

  $236,882 

All the Company hadentities in the above list are controlled by Quanzhong Lin. These advances to affiliates of our major shareholder of $19,055. The advances areand from related parties were for working capital purposes, payable on demand, and bear no interest.

Advances Yirong Shen was a shareholder of Aixin Shangyan Hotel prior to Related Parties for Acquisitionthe closing of Hotel Purchase Agreement and serves as the supervisor of Aixin Shangyan Hotel.

 

As of December 31, 2019, the Company had advances to multiple related parties in the aggregate amount of $4,053,587. The aggregate balance at December 31, 2019 consisted of balances of $697,699 to Aixin Pharmacy Co., Ltd, Xinjin Branch, $855,324 to Aixin Liucheng Pharmacy Co., Ltd, $654,776 to Aixin Pharmacy Co., Ltd. Jianyang Store, $71,821 to Aixin Shangyan Hotel Management Co., Ltd., and $1,773,967 to Aixin Pharmacy Co., Ltd. All of those related parties are entities controlled by Mr. Quanzhong Lin. The advances made were for the future acquisition of these related parties.

As of December 31, 2020, these advances were returned to the Company in full.

Acquisitions from a Major Shareholder

In September 2021, we completed the acquisition of nine pharmacies located in Chengdu by acquiring the entities which owned the pharmacies for an aggregate purchase price of RMB 34,635,845, or approximately US$5.31 million (“Transfer Price”). The Transfer Price will be reduced by an amount equal to any amounts paid or distributed by any of the entities to its shareholders after December 31, 2020 and increased by an amount contributed to any of the entities by its shareholders after such date. The pharmacies will be used to supplement our efforts to distribute our nutritional products.

In July we completed the acquisition of Aixin Shangyan Hotel. Shangyan Hotel Company owns and operates a hotel located in the Jinniu District, Chengdu City. The hotel covers more than 8,000 square meters and has a large restaurant that can accommodate 600 people, 6 luxury dining rooms, a 200 square meter music tea house, 13 private tea rooms, 108 guest rooms and other supporting facilities. We acquired the hotel through an acquisition of the outstanding equity of Aixin Shangyan Hotel for a purchase price of RMB 7,598,887, or approximately $1.16 million (“Transfer Price”). The Transfer Price will be reduced by an amount equal to any amounts paid or distributed by the hotel to its shareholders after December 31, 2020 and will be increased by an amount equal to any amounts contributed to the hotel by its equity owners after December 31, 2020.

In connection with the acquisition of the pharmacies and hotel we made payments to Mr Lin in the aggregate amount of $4.50 million.

Forgiveness of LoanLoan; Contribution of Shares

On December 31, 2021, our major shareholderMr. Lin forgave a loan previously made to the Company in the amount of $6,912,513. This was treated as a contribution to capital.

Office Lease from a Major Shareholder On March 1, 2023, for no consideration other than the expenses to be incurred by the Company in connection with this offering, Mr. Lin agreed to contribute to the capital of the Company seven million shares of the common stock of the Company.

 

In May 2014, we entered into a lease with our major shareholderMr. Lin for use of an office. We have renewed the lease until May 28, 2023,April 30, 2024, with monthly rent of RMB 5,000RMB5,000 ($766)[ ]), payable quarterly.

 

Other than the foregoing, none of the directors or executive officers of the Company, nor any person who owned of record or was known to own beneficially more than 5% of the Company’s outstanding shares of its Common Stock, nor any associate or affiliate of such persons or companies, had any material interest, direct or indirect, in any transaction that occurred since January 1, 2019,2023, or in any proposed transaction, which has materially affected or will affect the Company.

 

As of the date of this report, we do not have in place any policies with respect to whether we will enter into agreements with related persons in the future.

48

 

Item 14Principal Accountant Fees And Services.

 

The following is a summary of the fees billed to us for professional services rendered by our registered independent public accountants for the fiscal years ended December 31, 20212023 and December 31, 2020:2022:

 

 Fiscal year ended December 31,  Fiscal year ended December 31, 
 2021 2020  2023 2022 
          
Audit Fees $

220,000

  $180,000 
Audit Related Fees     -   -   -   - 
Tax Fees  -   -   -   - 
All Other Fees  -   -   -   - 
 $220,000    $180,000 

Audit Fees. Consists of fees billed for professional services rendered for the audit of our financial statements and review of interim financial statements included in quarterly reports and services that are normally provided in connection with statutory and regulatory filings or engagements.

44

 

Audit Related Fees. Consists of fees billed for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements and are not reported under “Audit Fees”.

 

Tax Fees. Consists of fees billed for professional services for tax compliance, tax advice and tax planning. These services include preparation of federal and state income tax returns.

 

All Other Fees. Consists of fees for product and services other than the services reported above.

 

Board of Directors’ Pre-Approval Policies

 

Our Board of Directors’ policy is to pre-approve all audit and permissible non-audit services provided by the independent auditors. These services may include audit services, audit related services, tax services, and other services. Pre-approval is generally provided for up to one year, and any pre-approval is detailed as to the particular service or category of services and is generally subject to a specific budget. The independent auditors and management are required to periodically report to the board of directors regarding the extent of services provided by the independent auditors in accordance with this pre-approval and the fees for the services performed to date. The board of directors may also pre-approve particular services on a case-by-case basis.

 

Our Board of Directors reviewed our audited financial statements contained in our Annual Report on Form 10-K for the 20212023 fiscal year. The board of directors also has been advised of the matters required to be discussed pursuant to PCAOB Rule 3526 (Communication with Audit Committees Concerning Independence), which includes, among other items, matters related to the conduct of the audit of our financial statements.

 

Our Board of Directors considered whether the provision of services other than audit services is compatible with maintaining auditor independence. Based on the review and discussions referred to above, the board of directors has determined that the audited financial statements be included in our Annual Report on Form 10-K for our 20212023 fiscal year for filing with the SEC.

 

49

PART IV

 

ITEM 15EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

 

(a)The following documents have been filed as a part of this Annual Report on Form 10-K.

 

1.Financial Statements

 

Years Ended December 31, 20212023 and 20202022

 

 Page
Report of Independent Registered Public Accounting Firm (PCAOB ID 2851)F-1
Financial Statements: 
Consolidated Balance Sheets as of December 31, 20212023 and 20202022F-3
Consolidated Statements of IncomeOperations and Comprehensive Income (Loss)Loss for the Years Ended December 31, 20212023 and 20202022F-4
Consolidated Statements of Stockholders’ Equity (Deficit) for the Years Ended December 31, 20212023 and 20202022F-5
Consolidated Statements of Cash Flows for the Years Ended December 31, 20212023 and 20202022F-6
Notes to Consolidated Financial StatementsF-7

 

2.Financial Statement Schedules.

 

All schedules are omitted because they are not applicable or not required or because the required information is included in the Financial Statements or the Notes thereto.

 

3.Exhibits. The following exhibits are filed as part of, or incorporated by reference into, this Annual Report:

45

 

Exhibit
Number

No.

Description of Document
3.1Articles of Incorporation (incorporated by reference to the Company’s Annual Report on Form 10-KSB for the fiscal year ended May 31, 2006 as filed with the SEC on March 7, 2007).
3.2Articles of Amendment to Articles of Incorporation (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on June 3, 2008).
3.3Articles of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.3 the Company’s Quarterly Report on Form 10-Q for the quarterly period ended November 30, 2017 as filed with the SEC on January 16, 2018).
3.4BylawsArticles of the RegistrantAmendment to Articles of Incorporation (incorporated by reference to Appendix A to the Company’s14C Information Schedule filed with the SEC on August 24, 2020).
3.5Articles of Amendment to Articles of Incorporation (incorporated by reference to Appendix A to Current Report on Form 8-K filed with the SEC on June 3, 2008).January 12, 2023)
3.6Statement of Correction (incorporated by reference to Current Report on Form 8-K filed with the SEC on February 15, 2023)
3.7Bylaws of the Company (incorporated by reference to Exhibit 3.6 of Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-268190) filed January 17, 2023).
4.1Description of Securities (incorporated by reference to the Company’s Annual Report on Form 10-K filed with the SEC on May 14, 2020)

10.1Consulting Agreement with Yao-Te Wang (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on December 14, 2017).
10.1
10.22019 Incentive Stock Plan (incorporated by reference to Exhibit 10.1 to the Company’s Registration Statement on Form S-8 filed on January 10, 2019).
10.2 
10.3

English Translation of Equity Transfer Agreement with Respect to Shangyan Hotel Company (Incorporated(incorporated by reference to Current Report on Form 8-K dated May 25, 2021).

10.3 
10.4

English Translation of Equity Transfer Agreement with respect to Chengdu AixinAiXin Pharmacy Co., Ltd. and affiliated entities (Incorporated(incorporated by reference to Current Report on Form 8-K dated June 2, 2021).

10.4English Translation of Equity Transfer Agreement among the Company, Chen Yun and Yunnan Sheng Shengyuan Technology Co., Ltd. (incorporated by reference to Current Report on Form 8-K dated July 7, 2022)
10.5English Translation of Supplementary Agreement to Equity Transfer Agreement among the Company, Yunnan Sheng Shengyuan Technology Co., Ltd. and Chen Yun. (incorporated by reference to Current Report on Form 8-K/A filed October 10, 2022).
10.6English Translation of Supplementary 2 Agreement to Equity Transfer Agreement among the Company, Yunnan Sheng Shengyuan Technology Co., Ltd. And Chen Yun. (incorporated by reference to Report on Form 8-K/A filed October 27, 2022).
10.7English translation of Framework Agreement for Project Cooperation in Intelligent Deep Processing of Agricultural Products with Plateau Characteristics (incorporated by reference to Exhibit 10.7 to Amendment No. 2 to Registration Statement on Form S-1 (File No. 333-268190) filed March 7, 2023).
10.8Contribution Agreement dated March 1, 2023, by Mr. Quanzhong Lin in favor of the Company(incorporated by reference to Exhibit 10.8 to Amendment No. 2 to Registration Statement on Form S-1 (File No. 333-268190) filed March 7, 2023).

14.1

Code of Business Conduct and Ethics (incorporated by reference to Exhibit 14.1 to Current Report on Form 8-K filed September 25, 2020).

19.1Insider Trading Policy
21.1List of Subsidiaries (incorporated by reference to Exhibit 21.1 to Amendment No. 7 to Registration Statement on Form S-1 (File No. 333-268190) filed February 9, 2024).
23.1Consent of Independent Registered Public Accounting Firm
31.1Certification of Chief Executive Officer pursuant to Rule 13a-14 or Rule 15d-14 of Securities Exchange Act of 1934.
31.2Certification of Chief Financial Officer pursuant to Rule 13a-14 or Ruleof 15d-14 of Securities Exchange Act of 1934.
32.1Certification of Chief Executive Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).
32.2Certification of Chief Financial Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002 (18    U.S.C. Section 1350).
99.1Executive Compensation Clawback Policy.
101.INSInline XBRL Instance Document
101.SCHInline XBRL Taxonomy Extension Schema
101.CALInline XBRL Taxonomy Extension Calculation
101.DEFInline XBRL Taxonomy Extension Definition
101.LABInline XBRL Taxonomy Extension Label
101.PREInline XBRL Taxonomy Extension Presentation
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

4650

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: April 15, 20228, 2024By:/s/ Quanzhong Lin
  

Quanzhong Lin

Chief Executive Officer

(Principal Executive Officer

   
 By:/s/ GuoluTianfeng Li
  

Chief Financial Officer

(Principal Financial Officer)

 

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on April 15, 2022.8, 2024.

 

Signature Title
   
/s/ Quanzhong Lin Chief Executive Officer and a Director
Quanzhong Lin (Principal Executive Officer)
   
/s/ GuoluTianfeng Li Chief Financial Officer
GuoluTianfeng Li (Principal Financial Officer)
   
/s/ Yao-Te Wang Director
Yao-Te Wang  
   
/s/ Chang-Ping LinHuiliang Jiao Director
Chang-Ping LinHuiliang Jiao  
   
/s/ Christopher Lee Director
Christopher Lee  

 

4751

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders of

AiXin Life International, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of AiXin Life International, Inc. (the “Company”) as of December 31, 20212023 and 2020,2022, the related consolidated statements of incomeoperations and comprehensive income (loss),loss, stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 20212023 and 2020,2022, and the results of its operations and its cash flows for the years ended December 31, 20212023 and 2020,2022, in conformity with the U.S. generally accepted accounting principles in the United States of America.

Consideration of the Company’s Ability to Continue as a Going Concern

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As described in Note 2 to the financial statements, the Company incurred recurring losses from operations and has an accumulated deficit, which raises substantial doubt about its ability to continue as a going concern. Management’s plans with regard to these matters are described in Note 2. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

F-1

 

Revenue Recognition – Identifying and evaluating the timing and amount of revenue recognition

 

Critical Audit Matter Description of the Matter

 

As described in Note 2 ofto the consolidated financial statements, the Company’s products revenue is derived from the delivery of its products. The sale of products by the Company provides advertising servicesis considered complete when the products are delivered at that time the ownership and risk of loss have been transferred to its customers, and revenue related to these services were recognized over the applicable service period. customer.

The Company also purchases products fromconsiders the samecontracts with its customer contain one performance obligation, and the Company is entitled to the consideration when performance obligation is satisfied at a point in time. The amount of revenue to be recognized is determined by the contracts between the Company and its customer. The Company recognizes revenue when the product is delivered.

The principal considerations for our determination that performing procedures relating to revenue recognition, specifically the identification and evaluation of the timing and amount of revenue recognition, is a critical audit matter, involved judgment exercised by management in identifying and evaluating the timing and amount of advertising revenue recognition.performance obligation. Auditor judgement is involved in performing our audit procedures to evaluate whether the timing and amount of revenue recognition on advertising was appropriately stated.

 

How Wethe Critical Audit Matter Will Be Addressed in the Matter in Our Audit

 

Our audit procedures over determining the time period over which the advertisingtiming and amount of revenue is recognizedrecognition involved, among others, evaluation of management’s assessment in regard to the timing and amountidentification of advertising revenue recognition.performance obligation of revenue. We selected customer agreementssales transactions and performed the following procedures:

 

Obtained and read the customer agreements or contracts for each selected agreement.
Evaluated and tested management’s identification of significant terms for completeness, including the identification of performance obligations.
From the terms in the customer agreement, evaluated the appropriateness of management’s application of their accounting policies, in their determination of revenue recognition conclusions.

- Evaluated the terms and conditions of each selected transaction and the appropriateness of the accounting treatment within the context of the five-step model prescribed by ASC 606, Revenue from Contracts with Customers, and evaluated whether management’s conclusions were appropriate.

 

For- Tested the payment made to customer, we evaluated the application of the Company’s accounting policies in the context of applicable accounting standards. In addition, we tested the mathematical accuracy of management’s calculationsrecognition of revenue andfor the associated timing and amount of revenue recognized in the consolidated financial statements.performance obligation.

 

/s/KCCW Accountancy Corp. 

 

We have served as the Company’s auditor since 2019.

Diamond Bar, California

April 15, 20225, 2024

 

F-2

 

 

AIXIN LIFE INTERNATIONAL, INC.

CONSOLIDATED BALANCE SHEETS

 

 December 31 December 31  December 31, December 31, 
 2021  2020  2023  2022 
          
Assets                
Current assets                
Cash and cash equivalents $8,556,642  $7,676,689  $443,758  $510,128 
Restricted cash  44,211   -   23,208   109,772 
Accounts receivable, net  45,923   - 
Accounts receivable, including related parties, net  253,586   562,581 
Other receivables and prepaid expenses  143,281   32,323   170,831   42,631 
Advances to suppliers  162,969   155,686   152,563   168,523 
Inventory  233,454   45,535 
Advances to related parties  19,055   15,739 
Inventory, net  441,098   499,252 
Due from related parties  12,400   83,102 
Total current assets  9,205,535   7,925,972   1,497,444   1,975,989 
        
Property and equipment, net  290,148   67,817   1,679,675   1,971,793 
Intangible asset, net  1,940   - 
Intangible assets, net  3,917   1,269 
Deferred tax asset  18,795   -   -   15,556 
Security deposit  94,153   -   84,508   86,992 
Operating lease right-of-use assets  2,049,775   100,029   1,576,814   999,285 

Goodwill, net

  

-

   - 
Total assets $11,660,346  $8,093,818  $4,842,358  $5,050,884 
                
Liabilities and stockholders’ equity                
Current liabilities                
Accounts payable $406,163  $39,122  $478,456  $398,469 
Accounts payable - related party  1,776   165,958 
Accounts payable $478,456  $398,469 
Unearned revenue  171,408   -   172,753   139,502 
Taxes payable  232,637   283,495   49,249   104,100 
Accrued liabilities and other payables  752,400   514,239   2,163,066   2,356,490 
Government grant  923,238   950,371 
Loan from third parties  94,153   -   84,508   86,992 
Operating lease liabilities  848,230   70,780   864,519   883,583 
Advance from related parties  1,947,154   264,850 
Due to related parties  1,226,885   236,882 
Total current liabilities  4,452,145   1,172,486   5,964,450   5,322,347 
Operating lease liabilities - non-current  1,138,710   29,250   789,489   194,725 
Total liabilities  5,590,855   1,201,736   6,753,939   5,517,072 
                
Stockholders’ equity        
Undesignated preferred stock, $0.001 par value, 20,000,000 shares authorized, NaN issued and outstanding  -   - 
Common stock, par value $0.00001 per share, 500,000,000 shares authorized; 49,999,891 shares issued and outstanding as of December 31, 2021 and 2020  500   500 
Stockholders’ deficit        
Undesignated preferred stock, $0.001 par value, 20,000,000 shares authorized, none issued and outstanding  -   - 
Common stock, par value $0.00001 per share, 500,000,000 shares authorized; 24,999,834 shares issued and outstanding as of December 31, 2023 and December 31, 2022  250   250 
Additional paid in capital  14,086,793   11,115,765   14,975,423   14,458,583 
Statutory reserve  151,988   151,988   151,988   151,988 
Accumulated deficit  (8,880,613)  (4,964,711)  (17,220,392)  (15,249,858)
Accumulated other comprehensive income  710,823   588,540   181,150   172,849 
Total stockholders’ equity  6,069,491   6,892,082 
Total stockholders’ deficit  (1,911,581)  (466,188)
                
Total liabilities and stockholders’ equity $11,660,346  $8,093,818 
Total liabilities and stockholders’ deficit $4,842,358  $5,050,884 

The accompanying notes are an integral part of these financial statements

 

F-3

 

 

AIXIN LIFE INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF INCOMEOPERATIONS AND COMPREHENSIVE INCOME (LOSS)LOSS

 

 2021 2020  2023  2022 
 Years Ended December 31,  Years Ended December 31, 
 2021 2020  2023  2022 
          
Sales revenue        
Sales revenue:        
Products $742,624  $580,712  $2,894,970  $1,851,676 
Advertising  1,944,811   1,870,343 
Room revenues  114,086   -   598,252   262,605 
Food and beverage revenues  201,755   -   498,029   475,746 
Others  62,957   -   98,548   118,533 
Total revenue, net  3,066,233   2,451,055   4,089,799   2,708,560 
                
Operating costs and expenses                
Cost of goods sold  535,485   224,675   1,613,950   1,103,160 
Hotel operating costs  744,594   -   1,811,065   1,739,948 
Selling  470,798   244,200   888,745   787,637 
General and administrative  1,033,830   802,556   1,947,294   1,395,008 
(Reversal of) provision for bad debts  (63,076)  13,624   (43,988)  (119,274)
Stock-based compensation  371,540   371,540   371,540   371,540 
Total operating costs and expenses  3,093,171   1,656,595   6,588,606   5,278,019 
                
(Loss) income from operations  (26,938)  794,460 
Loss from operations  (2,498,807)  (2,569,459)
                
Non-operating income (expenses)                
Interest income  4,113   537,580   838   4,876 
Impairment loss  -   (3,823,770)
Other income  63,064   28,924   438,348   51,856 
Other expenses  (33,154)  (3,326)  (11,554)  (31,651)
Total non-operating income, net  34,023   563,178 
Total non-operating income (loss), net  427,632   (3,798,689)
                
Income before income tax  7,085   1,357,638 
Loss before income tax  (2,071,175)  (6,368,148)
                
Income tax expense  274,321   340,127   19,519   1,097 
                
Net (loss) income  (267,236)  1,017,511 
Net loss  (2,090,694)  (6,369,245)
                
Other comprehensive items                
Foreign currency translation gain  122,283   437,059 
Foreign currency translation gain (loss)  8,301   (537,974)
                
Comprehensive (loss) income $(144,953) $1,454,570 
Comprehensive loss $(2,082,393) $(6,907,219)
                
(Loss) income per share - basic and diluted $(0.005) $0.016 
Income per share - basic and diluted $(0.084) $(0.255)
                
Weighted average shares outstanding  49,999,891   65,609,450   24,999,834   24,999,842 

The accompanying notes are an integral part of these financial statements

 

F-4

 

 

AIXIN LIFE INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITYDEFICIT

 

  Shares  Amount  capital  reserves  deficit  income  Total 
  Common Stock  Additional
paid in
  Statutory  Accumulated  Accumulated other
comprehensive
    
  Shares  Amount  capital  reserves  deficit  income  Total 
                      
Balance at December 31, 2019  85,049,576  $850  $10,743,875  $11,721  $(5,841,955) $151,481  $5,065,972 
Cancellation of shares  (35,049,685)  (350)  350   -   -   -   - 
Statutory reserve  -   -   -   140,267   (140,267)  -   - 
Stock-based compensation  -   -   371,540   -   -   -   371,540 
Net income  -   -   -   -   1,017,511   -   1,017,511 
Foreign currency translation  -   -   -   -   -   437,059   437,059 
Balance at December 31, 2020  49,999,891   500   11,115,765   151,988   (4,964,711)  588,540   6,892,082 
Stock-based compensation  -   -   371,540   -   -   -   371,540 
Acquisition of subsidiaries  -   -   (4,313,025)  -   (3,648,666)  -   (7,961,691)
Debt forgiven by major shareholder  -   -   6,912,513   -   -   -   6,912,513 
Net loss  -   -   -   -   (267,236)  -   (267,236)
Net Income (loss)  -   -   -   -   (267,236)  -   (267,236)
Foreign currency translation  -   -   -   -   -   122,283   122,283 
Balance at December 31, 2021  49,999,891  $500  $14,086,793  $151,988  $(8,880,613) $710,823  $6,069,491 
  Shares  Amount  paid in capital  reserves  deficit  income  Total 
  Common Stock  Additional  Statutory  Accumulated  Accumulated
other
comprehensive
    
  Shares  Amount  paid in capital  reserves  deficit  income  Total 
                      
Balance at December 31, 2021  24,999,842  $250  $     14,087,043  $151,988  $(8,880,613) $710,823  $6,069,491 
Stock-based compensation  -   -   371,540   -   -   -   371,540 
Net loss  -   -   -   -   (6,369,245)  -   (6,369,245)
Foreign currency translation  -   -   -   -   -   (537,974)  (537,974)
Balance at December 31, 2022  24,999,842   250   14,458,583   151,988   (15,249,858)  172,849   (466,188)
Balance  24,999,842   250   14,458,583   151,988   (15,249,858)  172,849   (466,188)
Stock-based compensation  -   -   371,540   -   -   -   371,540 
Disposal of subsidiary  -   -   -   -   120,160   -   120,160 
Shareholder contribution  -   -   145,300   -   -   -   145,300 
Reverse stock split adjustment  (8)  -   -   -   -   -   - 
Net loss  -   -   -   -   (2,090,694)  -   (2,090,694)
Foreign currency translation  -   -   -   -   -   8,301   8,301 
Balance at December 31, 2023  24,999,834  $250  $14,975,423  $151,988  $(17,220,392) $181,150  $(1,911,581)
Balance  24,999,834  $250  $14,975,423  $151,988  $(17,220,392) $181,150  $(1,911,581)

 

The accompanying notes are an integral part of these financial statements

 

F-5

 

 

AIXIN LIFE INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

 2021 2020  2023  2022 
 For the Years Ended December 31  Years Ended December 31, 
 2021 2020  2023  2022 
          
CASH FLOWS FROM OPERATING ACTIVITIES:                
Net (loss) income $(267,236) $1,017,511 
Adjustments required to reconcile net income to net cash provided by (used in) operating activities:        
Net loss $(2,090,694) $(6,369,245)
Adjustments required to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization  96,106   43,462   410,690   185,565 
Provision for bad debt allowance  -  13,624 
Loss on disposal of fixed assets  362   - 
(Reversal of) provision for bad debts  (47,762)  45,953 
Provision for inventory reserve  7,770   54,899 
Operating lease expense  411,607   151,730   817,179   837,425 
Stock based compensation  371,540   371,540 
Stock-based compensation  371,540   371,540 
Deferred tax  (18,570)  -   15,152   1,858 
Changes in net assets and liabilities:        
Impairment loss  -   3,823,770 
Government grant income  (369,857)  - 
Changes in assets and liabilities:        
Accounts receivable  (7,731)  -   564,502   (425,961)
Accounts receivable - related parties  13,618   -   (86,551)  (42)
Accounts receivable  564,502   (425,961)
Other receivables and prepaid expenses  94,992   20,003   (132,455)  109,439 
Advances to suppliers  1,372  136,479   133,513   103,016 
Inventory  69,738   6,866   36,240   150,872 
Accounts payable  93,682   (71,153)
Accounts payable - related parties  (159,843)  140,608 
Accounts payable  (27,341)  -   93,682   (71,153)
Unearned revenue  (122,897)  -   37,275   (24,401)
Taxes payable  (57,467)  169,734   (52,010)  (137,711)
Payment of operating lease liabilities  (473,508)  (151,730)  (779,599)  (710,865)
Accrued liabilities and other payables  (142,027)  (166,012)  (161,393)  289,868 
Net cash (used in) provided by operating activities  (57,804)  1,613,207 
Net cash used in operating activities  (1,392,259)  (1,624,565)
                
CASH FLOWS FROM INVESTING ACTIVITIES:                
Cash disposed at disposal of subsidiary  (3,319)  - 
Cash acquired at acquisition of subsidiary  -   446,381 
Purchase of property and equipment  (1,341)  (2,173)  (295,487)  (156,723)
Cash acquired at acquisition of subsidiaries  87,448   - 
Return of (payment for) acquisition  (4,517,620)  4,087,409 
Net cash (used in) provided by investing activities  (4,431,513)  4,085,236 
Purchase of intangible asset  (4,032)  - 
Payment for acquisition of subsidiary  -   (3,812,027)
Net cash used in investing activities  (302,838)  (3,522,369)
                
CASH FLOWS FROM FINANCING ACTIVITIES:                
Proceeds from related parties  1,204,442   1,546,854 
Repayment of loan from third parties  (368,648)  - 
Change in advance from related parties  1,048,409   (2,389,593)
Proceeds from government grant  369,857   - 
Capital contribution  4,386,070   -   142,200   - 
Net cash provided by financing activities  5,221,864   1,546,854 
Net cash provided by (used in) financing activities  1,560,466   (2,389,593)
                
EFFECT OF EXCHANGE RATE CHANGE ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH  191,617   421,559   (18,303)  (444,426)
                
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH  924,164   7,666,856 
NET DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH  (152,934)  (7,980,953)
                
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF YEAR  7,676,689   9,833   619,900   8,600,853 
                
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, END OF YEAR $8,600,853  $7,676,689  $466,966  $619,900 
                
Supplemental Cash flow data:                
Income tax paid $404,276  $149,393  $4,367  $71,163 
Interest paid $-  $-  $-  $- 
        
Non-cash investing and financing activities:        
Capital contribution from forgiveness of related party loan $2,446,238  $- 

The accompanying notes are an integral part of these financial statements

 

F-6

 

 

AIXIN LIFE INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Aixin Life International, Inc. (the “Company” or “Aixin Life” or “we”) was incorporated under the laws of the State of Colorado on December 30, 1987 under the name Mercari Communications Group, Ltd (“Mercari”).1987. On February 2, 2017, Mr. Quanzhong Lin (Mr. Lin) purchased 7,380,35265.0 shares% of the Company’s common stock, 65.0% of its outstanding shares from China Concentric Capital Group for $300,000, pursuant to a Stock Purchase Agreement dated December 21, 2016, which resulted in a change in control of our company.the Company.

 

On December 12, 2017, pursuant to a Share Exchange Agreement, in consideration for all of the Company issued 56,838,151outstanding shares of common stock to Mr. Lin, the sole stockholder of AiXin (BVI) International Group Co., Ltd. a British Virgin Islands corporation (“AiXin BVI”), for his sharesthe Company issued to Mr. Lin, the sole stockholder of AiXin BVI, pursuant to a Share Exchange Agreement.shares of common stock then representing 71% of the outstanding of common stock of the Company.

 

As a result of the Share Exchange, AiXin BVI became the Company’s wholly-owned subsidiary, and the Company now owns all of the outstanding shares of HK AiXin International Group Co., Limited, a Hong Kong limited company (“AiXin HK”), which in turn owns all of the outstanding shares of Chengdu AiXinZhonghong Biological Technology Co., Ltd., a Chinese limited company (“AiXinZhonghong”), which markets and sells premium-quality nutritional products in China.

 

AiXin BVI was incorporated on September 21, 2017 as a holding company and AiXin HK was established in Hong Kong on February 25, 2016 as an intermediate holding company. AiXinZhonghong was established in the People’s Republic of China (“PRC”) on March 4, 2013, and on May 27, 2017, the local government of the PRC issued a certificate of approval regarding the foreign ownership of AiXinZhonghong by AiXin HK. Neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017.

 

For accounting purposes, the acquisition of AiXin BVI was accounted for as a reverse acquisition and treated as a recapitalization of the Company effected by a share exchange, with AiXin BVI as the accounting acquirer. Since neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017, the historical consolidated financial statements of AiXinZhonghong are now the historical consolidated financial statements of the Company. The assets and liabilities of AiXinZhonghong were brought forward at their book value and no goodwill was recognized.

 

Effective February 1, 2018, pursuant to Articles of Amendment to the Company’s Articles of Incorporation filed with the Secretary of State of Colorado, the Company changed its name to AiXin Life International., IncInternational, Inc. (“Aixin Life”).

 

The Company, through its indirectly owned AiXinZhonghong subsidiary, mainly develops and distributes consumer products by offering a line of nutritional products. The Company sells the products through exhibition events, conferences, and person-to-person marketing. Beginning in 2019, the Company began to provide advertising services to clients who engaged the Company to help distribute their products. The Company’s business mainly focuses on a proactive approach to its customers such as hosting events for clients, which it believes is ideally suited to marketing its products because sales of nutrition products are strengthened by ongoing personal contact and support, coaching and education of its clients, as to the benefits of a healthy and active lifestyle.

 

On May 25, 2021, AiXin HK entered into an Equity Transfer Agreement (the “Hotel Purchase Agreement”) with Chengdu Aixin Shangyan Hotel Management Co., Ltd (“Aixin Shangyan Hotel”), and its two shareholders Quanzhong Lin and Yirong Shen (“Transferor”). Pursuant to the agreement (the “HotelHotel Purchase Agreement”),Agreement, Aixin Life agreed to purchasepurchased 100% ownership of Aixin Shangyan Hotel from Mr. Lin and Ms. Shen.Transferor. Eighty percent of the equity of Aixin Shangyan Hotel was owned by Mr. Lin, and the remaining balance was owned by Ms. Shen. Under the terms of the Hotel Purchase Agreement, Aixin Life agreed to purchasepurchased all of the outstanding equity of Aixin Shangyan Hotel for a purchase price of RMB 7,598,887, or approximately $1.16 million (the “Transfer Price”). The Transfer Price will be reduced by an amount equal to any amounts paid or distributed by Aixin Shangyan Hotel to the Transferor after December 31, 2020 and will be increased by an amount equal to any amounts contributed to Aixin Shangyan Hotel by the Transferor after December 31, 2020. The acquisition was completed in July 2021.

 

F-7

 

 

On June 2, 2021, AiXin HK entered into an Equity Transfer Agreement (the “Pharmacies Purchase Agreement”) with Chengdu Aixintang Pharmacy Co., Ltd. and certain affiliated entities, each of which operates a pharmacy (together, “Aixintang Pharmacies”) and its three shareholders, Quanzhong Lin, Ting Li and Xiao Ling Li (“Transferor”). Mr. Lin owned in excess of 95% of the outstanding equity the Aixintang Pharmacies. The remaining equity interest was owned by Ting Li and Xiao Ling LiLi.. Pursuant to the agreement (the “PharmaciesPharmacies Purchase Agreement”),Agreement, AiXin HK agreed to purchasepurchased all of the outstanding equity of Aixintang Pharmacies for an aggregate purchase price of RMB 34,635,845, or approximately US$5.31 million (the “Transfer Price”). The Transfer Price will be reduced by an amount equal to any amounts paid or distributed by any of the Aixintang Pharmacies to the Transferor after December 31, 2020 and increased by an amount contributed to any of the Aixintang Pharmacies by the Transferor after such date. The acquisition was completed in September 2021.

 

On July 19, 2022, AiXin HK entered into an Equity Transfer Agreement with Yunnan Shengshengyuan Technology Co., Ltd, (“Yunnan Shengshengyuan”) and Yun Chen (together, the “Sellers”), the shareholders of Yunnan Runcangsheng Technology Company Ltd. (“Runcangsheng”). Yunnan Shengshengyuan owns in excess of 95% of the outstanding equity of Runcangsheng. The remaining equity interest is owned by Yun Chen. Pursuant to the Transfer Agreement, HK Aixin agreed to purchase all of the outstanding equity of Runcangsheng for an aggregate purchase price of $4,418,095 (RMB 31,557,820), adjusted by $116,802 the amount equal to the initial net worth minus the audited net worth. In addition to transferring their respective equity interest in Runcangsheng by the Sellers, both Sellers agree to forgive any loans Runcangsheng due to them. The acquisition was completed on September 30, 2022 (see Note 19).

On February 17, 2023, the Company effected a 1 for 2 reverse stock split. As a result of the reverse split, every two shares of the Company’s issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, par value $0.00001 per share. The Company has approximately 24,999,834 shares of outstanding common stock after the effect of reverse stock split and the elimination of fractional shares. All share and earnings per share information has been retroactively adjusted to reflect the reverse stock split.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Consolidation

 

The accompanying consolidated financial statements are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”). The functional currency of AiXinZhonghong, Aixin Shangyan Hotel, and Aixintang Pharmacies, and Runcangsheng is the Chinese Renminbi (“RMB”). The accompanying consolidated financial statements are translated from RMB and presented in U.S. dollars (“USD”).

 

The consolidated financial statements include the accounts of the Company and its current wholly owned subsidiaries, AiXin HK, AiXinZhonghong, Aixin Shangyan Hotel, Aixintang Pharmacies, and Aixintang Pharmacies.Runcangsheng. Intercompany transactions and accounts were eliminated in consolidation.

 

ReclassificationGoing Concern

 

Certain prior period amountsThe accompanying consolidated financial statements have been reclassifiedprepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The realization of assets and the satisfaction of liabilities in the normal course of business are dependent on, among other things, the Company’s ability to conformoperate profitably, to generate cash flows from operations, and to pursue financing arrangements to support its working capital requirements.

The Company has suffered net losses of $2,090,694 and $6,369,245 for the years ended December 31, 2023 and 2022, respectively, and used net cash in operating activities of $1,392,259 and $1,624,565 for the years ended December 31, 2023 and 2022, respectively, and has an accumulated deficit of $17,220,392 as of December 31, 2023. These facts and conditions raise substantial doubt about the Company’s ability to continue as a going concern. From January 1, 2023 through December 31, 2023, the Company’s cash and cash equivalents decreased from $510,128 to $443,758 mainly due to operating losses, and the use of cash to support operating activities.

F-8

Management believes that it has developed a liquidity plan, summarized below, that, if executed successfully, should provide sufficient liquidity to meet the Company’s obligations as they become due for a reasonable period of time, and allow the development of its core business. The plan includes:

● Gaining positive cash-inflow from operating activities through continuous cost reductions and the sales of higher margin products.

● Raising cash through loans from related parties and potential equity offerings.

While the Company’s management believes that the measures in its liquidity plan including those described above will be adequate to satisfy its liquidity requirements for the twelve months after the date that these financial statements are issued, there is no assurance that the liquidity plan will be successfully implemented. Failure to successfully implement the liquidity plan may have a material adverse effect on its business, results of operations and financial position, and may adversely affect its ability to continue as a going concern. These consolidated financial statements do not include any adjustments related to the current period presentationrecoverability and had no effect on previously reported consolidated net income (loss)classification of recorded assets or accumulated deficit.the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.

 

Covid – 19Global Uncertainties

 

On March 11, 2020,The Company’s liquidity may be adversely impacted by various risks and uncertainties, including, but not limited to future and current impacts of global events such as a widespread health crisis, the World Health Organization announced that infections caused by the corona virus disease of 2019 (“COVID-19”) had become pandemic. The Government of China has adopted various regulations and orders, including mandatory quarantines, limits on the number of people that may gather in one location, closing non-essential businesses and travel bans to limit the spreadcontinuation of the disease. Many of these measures have been relaxed due to the decreasewar in the prevalenceUkraine or the conflict in Palestine, the outbreak of Covid-19another conflict or the expansion of the conflict in China. However, since February 2022Palestine to date, COVID-19 cases have increased again in many cities of China. There has been only a slight increaseother countries, the ongoing tensions between the United States and China, the Russian Federation and certain countries in the number of casesMiddle East, increases in Sichuan Province, the Provinceinflation, and other risks detailed in which the Company is located, and the Company does not expect that the increase will impactin the Company’s operations.Annual Report on Form 10-K or other reports filed with the Securities and Exchange Commission.

 

Financial impacts related to COVID-19, includingWhile the invasion of Ukraine, the conflict in Palestine and responses thereto have not interrupted the Company’s actionsoperations, these or future developments which disrupt the international financial markets could make it difficult to access debt and costs incurred in response to the pandemic, were not material toequity capital on attractive terms, if at all, and impact the Company’s financial position, results of operations or cash flows for the year ended December 31, 2021. The Company has implemented proceduresability to promote employee and customer safety. These measures will not significantly increase its operating costs. However, the Company cannot predict with certainty what measures may be taken by its suppliers and customers and the impact these measures may have on its future financial position, results of operations or cash flows.fund business activities, including proposed acquisitions.

 

Use of Estimates

 

In preparing consolidated financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

 

F-8

Significant estimates required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.

Reclassification

Certain prior period amounts have been reclassified to conform to the current period presentation and had no effect on previously reported consolidated net income (loss) or accumulated deficit.

Cash and Cash Equivalents

 

For financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

 

F-9

Restricted Cash

 

The restricted cash was for the temporarycash maintained in temporarily frozen of bank accounts held by Aixintang Pharmacy Co., Ltd. (“Aixintang Pharmacy”) and its branches by the court for a complaintjudgement against the Aixintang Pharmacy while Aixintang Pharmacy is the process of appeal (see Note 1718 – litigation).

 

Accounts Receivable

 

The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of December 31, 20212023 and 2020,2022, the bad debt allowance was $213,78780,640 and $148,520272,550, respectively.

The following table summarizes the activity related to the Company’s accounts receivable allowance for doubtful accounts for the years ended December 31, 2023 and 2022:

SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE FOR DOUBTFUL ACCOUNTS

  2023  2022 
  For the years ended December 31, 
  2023  2022 
       
Beginning balance $272,550  $213,787 
(Reversal of) provision for bad debts  (47,762)  45,953 
Acquisition of subsidiary  -   196,164 
Recoveries/Write offs  (135,589)  (165,227)
Effect of translation  (8,559)  (18,127)
Ending balance $80,640  $272,550 

 

Inventories

 

Inventories mainly consists of health supplements, drugs, pharmaceutical and nutritional products, food and beverage, hotel supplies and consumables. Inventories are valued at the lower of average cost or market, cost being determined on a moving weighted average method at the end of the month. Management compares the cost of inventories with the net realizable value and an allowance is made for writing down inventories to market value, if lower. The Company recorded provision for inventory reserve of $07,770 inventory impairmentand $54,899 for the years ended December 31, 20212023 and 2020.

In July 2015, the FASB issued Accounting Standards Update (“ASU”) 2015-11, “Inventory (Topic 330) - Simplifying the Measurement of Inventory,” which requires that inventory within the scope of the guidance be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.2022, respectively.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation, and impairment losses, if any. Major repairs and betterments that significantly extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with 5% salvage value and estimated lives as follows:

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED LIVES

Office furniture5 years
Electronic equipment2-3 years
Machinery3 years
Leasehold improvements3 years
Vehicles5 years

 

F-9

Impairment of Long-Lived Assets

 

Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, but at least annually.

F-10

 

Recoverability of long-lived assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by it. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Based on its review, the Company believes that, as of December 31, 20212023 and 2020,2022, there were 0no significant impairments of its long-lived assets.

Goodwill

The Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions.

The Company completed the required testing of goodwill for impairment as of December 31, 2022, and determined that goodwill was impaired because of the current financial condition of the Company and the Company’s inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the uncertainty of the future cash flows indicates that the recoverability of goodwill is not reasonably assured.

The goodwill write-down was reflected as an impairment loss, $3,823,770, in non-operating expenses in the statement of operations and comprehensive income (loss) during the year ended December 31, 2022.

 

Income Taxes

 

Income taxes are accounted for using an asset and liability method. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

The Company follows Accounting Standards Codification (“ASC”) Topic 740, which prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740 also provides guidance on recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, accounting for income taxes in interim periods, and income tax disclosures.

 

Under ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in the statement of income.

 

F-11

At December 31, 20212023 and 2020,2022, the Company did 0tnot take any uncertain positions that would necessitate recording a tax related liability.

 

Revenue Recognition

 

ASU No. 2014-09, Revenue from Contracts with Customers (“Topic 606”), became effective for the Company on January 1, 2018. The Company’s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard. The Company applied the “modified retrospective” transition method for open contracts for the implementation of Topic 606. As revenues are and have been primarily from the delivery of products and the performance of services, and the Company has no significant post-delivery obligations, this did not result in a material recognition of revenue on the Company’s accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments to its previously-reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices under Topic 605, Revenue Recognition.

F-10

Revenue from sale of goods under Topic 606 is recognized in a manner that reasonably reflects the delivery of the Company’s products and services to customers in return for expected consideration and includes the following elements:

 

 executed contract(s) with customers that the Company believes is legally enforceable;

 identification of performance obligation in the respective contract;

 determination of the transaction price for each performance obligation in the respective contract;

 allocation of the transaction price to each performance obligation; and

 recognition of revenue only when the Company satisfies each performance obligation.

 

The Company’s revenue recognition policies for its various operating segments are as follows:

 

Advertising and Products

Advertising Revenue

Commencing in the third quarter of 2019, AiXin Zhonghong began to provide advertising services to its clients. Advertising contracts are signed to establish the price and advertising services to be provided. Pursuant to the advertising contracts, the Company provides advertising and marketing services to its clients through exhibition events, conferences, and person-to-person marketing. The Company performs a credit assessment of the customer to assess the collectability of the contract price prior to entering into contracts.

Most of the advertisement contracts designated that the Company perform such advertising services for its clients through exhibition events, conferences, and person-to-person marketing during the contracted period, regardless of the number of such events. As such, the Company determined that the performance obligation is satisfied over time during the contracted period and revenue is recognized accordingly. Such advertising revenue amounted to $1,944,811 and $1,863,785 for the years ended December 31, 2021 and 2020, respectively.

A smaller proportion of the Company’s advertising revenue is generated from services to its clients through exhibition events, conferences, and person-to-person marketing, and charges based on the number of promotional products sold. Such advertising revenue amounted to $0 and $6,558 for the years ended December 31, 2021 and 2020, respectively.

All of the advertising revenue is subject to the PRC VAT of 6%. This VAT may be offset by VAT paid by the Company on raw materials and other materials purchased in China.

Products Revenue

 

The Company’s revenue from salesales of products is recognized when goods are delivered to the customer and no other obligation exists. The Company does not provide unconditional return or other concessions to the customer. The Company’s sales policy allows for the return of unopened products for cash after deducting certain service and transaction fees. As an alternative to the product return option, the customers have optionsthe option of asking for an exchange for products with the same value.

 

Sales revenue of AiXin Zhonghong represents the invoiced value of goods, net of value-added taxes (“VAT”). All of the Company’s products sold in China are subject to the PRC VAT of 13% since April 1, 2019. This VAT may be offset by VAT paid by the Company on raw materials and other materials purchased in China. The Company records VAT payable and VAT receivable net of payments in the financial statements. The VAT tax return is filed offsetting the payables against the receivables. Sales and purchases are recorded net of VAT collected and paid as the Company acts as an agent for the government.

 

F-11

Hotel

 

Hotel revenues are primarily derived from the rental of rooms, food and beverage sales and other ancillary goods and services, including but not limited to souvenir, parking and conference reservation. Each of these products and services represents a distinct performance obligation and, in exchange for these services, the Company receives fixed amounts based on published rates or negotiated contracts. Payment is due in full at the time when the services are rendered or the goods are provided. Room rental revenue is recognized on a daily basis when rooms are occupied. Food and beverage revenue and other goods and services revenue are recognized when they have been delivered or rendered to the guests as the respective performance obligations are satisfied. All of the hotel’s goods sold in China are subject to the PRC VAT of 6%. This VAT may be offset by VAT paid by the Company on raw materials and other materials purchased in China.

 

Pharmacies

 

The Company’s retail drugstores (Aixintang Pharmacies) recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation. Aixintang Pharmacies generally receives payments from customers as it satisfies its performance obligations. The Company records a receivable when it has an unconditional right to receive payment and only the passage of time is required before payment is due. Sales revenue represents the invoiced value of goods, net of VAT. All of Aixintang Pharmacies’ products sold in China are eligible for the PRC VAT of 0% as it qualifies as a small businesses.business.

F-12

Manufacture and Sale

The Company’s new subsidiary Runcangsheng recognizes revenue at the time products are shipped as this satisfies its performance obligation. The Company records a receivable for its sales when it has an unconditional right to receive payment and only the passage of time is required before payment is due. Sales revenue represents the invoiced value of goods, net of value-added taxes (“VAT”). All of the Company’s products sold in China are subject to the PRC VAT of 13% unless it is a qualified small business subject to exemption.

 

Unearned Revenue

 

The Company’s unearned revenue primarily consists of advances received from customers for the purchase of products prior to the delivery of goods, and for the rental of hotel rooms prior to the delivery of service. The delivery of products and room rental services are delivered (normally within one year)is based upon contract terms and customer demand.demand, normally within one year.

 

Concentration of Credit Risk

 

The operations of the Company are in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, and by the general state of the PRC economy.

 

The Company has cash on hand and demand deposits in accounts maintained with state-owned banks within the PRC. Cash in state-owned banks is covered by insurance up to RMB 500,000 ($72,500) per bank. The Company has not experienced any losses in such accounts and believes they are not exposed to any risks on its cash in these bank accounts.

 

During the yearyears ended December 31, 2021,2023 and 2022, the Company had two major customersno customer that accounted for over 10%10% of its total revenue.

SCHEDULE OF CONCENTRATION OF RISK BY RISK FACTORS

Customer Net sales for the
year ended
December 31, 2021
  % of total revenue 
A* $1,286,792   42%
B  658,018   21%

 

During the year ended December 31, 2020,2023, the Company had one major customer that accounted for over 10% of its total revenue.

Customer Net sales for the
year ended
December 31, 2020
  % of total revenue 
A* $1,863,785   76%

F-12

During the year ended December 31, 2021, the Company had one major suppliertwo suppliers that accounted for over 10% of its total purchases.

 

Supplier Net purchases for the year ended
December 31, 2021
  % of total purchase 
C $233,187   40%

SCHEDULE OF CONCENTRATION OF RISK BY RISK FACTORS

Supplier Net purchases for the
year ended
December 31, 2023
  % of total purchase 
A $250,999   14%
B  195,202   11%

 

During the year ended December 31, 2020,2022, the Company had threetwo major suppliers that accounted for over 10% of its total purchases.

 

Supplier Net purchase for the year ended
December 31, 2020
  % of total purchase 
A* $110,037   55%
D  27,225   14%
E  20,000   10%
Supplier Net purchases for the
year ended
December 31, 2022
  % of total purchase 
B $189,150   14%
C (1)  149,806   11%

 

*(1)Represented advertising revenues from this customer during the years ended December 31, 2021 and 2020. The Company also purchased inventory from this customer duringsupplier, Runcansheng, in the yearsyear ended December 31, 2021 and 2020.2022. The Company acquired all of the outstanding equity of Runcangsheng on September 30, 2022 (see Note 19).

F-13

 

Leases

The Company adopted FASB Accounting Standards Codification, Topic 842, Leases (“ASC 842”) using the modified retrospective approach, electing the practical expedient that allows the Company not to restate prior to the adoption of the standard on January 1, 2019.

The Company applied the following practical expedients in the transition to the new standard allowed under ASC 842:

Practical ExpedientDescription
Reassessment of expired or existing contractsThe Company elected not to reassess, at the application date, whether any expired or existing contracts contained leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing leases.
Use of hindsightThe Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of right-to-use assets.
Reassessment of existing or expired land easementsThe Company elected not to evaluate existing or expired land easements that were not previously accounted for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will be evaluated under ASU No. 2016-02.
Separation of lease and non-lease componentsLease agreements that contain both lease and non-lease components are generally accounted for separately.
Short-term lease recognition exemptionThe Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities for leases with a term less than 12 months.

 

The Company determines if an arrangement is a lease at inception under FASB ASC Topic 842, Right of Use Assets (“ROU”) and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of its leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The ROU assets include adjustments for prepayments and accrued lease payments. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise such options.

 

F-13

ROU assets are reviewed for impairment when indicators of impairment are present. ROU assets from operating and finance leases are subject to the impairment guidance in ASC 360, Property, Plant, and Equipment, as ROU assets are long-lived nonfinancial assets.

 

ROU assets are tested for impairment individually or as part of an asset group if the cash flows related to the ROU asset are not independent from the cash flows of other assets and liabilities. An asset group is the unit of accounting for long-lived assets to be held and used, which represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. The Company recognized no impairment of ROU assets as of December 31, 20212023 and 2020.2022. Operating leases are included in operating lease ROU and operating lease liabilities (current and non-current), on the consolidated balance sheets.

 

Statement of Cash Flows

 

In accordance with ASC Topic 230, “Statement of Cash Flows,” cash flows from the Company’s operations are calculated based on the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.

 

Fair Value of Financial Instruments

 

The carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, accrued liabilities and accounts payable, approximate their fair value due to their short maturities. FASB ASC Topic 825, “Financial Instruments,” requires disclosure of the fair value of financial instruments held by the Company. The carrying amounts reported in the consolidated balance sheets for current liabilities each qualify as financial instruments and are a reasonable estimate of their fair value because of the short period of time between the origination of such instruments and their expected realization and the current market rate of interest.

 

Fair Value Measurements and Disclosures

 

ASC Topic 820, “Fair Value Measurements and Disclosures,” defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels are defined as follow:

 

 Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
 Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
 Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

F-14

As of December 31, 20212023 and 2020,2022, the Company did not identify any assets and liabilities that are required to be presented on the balance sheet at fair value.

 

Foreign Currency Translation and Comprehensive Income (Loss)

 

The functional currency of the Company is RMB. For financial reporting purposes, RMB is translated into USD as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet dates. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period.

F-14

 

Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity as “Accumulated other comprehensive income”. Gains and losses resulting from foreign currency transactions are included in income. There was no significant fluctuation in the exchange rate for the conversion of RMB to USD after the balance sheet date.

 

The Company uses FASB ASC Topic 220, “Comprehensive Income”. Comprehensive loss is comprised of net loss and all changes to the statements of stockholders’ equity, except those due to investments by stockholders, changes in paid-in capital and distributions to stockholders. Comprehensive income (loss) for the year ended December 31, 20212023 and 20202022 consisted of net income (loss) and foreign currency translation adjustments.

 

Earnings per Share

 

Basic income (loss) per share is computed on the basis of the weighted average number of common shares outstanding during the period.

 

Dilution is computed by applying the treasury stock method for options and warrants. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.

 

As of December 31, 20212023 and 2020,2022, the Company did 0tnot have any potentially dilutive instruments.

 

Stock-Based Compensation

 

The Company periodically grants stock options, warrants and awards to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option, stock warrant and stock award grants to employees based on the authoritative guidance provided by the FASB where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option, stock warrant and stock award grants to non-employees in accordance with the authoritative guidance of the FASB where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the employees and non-employees, option, warrant and award grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s chief operating decision maker organizes segments within the Company for making operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

 

The Company manages its business as threefour operating segments, advertising and products, pharmacies, hotel, and hotels,manufacture and sales, all of which are located in the PRC. All of its revenues are derived in the PRC. All long-lived assets are located in PRC.

 

F-15

 

 

The following table shows the Company’s operations by business segment for the yearyears ended December 31, 20212023 and 2020. Revenues and expenses for2022.

SCHEDULE OF SEGMENTS INFORMATION

  2023  2022 
  For the Years Ended December 31, 
  2023  2022 
Net revenue        
Products $1,159,134  $823,930 
Pharmacies  937,655   789,347 
Hotel  1,194,829   856,884 
Manufacture and sale  798,181   238,399 
Total revenues, net $4,089,799  $2,708,560 
         
Operating costs and expenses        
Products        
Cost of goods sold $393,862  $171,345 
Operating expenses  1,790,747   1,526,246 
Pharmacies        
Cost of goods sold  531,890   578,092 
Operating expenses  455,906   622,835 
Hotel        
Hotel operating costs  1,811,065   1,739,948 
Operating expenses  192,963   310,902 
Manufacture and sale        
Cost of goods sold  688,198   353,723 
Operating expenses  723,975   (25,072)
Total operating costs and expenses $6,588,606  $5,278,019 
         
Loss from operations        
Products $(1,025,475) $(873,661)
Pharmacies  (50,141)  (411,580)
Hotel  (809,199)  (1,193,966)
Manufacture and sale  (613,992)  (90,252)
Loss from operations $(2,498,807) $(2,569,459)

Segment assets As of
December 31, 2023
  As of
December 31, 2022
 
Products $270,932  $410,754 
Pharmacies  425,546   758,675 
Hotel  1,654,165   970,385 
Manufacture and sale  2,491,715   2,911,070 
Total assets $4,842,358  $5,050,884 

As the Pharmacies and Hotel segments commencedacquisition of Runcangsheng was consummated as of September 30, 2022 (see Note 19), the respective datesrevenues and operating results of the completionmanufacture and sale segment were included in the financial statements of their acquisitions:the Company beginning on October 1, 2022.

SCHEDULE OF INFORMATION SEGMENTS

  2021  2020 
Net revenue        
Advertising and products $2,406,988  $2,451,055 
Pharmacies  280,447   - 
Hotel  378,798   - 
Total revenues, net $3,066,233  $2,451,055 
         
Operating costs and expenses        
Advertising and products        
Cost of goods sold $316,750  $224,675 
Operating expenses  1,344,543   1,431,920 
Pharmacies        
Cost of goods sold  218,735   - 
Operating expenses  252,513   - 
Hotel        
Hotel operating costs  744,594   - 
Operating expenses  216,036   - 
Total operating costs and expenses $3,093,171  $1,656,595 
         
Income (loss) from operations        
Advertising and products $745,695  $794,460 
Pharmacies  (190,801)  - 
Hotel  (581,832)  - 
Income (loss) from operations $(26,938) $794,460 

Segment assets As of
December 31, 2021
  As of
December 31, 2020
 
Advertising and products $8,914,211  $8,093,818 
Pharmacies  931,706   - 
Hotel  1,814,429   - 
Total assets $11,660,346  $8,093,818 

 

New Accounting Pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluatingadoption of ASU 2016-13 did not have any impact on the impact that the standard will have on itsCompany’s consolidated financial statements.statements presentation or disclosures.

F-16

 

In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its FV,fair value, not to exceed the carrying amount of goodwill. The guidance should be adopted on a prospective basis. As a smaller reporting company, the standard will be effective for the Company for interim and annual reporting periods beginning after December 15, 2022, with early adoption permitted. The Company is currently evaluating theadoption of ASU 2017-04 did not have any impact of adopting this standard on the Company’s consolidated financial statements presentation or disclosures.

F-16

 

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2021 including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The adoption of ASU 2020-06 is not expected to have any impact on the Company’s consolidated financial statements presentation or disclosures.

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The adoption of ASU 2021-04 is not expected to have any impact on the Company’s consolidated financial statements presentation or disclosures.

The Company’s management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

 

3. OTHER RECEIVABLES AND PREPAID EXPENSES

 

Other receivables and prepaid expenses consisted of the following at December 31, 20212023 and 2020:2022:

SCHEDULE OF OTHER RECEIVABLES AND PREPAID EXPENSES 

 December 31, 2021 December 31, 2020  December 31, 2023  December 31, 2022 
Deposits $68,433  $6,624  $8,978  $15,546 
Prepaid expenses  50,221   12,884 
Prepaid expenses including related party (see Note 13)  128,378   9,490 
Employees’ social insurance  13,839   7,562   8,667   10,124 
Others  10,788   5,253   24,808   7,471 
Total $143,281  $32,323  $170,831  $42,631 

4. ADVANCES TO SUPPLIERS

 

The Company had advances to suppliers of $162,969152,563 and $155,686168,523 as of December 31, 20212023 and 2020,2022, respectively. Advances to suppliers primarily include prepayments for products and equipment expected to be delivered subsequent to balance sheet dates.

 

F-17

5. INVENTORIES

 

Inventories consisted of the following at December 31, 20212023 and 2020:2022:

 

SCHEDULE OF INVENTORIES

  December 31, 2021  December 31, 2020 
Finished goods – health supplements $6,201  $45,535 
Drugs, pharmaceutical and nutritional products  122,966   - 
Food and beverage, hotel supplies and consumables  104,287   - 
Total $233,454  $45,535 

 

F-17

  December 31, 2023  December 31, 2022 
Raw material $114,005  $62,462 
Work in process  -   15,315 
Finished goods-health supplements  -   521 
Drugs, pharmaceutical and nutritional products  324,588   412,129 
Food and beverage, hotel supplies and consumables  81,969   82,646 
Total $520,562  $573,073 
Less: reserve for inventory  79,464   73,821 
Total inventories, net $441,098  $499,252 

6. PROPERTY AND EQUIPMENT, NET

 

Property and equipment consisted of the following at December 31, 20212023 and 2020:2022:

SCHEDULE OF PROPERTY AND EQUIPMENT

 December 31, 2021  December 31, 2020  December 31, 2023  December 31, 2022 
Vehicles $295,502  $288,604�� $451,381  $426,836 
Office furniture  64,263   48,464   80,612   82,549 
Electronic equipment  22,304   14,852   25,899   20,607 
Machinery  106,080   -   1,314,902   1,241,778 
Leasehold improvements  256,548   -   1,125,581   1,139,087 
Other  6,374   -   11,997   17,485 
Total  751,071   351,920   3,010,372   2,928,342 
Less: Accumulated depreciation  (460,923)  (284,103)  (1,330,697)  (956,549)
Property and equipment, net $290,148  $67,817  $1,679,675  $1,971,793 

 

Depreciation expense for the years ended December 31, 20212023 and 20202022 was $95,026409,351 and $43,462183,542, respectively.respectively

 

7. INTANGIBLE ASSET, NET

 

Intangible asset consisted of the following at December 31, 20212023 and 2020:2022:

SCHEDULE OF INTANGIBLE ASSET

 December 31, 2021  December 31, 2020  December 31, 2023  December 31, 2022 
Software $7,896  $-  $12,516  $8,564 
Less: Accumulated amortization  (5,956)      (8,599)  (7,295)
Intangible asset, net $1,940  $-  $3,917  $1,269 

 

Amortization expense for the years ended December 31, 20212023 and 20202022 was $1,0801,339 and $02,023., respectively.

 

8. TAXES PAYABLE

 

Taxes payable consisted of the following at December 31, 20212023 and 2020:2022:

SCHEDULE OF TAX PAYABLE

 December 31, 2021  December 31, 2020  December 31, 2023  December 31, 2022 
Value-added $97,917  $32,318  $6,439  $56,806 
Income  109,396   235,300   29,998   30,919 
City construction  7,018   2,422   1,423   3,746 
Education  5,064   1,781   1,024   2,184 
Other  13,242   11,674   10,365   10,445 
Taxes payable $232,637  $283,495  $49,249  $104,100 

 

F-18

9. ACCRUED LIABILITIES AND OTHER PAYABLES

 

Accrued liabilities and other payables consisted of the following at December 31, 20212023 and 2020:2022:

SCHEDULE OF ACCRUED LIABILITIES AND OTHER PAYABLES

 December 31, 2021  December 31, 2020  December 31, 2023  December 31, 2022 
Accrued employees’ social insurance $327,735  $364,870  $231,983  $270,349 
Accrued payroll and commission  179,183   105,844   308,768   307,331 
Accrued rent expense  29,000   -   -   32,746 
Construction payable  111,807   -   1,229,775   1,384,674 
Payable for equipment purchase  30,307   32,278 
Accrued professional fees  50,840   16,927   250,505   233,894 
Deposit  12,239   -   10,986   11,308 
Other payables  41,596   26,598   100,742   83,910 
Total $752,400  $514,239  $2,163,066  $2,356,490 

 

F-18

10. GOVERNMENT GRANT

On December 1, 2021, The Company and Luquan Yizu Miaozu Autonomous County People’s Government (“the People’s Government”) entered a cooperation agreement for a cooperation term of 10 years. According to the agreement, the People’s Government will contribute RMB 8,000,000 ($1,194,400) as a one-time payment to the Company for supporting them on deep processing of Chinese herbs. The Company can retain the contributed amount at the end of the cooperation term if it passes the performance assessment by People’s Government; otherwise, it will return the full proceeds they received plus 20% penalty. As of December 31, 2023, the Company only received $923,238 from People’s Government, the Company plans to return the funds to the People’s Government as it is not the full amount the Peoples’ Government promised to contribute.

 

10.11. LOAN FROM THIRD PARTIES

 

As of December 31, 20212023 and 2020,2022, the Company had advances from former shareholders and unrelated third parties of Aixin Shangyan Hotel in an aggregate amount of $94,15384,508 and $086,992, respectively. There was no written agreement, and these loans are payable on demand and bear no interest.

11. LOAN TO THIRD PARTY

On June 8, 2020, the Company entered into an unsecured loan agreement with a third party, pursuant to which the Company agreed to lend RMB 50,300,000, equivalent to $7,408,389, to the third party. This loan bears interest of RMB 74,000, equivalent to $10,718, per day, and will mature on July 28, 2020. As of December 31, 2020, the Company has received the repayment of principal and interest in full amount, and recorded interest income of $535,906 during the year ended December 31, 2020.

12. LEASE

 

Concurrent with the completion of the sale ofAiXinZhonghong leases its rights to a portion of a building completed in 2019, the Company entered into an agreement to lease a portion of the building back from the buyer over a lease term of 2 years. The Company accounted for this lease as an operating lease right-of-use asset and a corresponding operating lease liability in accordance with the Lease Standard. As a result, $207,049 (RMB 1,389,731) was recorded as operating lease right-of-use asset and lease liability on March 31, 2019 when the lease commenced based on a 4.75% discount factor. The lease agreement expired on March 31, 2021. Commencing in April, 2021, the Company continues to lease the office on a monthly basis.

The Company AiXinZhonghong also has operating leases for other sales locations under various operating lease arrangements. The leases have remaining lease terms of approximately 0.50.33 to 5 years4.41. years.

 

Aixin Shangyan Hotel leases its hotel premises under an operating lease arrangement. The lease has a remaining lease term of approximately 2 years.

 

Aixintang Pharmacies lease retail pharmacy stores under operating lease arrangements, with remaining lease terms of 20.96 to 52.67 years.

Runcangsheng leases its office under an operating lease arrangement. The lease was expired as of December 31, 2023. In January 2024, the lease was renewed with the expiration date on December 31, 2024.

 

Balance sheet information related to the Company’s leases is presented below:

SCHEDULE OF OPERATING LEASE LIABILITIES

 December 31, 2021  December 31, 2020  December 31, 2023  December 31, 2022 
Operating Leases                
Operating lease right-of-use assets $2,049,775  $100,029  $1,576,814  $999,285 
                
Operating lease liabilities – current $848,230  $70,780  $864,519  $883,583 
Operating lease liability – non-current  1,138,710   29,250   789,489   194,725 
Total operating lease liabilities $1,986,940  $100,030  $1,654,008  $1,078,308 

F-19

 

The following provides details of the Company’s lease expenses:

SCHEDULE OF OPERATING LEASE EXPENSES

  2021  2020 
  Years Ended December 31, 
  2021  2020 
Operating lease expenses $411,607  $151,730 
  2023  2022 
  Years Ended December 31, 
  2023  2022 
Operating lease expenses $817,179  $837,425 

Other information related to leases is presented below:

SCHEDULE OF OTHER INFORMATION RELATED LEASES

  Years Ended December 31, 
  2021  2020 
Cash Paid For Amounts Included In Measurement of Liabilities:        
Operating cash flows from operating leases $473,508   151,730 
         
Weighted Average Remaining Lease Term:        
Operating leases  2.32 years   1.37 years 
         
Weighted Average Discount Rate:        
Operating leases  4.75%  4.75%

F-19

  Years Ended December 31, 
  2023  2022 
Cash Paid for Amounts Included In Measurement of Liabilities:        
Operating cash flows from operating leases $779,599   710,865 
         
Weighted Average Remaining Lease Term:        
Operating leases  1.99 years   1.45 years 
         
Weighted Average Discount Rate:        
Operating leases  4.75%  4.75%

 

Maturities of lease liabilities were as follows:

 

SCHEDULE OF MATURITIES OF LEASE LIABILITIES

        
For the year ending December 31:       
2022 $912,635 
2023  959,650 
2024  142,251  $921,869 
2025  52,176   759,052 
2026  24,280   37,370 
2027  8,451 
2028  3,521 
Total lease payments  2,090,992   1,730,263 
Less: imputed interest  (104,052)  (76,255)
Total lease liabilities  1,986,940   1,654,008 
Less: current portion  (848,230)  (864,519)
Lease liabilities – non-current portion $1,138,710  $789,489 

 

13. RELATED PARTY TRANSACTIONS

 

AdvanceAccounts receivable – related party

Accounts receivable – related party consisted of the following as of the periods indicated:

SCHEDULE OF ACCOUNTS RECEIVABLE RELATED PARTY

  December 31, 2023  December 31, 2022 
Chengdu WenJiang Aixin Nanjiang Pharmacy Co., Ltd. $2,451  $- 
Chengdu Lisheng Huiren Tang Pharmacy Co., Ltd.  4,309   - 
Chengdu Fuxiang Tang Pharmacy Co., Ltd.  2,028   - 
Chengdu Wenjiang district Heneng hupu Pharmacy Co., Ltd  2,028   - 
Xiaoyan Zhou  32,493   - 
Chengdu Aixin International Travel Service Co., Ltd  43,083   - 
Other  -   42 
Total $86,392  $42 
Accounts receivable – related party $86,392  $42 

The related party entities listed above are controlled by Mr. Quanzhong Lin (the Chairman, President and major shareholder of Aixin Life). Xiaoyan Zhou is the wife of Huiliang Jiao, the Company’s Director.

Prepaid expense – related party

Prepaid expense – related party consisted of the following as of the periods indicated:

SCHEDULE OF PREPAID EXPENSE AND ACCOUNTS PAYABLE TO RELATED PARTY

  December 31, 2023  December 31, 2022 
Chengdu Aixin International Travel Service Co., Ltd $120,483  $- 

Chengdu Aixin International Travel Service Co., Ltd is an entity owned by the Company’s CEO.

F-20

Accounts payable – related party

Accounts payable – related party consisted of the following as of the periods indicated:

  December 31, 2023  December 31, 2022 
Luquan Shengcaofeng Biotechnology Co., Ltd. $-  $165,958 
Sichuan Aixintang Xinfu Chain Pharmacy Co., Ltd.  

1,776

   - 
  $

1,776

  $

165,958

 

Luquan Shengcaofeng Biotechnology Co., Ltd. is an entity controlled by Mr. Huiliang Jiao, a Director of the Company.

Sichuan Aixintang Xinfu Chain Pharmacy Co., Ltd. is an entity controlled by Quanzhong Lin, CEO of the Company.

Due from related parties

Due from related parties consisted of the following as of the periods indicated:

SCHEDULE OF RELATED PARTY TRANSACTIONS

  December 31, 2023  December 31, 2022 
Chengdu WenJiang Aixin Nanjiang Pharmacy Co., Ltd. $563  $9,708 
Chengdu Fuxiang Tang Pharmacy Co., Ltd.  85   26,125 
Chengdu Zhiweibing Pharmacy Co., Ltd.  1,738   - 
Chengdu Wenjiang district Heneng hupu Pharmacy Co., Ltd  704   34,622 
Sichuan Aixin Investment Co. Ltd  9,310   145 
Chengdu Lisheng Huiren Tang Pharmacy Co., Ltd.  -   12,502 
Total $12,400  $83,102 
Due from related parties $12,400  $83,102 

Due to related parties

SCHEDULE OF RELATED PARTY TRANSACTIONS 

AdvanceDue to related parties consisted of the following as of the periods indicated:

 

  December 31, 2021  December 31, 2020 
Chengdu WenJiang Aixin Nanjiang Pharmacy Co., Ltd. $4,583  $- 
Qionglai Weide Pharmacy  -   10,421 
Sichuan Aixin Investment Co., Ltd  4,237   - 
Chengdu Xindu Cundetang Pharmacy Co., Ltd.  -   5,318 
Chengdu Lisheng Huiren Tang Pharmacy Co., Ltd.  10,235   - 
Total $19,055  $15,739 
  December 31, 2023  December 31, 2022 
Quanzhong Lin $1,051,429  $140,644 
Yirong Shen  87,325   89,892 
Huiliang Jiao  82,152   - 
Tianfeng Li  780   - 
Mianyang Aixin Cunshan Pharmacy Co. Ltd  112   - 
Chengdu Aixin International travel service Co, Ltd  5,087   6,346 
Total $1,226,885  $236,882 
Due to related parties $1,226,885  $236,882 

 

AdvanceThe amounts of due from related parties

Advance from and due to related parties consisted of the following as of the periods indicated:

  December 31, 2021  December 31, 2020 
Quanzhong Lin $1,822,705  $258,862 
Yirong Shen  97,292   - 
Branch manager  1,667   - 
Chengdu Aixin E-Commerce Company Ltd.  15,378   3,240 
Chengdu Aixin International travel service Co, Ltd  2,388   - 
Chengdu Beibang Pharmacy  -   2,748 
Aixin Life Beauty  7,724   - 
Total $1,947,154  $264,850 

described above were for working capital purposes, payable on demand, and bear no interest. All the related party entities listed above are controlled by Mr. Quanzhong Lin (the Chairman, President and major shareholder of Aixin Life). These advances to and from related parties were for working capital purpose, payable on demand, and bear no interest. Yirong Shen was a major shareholder of Aixin Shangyan Hotel prior to the closing of Hotel Purchase Agreement, and she serves as the supervisor of Aixin Shangyan Hotel. Mr. Huiliang Jiao is the Director of the Company. Tianfeng Li is the CFO of Aixin Life.

 

F-20

Office lease from a Major Shareholderleases

 

In May 2014, the Company entered a lease with its major shareholder for an office. The lease term was for three years expiring in May 2017 with an option to renew. The monthly rent was RMB 5,000 ($774704), the. The Company was required to prepay each year’s annual rent at 15th of May of each year. The Company renewed the lease until May 28, 20232028 with monthly rent of RMB 5,000 ($774704), payable quarterly. The future annual minimum lease paymentpayments at December 31, 2021 is2023 are $9,3008,450, $8,450, $8,450, $8,450, and $3,8753,521 for each of the years ended December 31, 2024, 2025, 2026, 2027, and 2028, respectively.

F-21

Runcangsheng has an office lease with Xiaoyan Zhou, wife of Huiliang Jiao, the Company’s Director, from March 2020 to February 2023 with a monthly rent of RMB 3,000 ($414). Runcangsheng renewed the lease until February 28, 2026 with monthly rent of RMB 5,000 ($690). In July 2023, Xiaoyan Zhou entered into an agreement with Runcangsheng to increase the monthly rent for 2022 by RMB 2,000and 2023, respectively.to change the lease expiration date to December 31, 2023. The lease will be converted to an annual contract starting from January 1, 2024.

 

14. INCOME TAXES

 

The Company was incorporated in the United States of America (“USA”) and has operations in one tax jurisdiction, i.e. the PRC. The Company generated substantially all of its sales from its operations in the PRC for the years ended December 31, 20212023 and 2020,2022, and recorded an income tax provision for each of suchthe periods.

 

China has a tax rate of 25% for all enterprises (including foreign-invested enterprises).

 

The components of the provision for income taxes for the years ended December 31, 20212023 and 20202022 consisted of the following:

 

SCHEDULE OF COMPONENTS OF THE PROVISION FOR INCOME TAXES

 2021  2020  2023  2022 
 For the Year Ended December 31,  For the Year Ended December 31, 
 2021  2020  2023  2022 
Current:             
China $292,891  $340,127  $4,367  $(761)
Total current  292,891   340,127   4,367   (761)
Deferred:                
China  (18,570)  -   15,152   1,858 
Total deferred  (18,570)  -   15,152   1,858 
Total income tax expense $274,321  $340,127  $19,519  $1,097 

 

Deferred tax assets as of December 31, 20212022 and 20202021 consisted of the following:

 

SCHEDULE OF DEFERRED TAX ASSETS

 December 31, 2021 December 31, 2010  December 31, 2023  December 31, 2022 
Deferred tax assets:                                  
Accumulated amortization $18,795  $-  $13,204  $15,556 
Less: valuation allowance  (13,204)  - 
Deferred tax assets, net $- $15,556 

 

The following table reconciles the statutory rates to the Company’s effective tax rate for years ended December 31, 20212023 and 2020:2022:

 

SCHEDULE OF EFFECTIVE INCOME TAX RATE

 2021 2020  2023  2022 
Statutory U.S. federal income tax rate  21.0%  21.0%  (21.0)%  (21.0)%
Foreign tax rate differential  216.5%  5.1%  (3.3)%  (3.8)%
Change in valuation allowances  3,634.4%  5.7%  25.2%  25.0%
Other (1) (1) -%  (6.7)%  -%  (0.2)%
Effective combined tax rate  3,871.9%  25.1%  0.9%  0.0%

 

(1)Primarily consists of utilization of net operating losses in China

As of December 31, 2021,2023, the Company had approximately $1,753,1395,371,806 of net operating loss carry-forwards available to offset future taxable income in China primarily from the acquisition of Aixin Shangyan Hotel and Aixintang Pharmacies. Some of theThe Company’s net operating loss carry-forwards if not utilized, will beginbegins to expire in 2022.

2024. After consideration of all information available, management believes that uncertainty exists with respect to future realization of its deferred tax assets resulted from net operating loss carry-forwards due to the Company’s net loss, and established a full valuation allowance of deferred tax assets resulted from net operating loss carry-forwards.

 

F-22

Uncertain Tax Positions

 

Interest associated with unrecognized tax benefits are classified as income tax, and penalties are classified in selling, general and administrative expenses in the statements of operations. For the years ended December 31, 20212023 and 2020,2022, the Company had 0no unrecognized tax benefits and related interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions.

 

15. STOCKHOLDERS’ EQUITY

 

On August 17, 2020, by unanimous written consent in lieu of a meeting, the Board adopted resolutions authorizing a one (1)-for-four (4) reverse stock. The reverse stock split became effective on October 27, 2020. According to the Articles of Amendment, the Company is authorized to issue 20,000,000 shares of blank check preferred stock at $0.001 par value and 500,000,000 shares of common stock at $.00001 par value per share.

Pursuant to resolutions adopted by the Board of Directors and the holders of a majority of the outstanding shares of common stock of AiXin Life International, Inc. on January 6, 2023, the Company filed an amendment to its Articles of Incorporation with respect to a proposed 1 for 2 “reverse” split of its common stock (the “Amendment”). Completion of the proposed reverse stock split was to be effected on a date determined by the Board of Directors only upon receipt of notice from the Financial Industry Regulatory Authority (“FINRA”) that it would process the proposed reverse stock split. The Company received notice from FINRA and its common stock began trading on a post-split basis on February 17, 2023.

As a result of the reverse split, every two shares of the Company’s issued and outstanding common stock were automatically combined and converted into one issued and outstanding share of common stock. The Company has approximately 24,999,834 shares of outstanding common stock after giving effect to the reverse stock split and the elimination of fractional shares.

All share and earnings per share information has been retroactively adjusted to reflect the reverse stock split.

 

As of December 31, 20212023, and 2020,2022, the Company had 49,999,89124,999,834 common shares issued and outstanding.outstanding, after reverse stock split adjustment.

In June 2020, 35,049,685 shares owned by Quanzhong Lin (the Chairman, President and major shareholder of Aixin Life) were cancelled.

F-21

 

Stock Awards Issued for Services

 

On October 22, 2019, the Company granted and issued 37,50018,750 shares to its employees and contractors under its 2019 Equity Incentive Plan. The stock awards were valued at $337,500 based on the post-split closing price of $918 on the grant date.

 

On October 24, 2019, the Company granted and issued 550,000275,000 shares to its employees and contractors under its 2019 Equity Incentive Plan. The stock awards were valued at $1,520,200 based on the post-split closing price of $2.7645.528 on the grant date.

 

The stock awards will vest over five (5) years from the grant date, and the grantee will forfeit a portion of the shares granted (“Shares Granted”) if the grantee is no longer employed by or contracted with the Company. Specifically, the grantee will forfeit 80% of Shares Granted if no longer employed by or contracted with the Company on the date that is one year from the grant date, forfeit 60% of Shares Granted if no longer employed by or contracted with the Company on the date that is two years from the grant date, forfeit 40% of Shares Granted if no longer employed by or contracted with the Company on the date that is three years from the grant date, and forfeit 20% of Shares Granted if no longer employed by or contracted with the Company on the date that is four years from the grant date. Effective on the 5th year from the grant date, none of the shares will be subject to forfeiture.

 

For the years ended December 31, 20212023 and 2020,2022, stock-based compensation expenses were $371,540 and $371,540., respectively. As of December 31, 2021,2023, unrecognized compensation expenses related to these stock awards are $1,044,207301,127. These expenses are expected to be recognized over 30.81 years.

 

F-23

Forgiveness of shareholder’s loanCapital Contribution

 

As ofDuring the year ended December 31, 2021, the Company’s major shareholder Mr. Lin forgave his loan to2023, the Company for $6,912,513. The Company recorded this forgiveness of shareholder loan as additional paid-in capital.

Acquisition of Subsidiaries

As of December 31, 2021, the Company completed the acquisitions of Aixin Shangyan Hotel and Aixintang Pharmacies (see Note 1). The acquisitions were accounted for as acquisitions of entities under common control. In connection with the acquisitions, the Company made payments to Mr. Linreceived capital contributions in the aggregate amount of $4.50145,300 million, or RMB 29 million. The difference betweenfrom Yunnan Shengshengyuan and Yun Chen, the consideration given andformer shareholders of Runcangsheng (see Note 1), who remained as related parties of the net assets received was recognized in equity, resulting in a decreaseCompany after the completion of additional paid-in capitalacquisition of $4,313,025.Runcangsheng.

 

16.OTHER INCOME

During the year ended December 31, 2023, the Company had $369,857other income, mainly consisted of local government grant for supporting Runcangsheng to become leading enterprise for plant, producing and marketing Chinese herbal medicine by utilizing local and natural resource of Chinese herb, building a primary processing plant with an annual processing capacity of 1,500 tons of Chinese medicinal materials, as well as supporting Runcangsheng on integrated innovation and application of deep processing technology for health products.

17. STATUTORY RESERVES

 

Pursuant to the PRC corporate law, the Company is now only required to maintain one statutory reserve by appropriating from its after-tax profit before declaration or payment of dividends. The statutory reserve represents restricted retained earnings.

 

Surplus reserve fund

 

The Company is required to transfer 10% of its net income, as determined under PRC accounting rules and regulations, to a statutory surplus reserve fund until such reserve balance reaches 50% of the Company’s registered capital. During the years ended December 31, 20212023 and 2020,2022, the Company makemade $0 and $140,2670 contribution to statutory reserve fund.

 

The surplus reserve fund is non-distributable other than during liquidation and can be used to fund previous years’ losses, if any, and may be utilized for business expansion or converted into share capital by issuing new shares to existing shareholders in proportion to their shareholding or by increasing the par value of the shares currently held by them, provided that the remaining reserve balance after such issue is not less than 25% of the registered capital.

 

F-22

Common welfare fund

 

Common welfare fund is a voluntary fund to which the Company can elect to transfer 5% to 10% of its net income, as determined under PRC accounting rules and regulations. The Company did not make any contribution to this fund during the years ended December 31, 20212023 and 2020.2022.

 

This fund can only be utilized on capital items for the collective benefit of the Company’s employees, such as construction of dormitories, cafeteria facilities, and other staff welfare facilities. This fund is non-distributable other than upon liquidation.

 

17.18. OPERATING CONTINGENCIES

 

The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environments and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

 

The Company’s sales, purchases and expenses are denominated in RMB and all of the Company’s assets and liabilities are also denominated in RMB. The RMB is not freely convertible into foreign currencies under the current law. In China, foreign exchange transactions are required by law to be transacted only by authorized financial institutions. Remittances in currencies other than RMB may require certain supporting documentation to affect the remittance.

 

F-24

Litigation

 

The Company is, from time to time, involved in litigation incidental to the conduct of its business regarding merchandise sold, employment matters, and litigation regarding intellectual property rights.

 

In DecemberOctober 2020, Jian Yiao (the “Plaintiff”) filed a complaint against Chengdu Aixintang Pharmacy Co., Ltd. (“Aixintang Pharmacy”, or the “Defendant”) in Zhangjiagang People’s Court in Jiangsu Province. The complaint alleges that Jian Yiao is entitled to $392,305 (RMB 2,500,000) from Aixintang Pharmacy for not fulfilling the contractual obligation of a purchase agreement entered in March 2020 (the “Purchase Agreement”). Aixintang Pharmacy claimed that the Purchase Agreement was falsely entered by an employee through forged documents, and that Aixintang Pharmacy did not enter the Purchase Agreement. The Court determined that Aixintang Pharmacy breached the Purchase Agreement by not delivering the products ordered and ordered Aixintang Pharmacy to pay $392,305 (RMB 2,500,000) to the Plaintiff. In December 2020, Aixintang Pharmacy filed a motion of appeal in the Jiangsu Suzhou Intermediate People’s Court against the determination reached from the first trial.

 

In February 2021, the judge in the Jiangsu Suzhou Intermediate People’s Court denied the Defendant’s motion and upheld the judgment from the first trial. In March 2021, Aixintang Pharmacy filed another motion of re-trial to the Jiangsu High People’s Court on the basis that the Purchase Agreement was forged. In February 2022, Aixintang Pharmacy filed an appeal inforged, the motion was accepted by Jiangsu High People's Court against the judgment reached by Jiangsu Suzhou Intermediate People’s Court in FebruaryJuly 2021. To date,Due to the impact of COVID-19 pandemic, Aixintang Pharmacy was unable to provide any new evidence to the Jiangsu High People’s Court. Consequently, in September 2022, the Court rejected the Defendant’s motion and upheld the judgment rendered in the second trial.

In April 2021, Jian Yiao applied for the first execution of the judgement; a total of $97,748 (RMB 694,000) was executed. On June 13, 2023, Jian Yiao applied for the restoration of execution. The total amount executed this legal proceeding remains pending.time was $110,818 (RMB 786,800), and the remaining amount including overdue interest of $139,692 (RMB 991,800) was not executed. As of March 27, 2024, the amount that was frozen from this case was $35,672 (RMB 253,266), the total amount executed was $212,412 (RMB 1.51 million), and the bank accounts of Chengdu Aixin Tang Haichuan Pharmacy Co., Ltd and its three branches were still frozen as of this report date.

 

In November 2021, the Company and Mr. Quanzhong Lin agreed that Mr. Lin shall assume any losses arising from this legal proceeding. As such, the Company did not accrue contingent losses from this legal proceeding as of December 31, 2021.2023.

 

The Company believes that current pending litigation will not have a material adverse effect on its consolidated financial position, results of operations or cash flows.

 

18.19. ACQUISITION OF SUBSIDIARIESSUBSIDIARY

 

In July and September, 2021, the Company completed the required governmental procedures and obtained the documents necessary to consider the acquisitions of Aixin Shangyan Hotel and Aixintang Pharmacies completed.Runcangsheng

 

F-23

On July 19, 2022, the Company entered into an Equity Transfer Agreement with Yunnan Shengshengyuan Technology Co., Ltd (“Shengshengyuan”) and Yun Chen (collectively “the Sellers”), who own 95% and 5% equity interest of Yunnan Runcangsheng Technology Co., Ltd (“Runcangsheng”), respectively.

Pursuant to

Under the Hotel Purchaseterms of the Transfer Agreement, dated May 25, 2021, AiXin HKthe Company purchased all of the outstanding equity interest of Aixin Shangyan Hotel from Mr. Lin and the other shareholderYunnan Runcangsheng for aan aggregate purchase price of RMB 7,598,88731,557,820, or $1.16 4,418,095million. The Transfer Price will be reduced, adjusted by an$116,802, the amount equal to any amounts paid or distributed by Aixin Shangyan Hotel to the Transferor afterinitial net worth estimate minus the audited net worth of Runcangsheng as of December 31, 2020 and will be increased by an amount equal to any amounts contributed to Aixin Shangyan Hotel by the Transferor after December 31, 2020.2021.

 

PursuantIn addition to transferring their respective equity interest in Runcangsheng, both Sellers agreed to forgive any loans due to them from Runcangsheng. The acquisition was completed on September 30, 2022.

F-25

The following table summarizes the Pharmacies Purchase Agreement entered on June 2, 2021, AiXin HK purchased 100% ownership of Aixintang Pharmacies from Mr. Lin and the other two shareholders for a purchase price of RMB 34,635,845 or $5.31 million. The purchase price will be reduced by an amount equal to any amounts paid or distributed by anyfair values of the Aixintang Pharmacies to Mr. Lin orassets acquired and liabilities assumed at the other two shareholders after December 31, 2020, and increased by an amount equal to any monies they contributed to anydate of acquisition. Goodwill as a result of the Aixintang Pharmacies after such date.acquisition of Runcangsheng is calculated as follows:

 

The acquisitions will be accounted for as acquisitionsSCHEDULE OF FAIR VALUES OF ASSETS ACQUIRED AND LIABILITIES ASSUMED

     
Total purchase considerations $4,301,293 
Estimated fair value of assets acquired:    
Cash $446,381 
Accounts receivable  144,813 
Accounts receivable-related party  133,011 
Advance to suppliers  3,455 
Other receivables and prepaid expense  127,909 
Inventory  469,594 
Property and equipment  1,677,272 
Intangible assets  1,406 
Operating lease right-of-use assets  1,990 
Total assets acquired  3,005,831 
Estimated fair value of liabilities assumed:    
Accounts payable  (89,801)
Accounts payable-related party  (160,911)
Advance from customers  (4,790)
Government grant  (921,473)
Taxes payable  (21,156)
Operating lease liability  (15,182)
Accrued liabilities and other payables  (1,314,995)
Total liabilities assumed  (2,528,308)
Total net assets acquired  477,523 
Goodwill as a result of the acquisition $3,823,770 

During the year ended December 31, 2022, the Company recorded a goodwill impairment equal to the goodwill resulting from the acquisition of entities under common control under ASC 805-50-15-6, and the assets and liabilities acquired will be measured and recorded at the carrying amount under ASC 805-50-30-5. Runcangsheng.

The following condensed unaudited pro forma consolidated results of operations for the Company, Runcangsheng, Aixin Shangyan Hotel and Aixintang Pharmacies for the yearsyear ended December 31, 2021 and 20202022 present the results of operations of the Company, Runcangsheng, Aixin Shangyan Hotel, and Aixintang Pharmacies as if the acquisitionsacquisition of Runcangsheng occurred on January 1, 2021 and 2020,2022, respectively.

The pro forma results are not necessarily indicative of the actual results that would have occurred had the acquisitionsacquisition been completed as of the beginning of the periods presented, nor are they necessarily indicative of future consolidated results.

SCHEDULE OF BUSINESS ACQUISITION PRO FORMA

 2021  2020  

For the

Year Ended

December 31, 2022

 
Revenue $4,241,991  $4,789,633  $3,168,061 
Operating costs and expenses  5,244,272   4,949,947   5,605,508 
Loss from operations  (1,002,281)  (160,314)  (2,437,447)
Other income (expense)  100,026   643,458 
Other income  34,839 
Income tax expense  274,321   340,155   1,097 
Net income (loss) $(1,176,576) $142,989 
Net loss $(2,403,705)

 

19.20. SUBSEQUENT EVENT

 

The Company follows the guidance in FASB ASC 855-10 for the disclosure of subsequent events. The Company evaluated subsequent events through the date the financial statements were issued and determined the Company has nothe following material subsequent events.event, on February 29, 2024, Aixin Shangyan Hotel moved to a new address for a total lease period of 121.5 months. During the initial five-year period, the total annual lease payments amounted to $169,016 per year (equivalent to RMB 1.2 million). Subsequently, for the remaining duration of the lease, there will be a yearly increase of 5% in the lease payments.

 

F-24F-26